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The physiological impact of severe levels of obstructive sleep apnoea and the benefits of treatment are 
well documented.  Yet more of the population suffer sleep apnoea of moderate severity.  However, we 
still have substantial gaps in our understanding on the physiological impact and treatment of people 
with sleep apnoea of moderate severity.  Our study addressed whether moderate obstructive sleep 
apnoea (OSA) had an impact on cerebral blood flow, cognition, or microsleeps.  It also explored the 
effect of 6–7 months of auto-titrating positive airway pressure (APAP) therapy on physiological 
measurements and quality-of-life in persons with moderate OSA.  
Twenty-four patients aged 32–79 years (median age 59, 10 female), who had previously presented to 
the Christchurch Hospital Sleep Unit and subsequently diagnosed with sleep apnoea of moderate 
severity consented to our study. Following a Level II polysomnography to confirm their suitability to 
participate, thirteen of these participants, aged 43–79 years (median age 59, 4 female), were placed on 
APAP therapy, with instructions to use it for at least 4 hr per night for 70% or more of the nights.  The 
remaining 11 participants aged 32–79 years (median age 62, 6 female), were placed in an untreated 
cohort.  Placement in the treated cohort was dependent on order of presentation with those first recruited 
offered a place in the treated cohort.  A third group of seven healthy controls aged 42–73 years (median 
age 62, 4 female) with an apnoea, hypopnea index (AHI) < 5 were recruited from a database of normal 
volunteers. The absence of sleep apnoea’s was confirmed by polysomnography in all seven participants.  
All three groups underwent an MRI ASL scan of cerebral perfusion, completed cognitive tests covering 
five cognitive domains – attention, executive functioning, memory, speed of processing, and 
visuospatial – and undertook a 30-minute task in which they were required to continuously track a 
constantly moving target for the purpose of detecting microsleeps.  This behavioural data, along with 
video recordings of eye movement and closure, were visually rated to identify microsleeps.  Finally, 
the Epworth sleepiness scale (ESS), Pittsburgh sleep quality index (PSQI), and Short-form 36 Health 
survey questionnaire (SF-36) were completed.  All measurements were repeated after the intervention 
period of 6–7 months during which time the treated cohort received APAP therapy. 
    Global cerebral perfusion did not differ at baseline between participants with sleep apnoea of 
moderate severity and healthy controls (mean 49.26 ml/100g/min vs 48.73 respectively, p = .899, d = 
0.06).  Furthermore, global cerebral perfusion rates at follow-up for the treated cohort, were not 
significantly different to baseline (mean 51.64 vs 48.56, p = .150, d =0.42).  Although a comparison of 
regional perfusion, as shown in the multi-sliced images, between the treated cohort, the untreated 
cohort, and the control group show a positive effect of change in the treated cohort over the other two, 
particularly in the right cerebral cortex/cingulate gyrus region and the right angular/supramarginal gyri, 
no statistically significant distinct regions of improved cerebral perfusion were identified. 
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The normalized and standardized composite cognitive score also did not differ at baseline between 
moderate OSA and healthy controls (median 0.26 vs 0.73, p = .166, d = -0.62).  Repeat testing of 
cognition at the completion of 6–7 months of APAP therapy found no evidence of a difference between 
baseline and follow-up on total cognition (mean = 0.22 vs 0.36, p = .560, d = -0.17.  However, despite 
memory showing a significant improvement (p = .001) there was a clear test-retest effect in all three 
groups.   
Microsleep was also tested at baseline.  Participants with moderate OSA (0–126 microsleeps, median 
0) and healthy controls (0–2 microsleeps, median 0) displayed a similar propensity to microsleeps (p = 
.253, d = 2.1).  No difference in microsleeps were observed between participants compliant with APAP 
treatment compared to their baseline result (median 0, range 0–5, vs. median 0, range 0–13, p = .344).  
Several markers of day-time sleepiness and quality of live improved in our treatment cohort: Epworth 
Sleepiness Scale (median 8 down from 11, p = .003, d =1.96), PSQI (mean 15.69 up from 14.23, p = 
.046, d = 0.94) and Minnesota Short Form 36 (mean 76.31 up from 66.09, p = .035, d = 0.93).   
This research was unable to demonstrate any change in cerebral perfusion, cognition, or microsleeps 
following 6-7 months of APAP treatment.  However, improvements in daytime sleepiness, sleep quality 
and quality of life are consistent with the observation that most participants who used APAP in this 
study wished to continue its use past its conclusion.  This indicates a clinical benefit in treating moderate 
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Chapter 1  Introduction 
Obstructive sleep apnoea (OSA) may be considered the most important of all sleep disorders in which 
the consequence of non-treatment is often a prolonged assault on the brain (Thomas & Chan, 2013).  
One possible sequela of that assault along with excessive daytime sleepiness is cognitive dysfunction, 
which was estimated (C Guilleminault et al., 1976) to adversely impact approximately 80% of all OSA 
patients (Weaver & George, 2011).  It has been postulated that this dysfunction is the result of both 
permanent and transient grey matter changes to the brain brought about by impairments to 
neurovascular autoregulation (Daulatzai, 2015; Innes et al., 2015).  This hypothesis still needs to be 
explored further, particular for those people with a moderate level of the disorder (what we refer to as 
moderate OSA).  Doing this is important because cognitive dysfunction can reasonably be expected to 
jeopardise participation in a full and active life, possibly rendering the patient a burden on family and 
society.  This need not be so, as pointed out by Daulatzai (2015), OSA is a modifiable disease and can 
be readily treated.  However, that treatment does come at a cost.  In New Zealand, with its health funding 
constraints patients with mild to moderate level of OSA severity have difficulty accessing publicly 
funded treatment (TSANZ, 2004).   
This is disappointing because within New Zealand, Maori are disproportionately affected by OSA 
(Mihaere et al., 2009).  With respect to risk factors (e.g., mean neck circumference, current smoker) 
and symptoms (e.g., witnessed apnoeas. snoring, never waking refreshed, never getting enough sleep, 
ESS > 10), Maori women and men are worse off in all instances than their non-Maori counterparts 
(Mihaere et al., 2009).  Moreover, they tend to be more likely diagnosed with severe OSA.  Furthermore, 
access to and quality of health care for Māori is less than for non-Māori (Ellison-Loschmann & Pearce, 
2006).  Clearly, these statistics point towards Maori carrying a greater health-cost burden than non-
Maori. 
The focus of this research is to develop a better understanding of the pathogenic mechanisms of OSA-
related cognitive dysfunction, particularly as it relates to OSA of moderate severity and cerebral 
perfusion.  This should help sufferers of the disorder, family members, healthcare providers, and society 
overall understand the benefits of treatment against the cost, and lead to the development of new rational 
therapeutic strategies (Pham & Schwartz, 2015). 
This pathology is thought to lead to permanent structural and physiological changes in the brain, as well 
as to other non-neurophysiological changes, with a consequential negative impact on overall health and, 
quality-of-life (Daulatzai, 2012; Vaessen et al., 2015).  If left untreated the co-morbidities of OSA are 
wide ranging and pervasive (Pinto et al., 2016).  For example, untreated OSA has been associated with 
cardiac arrhythmias, hypertension, cardiovascular disease, stroke, diabetes mellitus, fatigue and 
daytime hypersomnolence, along with mood disorders (Aaronson et al., 2014; Aloia & Arnedt, 2012; 
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Beebe, 2005; Beebe et al., 2003; Bucks et al., 2013; Chen et al., 2015; Chen et al., 2011; Daulatzai, 
2015; Idiaquez et al., 2014; Jehan et al., 2018; Kendzerska et al., 2014; Lindberg et al., 2012; McEvoy, 
2014; Mills & Dimsdale, 2004; Picano et al., 2014; Ramos et al., 2013; Roman et al., 2002; Vaessen et 
al., 2015; Wallace & Bucks, 2013; Wen et al., 2012).  Also, there is a high social cost resulting from 
OSA related daytime hypersomnolence and fatigue, which is reported to be the most common complaint 
in people with OSA (Cao et al., 2011).   
The public cost must also be considered.  A recent study by Walter et al. (2017) into healthcare 
utilization found that untreated apnoeics had greater health costs than those who were treated, regardless 
of severity level.  Within New Zealand, the societal cost of OSA in people aged 30–60 years has also 
been estimated to be in excess of the nett cost of treatment, with an estimated incremental net direct 
medical cost per quality of life year of $94 (range $56–$310) (Gander et al., 2010).  A recent population-
based study in Lausanne, Switzerland, found approximately 23% of women and 50% of men with a 
median age of 57 years (IQR 49–68 and 40–85 respectively) to have moderate or severe OSA (Heinzer 
et al., 2015), which emphasizes that the societal and personal consequences of untreated OSA are far 
from trivial. 
OSA can be treated with CPAP.  CPAP  therapy, first described by Sullivan et al. (1981), was considered 
the gold standard for moderate to severe instances of the disorder (Andrade et al., 2014; Buchanan & 
Grunstein, 2011; TSANZ, 2004).  The principal idea is that CPAP applied via a facial mask would act 
as a pneumatic splint, moving the soft palate and tongue anteriorly away from the posterior 
oropharyngeal wall, thereby maintaining upper airway patency during sleep, (Andrade et al., 2014; 
Sullivan et al., 1981).  However, during more recent times, the auto-titrating positive air pressure 
(APAP) machine has been developed based on the principles of CPAP but unlike the constant air 
pressure characteristic of CPAP, the APAP machine adjusts the air pressure in response to changes in 
breathing patterns, allowing the pressure to vary across the night. They have an algorithm that increases 
the air pressure when breathing is compromised and lowers the air pressure following a period of normal 
respiration.  Unfortunately, the initial cost of CPAP or APAP machinery can be expensive for many, 
and within New Zealand with its funding constraints, those with mild to moderate OSA can experience 
difficulty accessing PAP treatment and therefore, will remain vulnerable to the morbid effects of the 
disorder (TSANZ, 2004).  This is a concern for the wellbeing of an increasingly aging population, given 
that one of the many factors increasing OSA vulnerability is age (Punjabi, 2008; Young et al., 2002).   
1.1 The problem 
To the sequelae of OSA, must be added deteriorated mental health and, the well-recognized, detrimental 
impact of OSA on cognition (Daulatzai, 2012; Olaithe & Bucks, 2013; Olaithe et al., 2015a; Olaithe et 
al., 2015b; Wallace & Bucks, 2013).  According to Daulatzai (2012), it is neuroinflammation, 
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cerebrovascular endothelial dysfunction, and oxidative stress from OSA-related intermittent hypoxia 
and sleep fragmentation that underscore this cognitive decline through permanent neurodegenerative 
changes in the brainstem and neocortex.  A proposed mechanism by which this could occur is through 
hypoperfusion as a consequence of neurovascular pathology resulting from OSA associated 
hypoxaemia and fragmented sleep (Alosco et al., 2013; Baril et al., 2015; Daulatzai, 2015; Innes et al., 
2015; Macey et al., 2008).   
Although hypoperfusion is a sequela of OSA, debate remains about OSA severity levels and the 
manifestation of hypoperfusion (Baril et al., 2015; Daulatzai, 2012; Innes et al., 2015; Yadav et al., 
2013).  Innes et al. (2015) observed that cerebral perfusion was decreased whilst awake in regions of 
brains belonging to people with either moderate or severe OSA.  Of particular interest, was the finding that 
these regions of reduced cerebral perfusion are similar to the regions that previously had demonstrated 
reduced grey matter volume in people with severe OSA (Canessa et al., 2011; Gale & Hopkins, 2004; 
Morrell et al., 2010; Torelli et al., 2011; Yaouhi et al., 2009).  This finding led Innes et al. (2015) to 
conclude that the blood oxygen deficits from OSA may be evident before, and possibly underlie 
structural changes in the brain that adversely impact cognition.  However, Baril et al. (2015) found that 
cerebral perfusion was only reduced in those with severe OSA.  While this disparity could be the result 
of study design – Innes et al. used arterial spin labeling (ASL) to quantify cerebral perfusion, Baril et 
al. used single-photon emission computed tomography – neither result should be dismissed out of hand, 
thereby leaving open the question of cerebral perfusion risks in patients diagnosed with a moderate 
OSA severity level. 
One way to elucidate this question is to utilize the properties of arterial spin labeling (ASL).  ASL is a 
Magnetic Resonance Imaging (MRI) procedure. Its high spatial resolution capabilities (Petersen et al., 
2006), along with its non-invasiveness and ability to quantitatively measure tissue perfusion 
(Petcharunpaisan et al., 2010), make it ideal for understanding many aspects of cerebral perfusion 
physiology.  ASL’s absolute perfusion quantification feature permits comparisons to be made between 
multiple measurements such as those of a longitudinal study.  Moreover, correlating objective ASL 
measures of cerebral perfusion against cognition scores from those with OSA both before and after 
APAP therapy, should contribute to a better understanding of the relationship between perfusion and 
cognition. 
However, the effect of hypoperfusion on cognition is not the only question we hope to answer.  Intrusive 
and unwanted lapses of responsiveness often occur in the real world despite the robust nature of human 
information processing (Moller et al., 2006).  Typically, the outcomes of these lapses are trivial, but 
they can be of concern in some instances.  During those occasions where safety depends on extended 
periods of unimpaired performance, lapses can lead to severe outcomes i.e., motor vehicle accidents 
(Poudel et al., 2014).  A study by Buckley et al. (2014) compared two types of lapses, attention lapses 
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and microsleeps.  The authors concluded attention lapses were the result of resource depletion due to 
cognitive demands.  On the other hand, microsleeps are arousal related lapses characterized by clear 
overt behavioural signs of either drowsiness, or sleep accompanied by a coincidental response 
disruption (Buckley et al., 2014; Innes et al., 2013).  They are thought to be the result of low arousal 
ion levels being overwhelmed by the homeostatic drive for sleep (Poudel et al., 2014), which suggests 
apnoeics will be vulnerable to the deleterious effects of those types of lapses.  Furthermore, microsleeps 
are not infrequent.  For example, Peiris et al. (2006) unexpectedly found frequent lapses in a substantial 
number of healthy non-sleep-deprived participants; as did Poudl et al.  Poudel et al. (2014) tested 20 fit 
and healthy non-sleep deprived young adults and found that the mean microsleep rate per hour was 79 
(range 0–190).  Although it is well established that attention is not immune to the deleterious impact of 
OSA (Deering et al., 2016; Simoes et al., 2018), the impact of OSA on microsleeps has had less attention 
with Embase listing only one reference that  addresses the impact of OSA on microsleep (Morrone et 
al., 2020).  Clearly, both sustained attention lapses and microsleeps are frequent and can have serious 
real-life consequences.  Therefore, it is important to clarify the relationship between OSA and these two 
types of lapses. 
1.2 Solution 
This research will investigate the effect of moderate OSA on brain structure, cerebral perfusion using 
arterial spin labelling, neurocognition, and physiology, including microsleeping propensity, both before 
and following six-months of APAP treatment.  The aim of this research was to determine if moderate-
severity OSA has an adverse effect on brain function and if so, whether this can be offset/prevented by 
APAP.  Treatment may also reduce OSA-related cognitive impairment, and microsleep-related deaths 
and injuries. 
1.3 Research Questions and Hypotheses 
Six hypotheses are proposed:   
H1)  Perfusion is reduced in moderate OSA:  A study by Innes et al. (2015) found that an apnoeic cohort, 
which consisted of people with either a moderate or severe severity level of OSA, had reduced perfusion 
in three regions of the brain compared to a non-apnoeic cohort.  Whether this difference would be true 
for a ‘moderate only’ cohort has yet to be demonstrated.  It is hypothesized that cerebral perfusion 
in people with a moderate level of OSA will be reduced while awake compared to perfusion rates 
in non-apnoeic people. Supportive of this hypothesis are the findings of early transcranial Doppler 
studies by Placidi et al. (1998) and Franklin (2002) that found cerebral blood flow was impacted by 
OSA.  Also, more recently, studies by Yadav et al. (2015), and Baril et al. (2015) found perfusion 
changes in people with OSA.  
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H2)  Cognition is reduced in moderate OSA:  Although several studies have investigated the impact of 
OSA severity levels on cognition, (Stranks & Crowe, 2016) few have specifically confined their 
analysis to just those with moderate level OSA.  Most studies reviewed cognition in moderate apnoeics 
in conjunction with mild and severe severity levels and in Stranks and Crowe’s metanalysis, only one 
of the 19 reviews was limited to moderate OSA.  However, that paper only assessed memory (Kloepfer 
et al., 2009).  Our study is confined to an analysis of moderate OSA in conjunction with those with an 
AHI equal to or less than 5.  So, given our study does measure cognition, we are in a rare position of 
assessing the effects of moderate OSA on cognition.  Accordingly, it is hypothesized that moderate 
severity apnoeics (AHI > 15 < 29) will have lower cognition scores than those with an AHI < 5.  
The rationale for this position is the number of studies that in addition to either testing mild and severe 
OSA, have also included moderate OSA and that have found cognitive differences in both verbal and 
visual memory, attention, and spatial awareness.  
H3)  Microsleeps are increased in people with moderate OSA.  OSA is known to have a deleterious 
effect on daytime sleepiness, assumed to be because of the increased number arousals from sleep 
associated with OSA (Slater & Steier, 2012) although hypoxemia (Dewan et al., 2015) and 
inflammation (Kheirandish-Gozal & Gozal, 2019) cannot be discounted.  Microsleeps are thought to be 
influenced by drowsiness levels with greater propensity related to an increased drowsy state (Innes, 
Poudel, & Jones, 2013; Poudel, Innes, Bones, Watts, & Jones, 2014).  Nonetheless, the link between 
sleep apnoea and microsleeps has not been thoroughly researched.  It is hypothesize that the incidence 
of microsleeps will be higher in people with a moderate level of OSA compared to people without 
OSA.  This hypothesis will be addressed by comparing measurements of microsleeps taken at baseline 
and again six-months later from all three research cohorts.      
H4)  Impaired perfusion when awake can be improved by APAP treatment.  The literature on OSA has 
not satisfactorily explored the effect of APAP treatment of those with moderate OSA (McEvoy, 2014).  
It has not addressed whether such treatment will prevent or even reverse the deleterious effects of 
cerebral perfusion seen in sleep apnoea.  It is hypothesized that APAP treatment will improve 
cerebral perfusion in those with moderate levels of OSA while awake at the 6-month follow-up.  
Supportive of this hypothesis is that OSA may progressively worsen over time and that APAP treatment 
has been shown in some, but not all, studies to reverse the mild cognitive dysfunction.   
H5)  Impaired cognition in people with a moderate severity level of OSA can be improved by APAP 
treatment.  The effects of cerebral perfusion on neurocognitive function in people with moderate level 
of OSA remain poorly understood.  It is hypothesized that decreased cerebral perfusion in people 
with moderate level of OSA will be positively correlated to their cognitive functioning.  Evidence 
from studies into cardiovascular disease suggest a positive correlation between cerebral perfusion and 
cognitive functioning and changes to total brain volume.    
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H6)  Increased microsleeps in people with a moderate severity level of OSA can be reduced by APAP 
treatment.  A consequence of OSA is often excessive daytime sleepiness that may increase propensity 
for microsleeping. However, the relationship between microsleeping and OSA has not been completely 
established.  It is hypothesized that APAP treatment will reduce microsleeps.  Effective APAP 
treatment should reduce the number of micro arousals that are often associated with the restoration of 
upper airway patency.  This should allow for the restoration of normal sleep architecture and improve 
daytime sleepiness levels.  
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Chapter 2  The cerebrovascular sequalae of moderate OSA 
whilst awake 
2.1 Introduction 
Adequate Cerebral perfusion is important for wellbeing and health outcomes (Azad et al., 2003; De Wit 
et al., 2018; Jafari, 2018; Wolters et al., 2017).  It is, therefore, concerning that cerebral perfusion can 
be impaired because of intermittent hypoxemia and hypercapnoea; both being hallmarks of OSA 
(Castello‐Branco et al., 2020; Daulatzai, 2012; Jensen et al., 2018; Nie et al., 2017; Ponsaing et al., 
2018; Silverman & Petersen, 2019; Urbano et al., 2008; Wu et al., 2019).  This cerebral perfusion 
impairment can result in hypoperfusion of the brain that negatively impacts the delivery of oxygen and 
nutrients to brain tissue (Mount & Das, 2020; Torabi-Nami et al., 2015).  Furthermore, the 
pathophysiology of OSA, has been demonstrated to impact cognitive functioning (Aaronson et al., 
2014; Aloia & Arnedt, 2012; Beebe et al., 2003; Bucks et al., 2013; Chen et al., 2011; Idiaquez et al., 
2014; Wen et al., 2012), which along with excessive daytime sleepiness contributes to a reduced quality-
of-life (Vaessen et al., 2015).  In particular, concentration, memory, executive functioning (Kylstra et 
al., 2013; Vaessen et al., 2015), depression, anxiety (Aloia et al., 2004; Olaithe et al., 2015a; Rezaeitalab 
et al., 2014), and fatigue (Olaithe et al., 2015a) are worrying psychological sequelae for many with 
OSA.  Understanding this impact of OSA on a person’s general life experiences is an important part of 
case management and of course, research.  How that understanding is developed though, does depend 
on the context of the research and the type of instruments used within it.  Therefore, the choice of tests 
used in research becomes an important assignment.   
The literature review explores the effect of moderate OSA on cerebral perfusion during the awake 
period and our current understanding of cerebral perfusion on cerebrovascular pathology.  I review the 
literature on cognition and OSA, with an emphasis on a moderate level of the disorder.  I also cover the 
various instruments used to measure the neurocognitive sequelae of obstructive sleep apnoea.  Also 
reviewed is the literature concerning microsleeps, the frequency of which has been linked to fatigue and 
daytime sleepiness, and therefore could be an important metric for OSA.  In addition, I look at the 
arterial spin labelling process used to quantify cerebral perfusion and how it is undertaken.  Finally, I 
review the key literature on the role of APAP therapy in the management of sleep apnoea.   
2.2 Definitions  
Cerebral autoregulation:  cerebral autoregulation is a process that is defined as the ability of the cerebral 
vasculature to maintain a relatively constant, stable blood flow despite wide-ranging changes in cerebral 
perfusion pressure (Cipolla, 2009; Filosa & Iddings, 2013; Mount & Das, 2020; Silverman & Petersen, 
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2019; Zeiler et al., 2020).  Under normal conditions, this is mediated via changes in arteriolar diameter, 
which in turn leads to changes in cerebrovascular resistance that is expressed in an equation known as 
the Hagen-Poiselle equation (Silverman & Petersen, 2019). 
Cerebral blood flow:  Two terms are used to express the delivery of blood to the brain.  Blood flow 
measured in the arteries is often called CBF, while blood flow measured in the capillaries in the brain 
parenchymal is normally labelled as perfusion.  These terms are often used interchangeably. 
Petcharunpaisan et al. (2010) noted that cerebral perfusion can in clinical practice refer to a broad range 
of quantitative and qualitative measures of blood flow and blood hemodynamic properties, including 
blood volume, blood velocities and blood transit times.  Used quantitatively it refers to the rate at which 
blood is delivered to tissue, or in other words, the volume of blood per unit of tissue mass per unit of 
time (ml/g/min) and is essentially the same measure as CBF (Engblom et al., 2017).  Typically, CBF in 
a normotensive person would be ≈60 ml/100g/min (Desmidt et al., 2018), although for an earlier 
estimate, Lassen (1985) place mean normal CBF at 45 – 55 ml/100 g/min. 
Additionally, the literature refers to global cerebral perfusion and regional cerebral perfusion.  They are 
different constructs.  Global cerebral perfusion is dominated by pressure and clinical drives including 
the autonomic nervous system, whereas regional cerebral perfusion is inextricably linked to local 
change in neuron activity, particularly in the Limbic system (Macey, 2015). 
Cerebral blood flow velocity:  CBF velocity is a measure of the speed at which blood flows though the 
arteries.  Its unit of measurement is cm/s (Desmidt et al., 2018).  It is common for transcranial Doppler 
studies to report CBF velocity but as it is unable to measure the diameter of the artery at the point of 
insonation and hence cannot quantitatively assess CBF in terms of volume per period of time (Silverman 
& Petersen, 2019; Sorond et al., 2010).  Nonetheless, it is a clinically useful index because the CBF 
velocity is directly proportional to the rate of blood flow provided the diameter of the vessel remains 
constant throughout the period of measurement (Durgan & Bryan, 2012). 
Cerebrovascular reactivity:  Cerebrovascular reactivity  is defined as the response of cerebral blood 
vessels to changes in the partial pressure of carbon dioxide and oxygen (Castello‐Branco et al., 2020)..  
Cerebrovascular reactivity is also referred to by the literature as a measure of cerebrovascular 
homeostasis (e.g. Catchlove et al., 2018; Fierstra et al., 2013; Halani et al., 2015; Ryan et al., 2018; 
Zeiler et al., 2020), and is an indicator of vascular reserve and autoregulatory efficiency (Halani et al., 
2015). 
Cerebrovascular tone:  Cerebrovascular tone is the degree a blood vessel has constricted relative to its 
maximally dilated state (Klabunde, 2012).  Cerebrovascular tone has been referred to as a measure of 
cerebrovascular homeostasis (Cipolla, 2009; Filosa & Iddings, 2013; Klabunde, 2012).   
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Microsleeps:  Microsleeps are arousal-related lapses characterized by clear overt behavioural signs of 
either drowsiness, or sleep and a coincidental response disruption (Innes et al., 2013; Peiris et al., 2007; 
Poudel et al., 2014) lasting between 0.5–15 s with lapses greater than 15 s being classified as sleep.  The 
behavioural signs are full or at least 80% eyelid closure accompanied by clear indications of drowsiness 
– which may include prolonged eyelid closure, slow roving eye movements, head nodding and slumped 
posture, all of which are sometimes followed by abrupt reactions – coincident with flat responses, where 
the subject has stopped responding to the task at hand.    They are distinct from the microsleep first 
described by Harrison and Horne (1996) that was based on a Spectral analysis of the EEG. 
Obstructive sleep apnoea:  Obstructive sleep apnoea (OSA) is a sleep-related breathing disorder that 
involves a decrease or complete cessation of ventilation despite an ongoing effort to breathe during 
sleep. It occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to 
collapse and obstruct the upper airway. This leads to partial reductions (hypopnoeas) and complete 
pauses (apnoeas) in breathing that to be counted needed to last at least 10s during sleep.  Most pauses 
last between 10 and 30s, but some may persist for one minute or longer. This can lead to reductions in 
blood oxygen saturation, with oxygen levels measured peripherally falling as much as 40% or more in 
severe cases (Medicine, 2014). 
2.3 Obstructive sleep apnoea 
Obstructive sleep apnoea occurs when muscles that normally maintain upper airway patency during 
respiratory inhalation, become atonic during periods of sleep and cannot counter the collapsing forces 
associated with ventilation.  This results in the pharyngeal Figure 2-1, a section of the airway not 
supported by cartilaginous tissue, repeatedly becoming either completely or partially blocked specific 
to the sleep state, often for periods two minutes or more (Cao et al., 2011; Dempsey et al., 2010).  In 
severe cases these obstructive episodes can occur hundreds of times per night.  However, even in, what 
is considered by the American Sleep Association to be moderate cases of this sleep disorder, their 
occurrence is still between 15 and 29 times per hour of sleep that nonetheless equates to almost 240 
times per 8-hour period of sleep (Hudgel, 2016; Ruehland et al., 2009).   
These obstructive events are either apnoeas or hypopnoeas.  An apnoea is defined as a drop in the peak 
signal excursion by >90% of the pre-event baseline with a duration > 10 seconds, whilst a hypopnoea 
is defined as a peak signal excursion drop by > 30% of the pre-event baseline with a duration of > 10 
seconds, and a > 3% desaturation from the pre-event baseline or the event is associated with an arousal 
(American Academy of Sleep, 2020).  Hypopnoeas have an equivalent pathophysiology to an apnoea 
(Daulatzai, 2015) with the likely consequences of these apnoeic/hypopnoeic events being chronic 
intermittent hypoxaemia, with brain blood oxygen saturation dropping to low levels (Aloia et al., 2004), 
or intermittent hypercapnoea (Brillante, 2017).   
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Figure 2-1  A sagittal view of the pharynx showing the soft palate or velum, the primary site for OSA. 
This in turn results in increased respiratory effort, and sleep disturbances that are thought to promote 
ventilatory instability (Cao et al., 2011; Younes, 2004), thereby disrupting sleep architecture.  Both 
apnoeas and hypopnoeas are associated with a disturbed sleep architecture, in particular loss of REM 
sleep and stage three of NREM sleep.  Consequently, many of the restorative benefits of sleep are 
reduced (Daulatzai, 2012; Dempsey et al., 2010). This is reflected in the main symptom of severe OSA 
being increased daytime sleepiness (Vakulin et al., 2019).  
However, a considerable proportion of people with moderate or severe OSA exhibit no significant 
daytime symptoms (Ryan, 2019).  Estimates from recent population studies based on the American 
Academy of Sleep Medicine (AASM) 2012 criteria are that 49.7% of men and 23.4% of women aged 
40 years or more have an AHI > 15 events per hour, but only 2-7% of them complain of sleepiness, i.e. 
have an ESS > 10 (Adams et al., 2016; Heinzer et al., 2016; Vakulin et al., 2019).  This is in stark 
contrast to the conclusion reached by Weaver and George (2011) who, citing Guilleminault, Hoad and 
Mitler, (1978) reported that approximately 80% of OSA patients complain of both excessive daytime 
sleepiness and cognitive impairments, with half of the patients also reporting personality changes. 
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This work will explore the physiological correlations between intermittent nocturnal hypoxia and 
possible permanent adjustments of the brain.  Much is known about the effects OSA interrupting sleep 
architecture, far less is known on the effect of OSA on the brain during the awake period.  
2.4 Phenotypes in OSA 
“Zinchuk et al. (2018) vary considerably between individuals (Eckert, 2018).  It is, as noted by Zinchuk 
et al. (2017), a complex heterogeneous condition in which the diverse spectrum of features cannot be 
captured just by the AHI (See also, Dempsey et al., 2010; Ryan & Bradley, 2005; Subramani et al., 
2017).  Accordingly, to help make sense of this heterogeneity in OSA, several studies have defined 
various phenotypes (e.g., Ayas et al., 2015; Jennum & Riha, 2009; Mukherjee et al., 2018; Pien et al., 
2018; Subramani et al., 2017; Ye et al., 2014; Zinchuk et al., 2017; Zinchuk et al., 2018).  However, the 
identification of a set of phenotypes useful in studies of cerebral perfusion, cognition, and microsleeps 
have yet to be elucidated with the majority of OSA-related phenotypes used in clinical settings to target 
therapeutic interventions.   
One definition of phenotype is: “A category of patients with OSA distinguished from others by a single 
or combination of disease features, in relation to clinically meaningful attributes (symptoms, response 
to therapy, health outcomes, quality of life)” (Zinchuk et al., 2017, p. 3).  However, that definition is 
primarily written for the clinician.  To that end, the definition by Subramani et al. (2017) is more 
appropriate for research and clinical settings.  Subramani et al. defined (p. 3) a phenotype “…is an 
observable expression of an individual's characteristics that result from the interaction between the 
individual's genes (genotype) and the environment, without any implication of a mechanism.”   
This study is interested in six primary measures: (1–3) the impact of moderate OSA on cerebral 
perfusion, cognition, and microsleeps, and (4–6) the impact of six-months CPAP treatment on cerebral 
perfusion, cognition, and microsleeps.  The question asked is if these constructs can be explained by a 
phenotypic approach. 
A systemic review of OSA-related phenotypes was conducted by Ramos et al. (2017) who found that 
approximately half of the articles (8 out of 17) used clinical symptoms to identify a phenotype, reflecting 
the high use of phenotypes to inform individualized treatments.  The next largest selection were articles 
covering experimental or data driven phenotypes (5 out of 17), while molecular-genetic studies made 
up the balance (4 out of 17).  Of particular interest to this study is the experimental-analytical approach.  
For example, the Icelandic Sleep Apnea Cohort using cluster analysis (n = 822) with an AHI > 15 
identified and described three different phenotypic groups that did not differ in age, sex, BMI, AHI, or 
oxygen desaturation.  One cluster had predominantly insomnia symptoms, cluster two had minimal 
symptoms compared to the other clusters, while cluster three was characterized by excessive daytime 
sleepiness (Ye et al., 2014). 
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Schmickl et al. (2018) identified four underlying mechanisms contributing to OSA, the relative 
contribution of which they say help form an individual’s phenotype.  These are 1) a compromised upper 
airway anatomy, 2) a poor pharyngeal muscle responsiveness, 3) respiratory control instability (high 
loop gain), and 4) a low arousal threshold (wake up too easily. (See also, Malhotra & Jordan, 2016).   
Zinchuk et al. (2018) used polysomnogenic data to identify physiological phenotypes.  Using sleep 
architecture disturbance, autonomic dysregulation, breathing disturbances and hypoxia measures, they 
identified seven patient clusters that can be used to classify patients into subgroups reflecting different 
pathophysiological processes (see Table 2-1) 
Table 2-1  Descriptions and labels for the seven polysomnographic clusters based on distinguishing 
features. 
 OSA severity definitions: none/mild (AHI <15), moderate (15≤ AHI<30) and severe (AHI ≥30). AHI was not used in 
generating patient clusters. Median AHIs and severity categories based on median AHI for each cluster are shown for 
descriptive purposes only (mean AHIs were 7.5, 13.6, 24.0, 25.0, 47.6, 72.6 and 82.4 for clusters A, B, C, D, E, F, and G, 
respectively).  AHI, apnoea-hypopnoea index; NREM, non-rapid eye movement; OSA, obstructive sleep apnoea; PLMS, 
periodic limb movements of sleep; REM, rapid eye movement (Zinchuk et al., 2018). 
 
 All these approaches suggest different ways of formulating and identifying phenotypes.  Although most 
phenotypic studies are used to inform clinical interventions, there is considerable utility in using a 




AHI* (events/hour) Conventional OSA severity* 
Mild 4 None/mild 
PLMS 10 
 
NREM and poor sleep 19 Moderate 
REM and hypoxia 19 
 
Hypopnoea and hypoxia 44 Severe 
Arousal and poor sleep 68 
 
Combined severe 84 
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2.5 Cerebrovascular pathophysiology 
The brain’s demand for 15–20% of total cardiac output, despite only contributing approximately two 
percent of body weight, makes it one of the most highly perfused organs in the body (Bor-Seng-Shu et 
al., 2012; Cipolla, 2009; Durgan & Bryan, 2012; Jafari, 2018).  Moreover, because most of the brain’s 
energy is obtained from aerobic metabolic processes (Bor-Seng-Shu et al., 2012), this renders the brain 
susceptible to disruptions in the supply of nutrients and oxygen.  As a result, even relatively short 
disruptions in supply can have significant pathological consequences (Durgan & Bryan, 2012).  The 
brain remains metabolically active during sleep, so maintaining a tight control over blood flow and 
oxygen delivery, during both sleep and wakefulness is critical (Cipolla, 2009; Klingelhofer, 2012).  
Moreover, the brain is enclosed in a rigid vault (i.e., the skull) that does not allow for the expansion of 
brain tissue or extracellular fluids, outside of very narrow limits (Rodríguez-Boto et al., 2015).  
Accordingly, the need to maintain intracranial pressure within tight limits, yet still provide an 
appropriate ionic environment for the exchange of water and solutes between blood and brain 
parenchyma, places special demands on cerebrovascular physiology and on cerebral perfusion 
homeostasis. 
2.5.1 Cerebral perfusion homeostasis 
In healthy adults under normal physiological conditions, cerebral perfusion pressure is maintained 
between 50 and 150 mmHg (Armstead, 2016).  Cerebral perfusion pressure is the net pressure gradient 
that drives oxygen delivery to cerebral tissue (Mount & Das, 2020) and is the difference between mean 
arterial pressure and venous pressure.  However, because venous pressure is directly influenced by 
intracranial pressure, cerebral perfusion pressure can be considered as the difference in mean arterial 
pressure and intracranial pressure (Mount & Das, 2020).  Intracranial pressure is directly related to 
intracranial volume with any increase in volume reflected in an increase in pressure (Figure 2-2 next 
page) (Pinto et al., 2020).  As previously mentioned, the cranial vault is a fixed and rigid anatomical 
structure and, accordingly, its ability to accommodate increases in intracranial volume without 
excessive increases in intracranial pressure is determined by intracranial compliance (Rodríguez-Boto 
et al., 2015).  
2.5.2 Intracranial compliance and cerebral autoregulation 
Intracranial compliance, along with cerebral autoregulation, are key determinants in meeting the special 
demands of cerebrovascular physiology.  Intracranial compliance represents a change in volume per 
unit change in intracranial pressure and is explained by the Monro-Kellie hypothesis which states that 
the sum of brain parenchyma, cerebral spinal fluid and cerebral blood volumes is constant and that any 
increase in volume of any one of the three constituents, must be compensated for by a decrease in one 
or two of the other constituents (Mokri, 2001).  This makes it relevant to OSA pathology, which is 
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known to cause intermittent increases in intracranial pressure because of the associated hypercapnoea, 
hypoxia, and cerebral vasodilation (Thurtell et al., 2013).   
 
Figure 2-2  The relationship between intracranial pressure and volume.  ICP: intracranial pressure.  
(Nag et al., 2019) 
Three stages contribute to intracranial compliance in a process that Tameem and Krovvidi (2013) 
labelled as volume buffering.  In the first stage, an increase in cerebral volume results in cerebral spinal 
fluid moving into the spinal subarachnoid space, sometimes referred to as the lumbar cistern; this is the 
principal buffer (Rodríguez-Boto et al., 2015).  Secondly, and to a lesser extent, changes to cerebral 
blood volume can quickly be modified by changes to cerebral venous volume, (Tameem & Krovvidi, 
2013).  Finally, in the third stage, brain parenchyma can reduce, albeit much more slowly, to 
accommodate chronic increases in brain volume (Rodríguez-Boto et al., 2015).  
In addition to intracranial compliance processes, cerebral autoregulation also plays a key role in CBF 
homeostasis.  Cerebral autoregulation is the ability of the cerebral vasculature to maintain a stable blood 
flow despite changes in cerebral perfusion pressure, which under normal circumstances, would involve 
changes in arteriolar diameter, that would drive changes in cerebrovascular resistance (Figure 
2-3)  (Silverman & Petersen, 2019).   In normotensive adults, cerebral perfusion is maintained at 
approximately 50 mL per 100 g of brain tissue per minute provided cerebral perfusion pressure is 
between approximately 50 to 160 mmHg (Armstead, 2016; Lassen, 1985).  Outside of those limits, 
autoregulation is lost and cerebral perfusion becomes linearly dependent on mean arterial pressure 
(Cipolla, 2009).  To some extent, reductions in cerebral perfusion resulting from cerebral perfusion 
pressure falling below the lower limits of autoregulation are compensated for by an increase in oxygen 
extraction.  However, if cerebral perfusion falls too low, hypoperfusion occurs which may eventually 




Figure 2-3  Schematic drawing showing the relationship between cerebral perfusion pressure and CBF 
and the influence of the cerebrovascular autoregulation process. 
The impact of OSA on cerebral autoregulation has been the subject of research (e.g., Beaudin et al., 
2017; Urbano et al., 2008; Waltz et al., 2016).  Urbano et al. (2008) used transcranial Doppler to 
measure CBF velocities in 28 patients with severe OSA (mean AHI = 78.4 ± 7.1) and 26 controls (Mean 
AHI = 1.8 ± 0.3) and found that those with OSA had a significantly slower rate of recovery of blood 
pressure, CBF velocity and cerebrovascular conductance than the control group, indicating the 
compensatory response to hypoperfusion was impaired. They also found that although OSA patients 
had reduced CBF velocities when compared to controls (48 ± 3 cm/s and 55 ± 2 cm/s respectively) 
following an orthostatic task, there was no difference between the two cohorts in their vasodilation 
response to hypocapnia which was normal. 
Beaudin et al. (2017) reviewed current literature on whether OSA had a hermetic effect on vascular 
health because of OSA’s associated chronic intermittent hypoxia and concluded that patients with 
severe OSA were at higher risk of vascular disease, but that the data was equivocal for older OSA 
patients and those with mild OSA.  This they attribute to the protection given by advanced age, and 
short-duration, low-intensity intermittent hypoxia against myocardial infarction and stroke respectively, 
albeit they concede that additional research is still required to confirm this premise.  The second study 
by Waltz et al. (2016) investigated whether impaired cerebral autoregulation in OSA is further 
exacerbated by isocapnic-hypoxia and whether this impairment can be improved by CPAP treatment.  
Their conclusion was that cerebral autoregulation is altered in severe OSA patients during normoxia 
but not during isocapnic-hypoxia, and that CPAP treatment had no impact on cerebral autoregulation.   
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Table 2-2.  Summary of the four cerebral autoregulation mechanisms 
Cerebral autoregulation mechanisms 
 The endothelial response is based on shear stress influencing the endothelium lining to release both 
vasoconstrictors, e.g., nitric oxide, endothelium derived hyperpolarizing factor, prostacyclin, and 
prostaglandin, and vasodilators, e.g., E2 endothelial-1, thromboxane A2, and prostaglandin F2.  
These molecules may act directly on smooth muscles cells (Cipolla, 2009; Silverman & Petersen, 
2019; Zeiler et al., 2020).   
The myogenic response is a factor of muscular stretch and is an intrinsic property of smooth muscles 
in both large and small arterioles to constrict in response to increased pressure and dilate in response 
to decreased pressure.  It is understood that through the myogenic tone, transmural pressure 
influences arterial diameter by acting through smooth muscle contraction or relaxation (Cipolla, 
2009; Durgan & Bryan, 2012; Silverman & Petersen, 2019).   
The neurogenic mechanism involves direct neural input through the release of various 
neurotransmitters, such as cholinergic, serotonergic, dopaminergic, and adrenergic/noradrenergic, 
which have vasoactive properties.  For example, acetylcholine and nitric acid are potent dilators while 
serotonin and neuropeptide Y, stimulate vasoconstriction (Silverman & Petersen, 2019).  Moreover, 
astrocytes and microglia are considered to have vasoactive properties (Attwell et al., 2010; Howarth, 
2014; Marina et al., 2020; Silverman & Petersen, 2019).   
The metabolic response occurs in smaller vessels that, according to (Silverman & Petersen, 2019), 
are subject to changes in the local environment and not necessarily be directly influenced by cerebral 
perfusion pressure.  Silverman and Peterson note as an example, that increased concentrations of 
cerebral carbon dioxide, such as occurs during hypoperfusion, can accumulate causing vasodilation 
with as little as a 1 mmHg increase in the partial pressure of carbon dioxide resulting in approximate 
a 4% increase in CBF (Silverman & Petersen, 2019), or as noted by Cipolla (2009) a 5% increase in 
carbon dioxide inhalation can result in a CBF increase of 50% whilst a 7% increase in carbon dioxide 
inhalation increases CBF by 100%.   
 
The common link between these three studies is severity level of OSA.  However, as acknowledged by 
Beaudin et al. (2017), despite findings from both animal and human experimental models establishing 
a detrimental irreversible impact of intermittent hypoxia upon vascular regulation, the link between the 
uration and frequency of the intermittent hypoxic dose and vascular changes is unknown. 
Although research has shed some light on the underpinning mechanisms of cerebral autoregulation, the 
exact molecular means underlying autoregulation remain elusive (Silverman & Petersen, 2019).  
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Nonetheless, various processes, including endothelial, myogenic, neurogenic, and metabolic responses, 
have been implicated, albeit the interplay and relative contribution of each of these mechanisms are 
overly complex and not fully understood (Armstead, 2016; Cipolla, 2009; Silverman & Petersen, 2019).  
These four mechanisms are briefly described in Table 2-1.   
2.5.3 The vasodilatory response to moderate OSA 
Under healthy physiological conditions, cerebral autoregulation mechanisms result in marked 
vasodilation of cerebral arteries and arterioles in response to increased concentrations of carbon dioxide 
(Silverman & Petersen, 2019) or decreased levels of oxygen (Cipolla, 2009; Johnston et al., 2003).  For 
example, findings have shown that in humans a 5% carbon dioxide inhalation caused cerebral perfusion 
rates to increase by as much as 50%, and a 7% carbon dioxide inhalation resulted in blood flow 
increasing by as much as 100% (Cipolla, 2009; Kety & Schmidt, 1948).  Hypocapnoea on the other 
hand has been reported to reduce concentrations of vascular carbon dioxide with a resultant 
vasoconstriction and reduced cerebral perfusion (Cipolla, 2009).  Similarly, acute hypoxia can lead to 
the dilation of cerebral blood vessels and a concurrent increase in blood flow by as much as 400% 
(Johnston et al., 2003) via activation of adenosine triphosphate-sensitive K+ channels, increased nitric 
oxide and adenosine production and changes in capillary density (Cipolla, 2009; Golanov & Reis, 1999; 
Taguchi et al., 1994). 
This vasodilatory and subsequent increase in cerebral perfusion response to hypercapnoea/hypoxia, has 
also been reported in people with OSA.  Balfors and Franklin (1994) reported as early as 1994 that both 
CBF velocity and mean arterial pressure increased after an apnoea/hypopnoea event when compared to 
pre-apnoea levels.  They tested six patients with OSA using transcranial Doppler ultrasound and found 
that during an apnoeic/hypopnoeic event there was a concomitant increase of mean arterial pressure and 
CBF velocity of 11 ± 6% (p < .001) and 15 ± 6% (p < .001) over baseline, respectively.  However, 
immediately after termination of the apnoea/hypopnoea, mean arterial pressure and CBF velocity 
decreased to a minimum of -8 ± 2% (p < .001) and -23 ± 8% (p < .001), respectively, returning to normal 
values within 60s, except during repetitive apnoeas, which were associated with prolonged periods of 
reduced mean arterial pressures and CBF velocities.  Also, Durgan and Bryan (2012), reported that CBF 
velocity in the middle cerebral artery increased by as much as 200% during an OSA episode before 
recovering to normal levels on termination of the apnoea/hypopnoea event.  Coincidentally, they also 
found that arterial blood pressure increased during the apnoea/hypopnoea before falling below baseline 
after the apnoea event had terminated (Figure 2-4). 
However, there is evidence that the normal vasodilatory response to increased changes in blood levels 
of carbon dioxide or decreased levels of oxygen can breakdown, resulting in vasoconstriction and 
reduced cerebral perfusion (Gregori-Pla et al., 2018; Harper et al., 1972; Reichmuth et al., 2009; 
Silverman & Petersen, 2019; ter Laan et al., 2013).  For example, Durgan and Bryan (2012) reported 
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that two weeks of intermittent hypoxia was sufficient to completely abolish the normal vasodilator 
response.  They also reported that cerebral perfusion in patients with OSA decreased during both sleep 
and wakefulness compared to people without OSA and that these decreases occurred even though end-
tidal carbon dioxide levels were significantly higher in those with OSA during both wakefulness and 
sleep, which is contrary to the normal cerebral autoregulation response (Meyer et al., 1987; Meyer et 
al., 1980).  Netzer et al. (1998), found from their transcranial Dopler study that a reduction in CBF 
occurred in the middle cerebral artery in 76% (169/223) of observed obstructive hypopnoeas and in 
80% (98/123) of obstructive apnoeas.   
 
 
Figure 2-4  Changes in blood flow velocity in the middle cerebral artery (CBFV; top) and mean arterial 
blood pressure (MABP; bottom) during an episode of apnoea (shaded in light blue) under healthy 
physiology (Durgan & Bryan, 2012). 
Macey (2015) asked the question, “Whether the resting CBF differences with respect to healthy people 
are pathological or reflective of normal cerebral autoregulation in the presence of abnormal physiology 
associated with OSA” (p.1345).  He noted that Shiota et al. (2014) and (Meyer et al., 1987; Meyer et 
al., 1980) had reported that, when awake, the decrease in rCBF observed in patients with severe OSA 
was reversible when treated and that this was clear evidence that the hypoperfusion in patients with 
untreated OSA was not due to permanent damage to cerebral vessels.  Another study to conclude that 
OSA-induced brain damage could be reversed was Maresky et al. (2019).  They. found that CPAP 
19 
treatment improved brain microstructural integrity and perfusion and concluded that this is suggestive 
of repair and healing of OSA-induced brain damage. 
While Macey was not able to reach a firm conclusion as to the cause of the improvement, Waltz et al. 
(2016) suggested that the altered cerebral autoregulation seen in more severe OSA may be the result of 
an overactive sympathetic system, caused by the repetitive episodes of apnoeas during sleep.  Similarly, 
Ficker et al. (1997) attributed the altered rCBF, seen in the frontal lobe, to repetitive cortical arousals.  
Jafari (2018) noted that while the exact mechanism of cerebral autoregulation is unclear, it can be 
explained by either the metabolic or myogenic hypotheses. According to metabolic hypothesis, blood 
flow and tissue metabolism are tightly bound in such a way that any reduction in CBF results in 
accumulation of vasodilator factors in the tissue.  However, according to the myogenic hypothesis, it is 
the intravascular pressure as a stimulus that causes the vasoconstriction.  A further possible mechanism 
of autoregulation involves the release of vasoactive factors such as nitric acid (an endothelium-derived 
relaxing factor), prostacyclin, and endothelium-derived hyperpolarizing factors, and under 
pathophysiological conditions, endothelium can produce endothelin, a potent contracting factor (Faraci 
& Heistad, 1998). 
According to Chen et al. (2017b), the change to the vasodilatory response may be due to aberrant local 
perfusion changes induced by frequent hypoxic episodes, blood pressure surges, cerebral autoregulation 
failure or endothelial changes because of epigenetic processes.  This conclusion is in line with Maresky 
et al. (2019) who proposed that the reduced cerebral perfusion was the result of persistent state of 
oxygen deprivation damaging cerebral vasculature and loss of autoregulatory mechanisms.  However, 
Reichmuth et al. (2009) attributed the change to increased sympathetic nerve activity as did Macey 
(2015).  In a review of cerebral perfusion and sympathetic tone, M. ter Laan et al. (2013) concluded 
that the sympathetic nervous system had a significant role in regulating cerebral perfusion during 
severely challenging circumstances. This conclusion is consistent with a number of other studies that 
have linked OSA with sympathetic hyperactivity and inflammation of vascular beds (Daulatzai, 2015; 
Dematteis et al., 2008; Idiaquez et al., 2014; Iturriaga & Idiaquez, 2014; Kato et al., 2000; Somers et 
al., 1995; Winklewski & Frydrychowski, 2013; Zwillich, 1998), because of systemic hypertension 
(Daulatzai, 2015; Kato et al., 2000), and autonomic dysfunction (Somers et al., 1995; Zwillich, 1998), 
including endothelial dysfunction, hypoperfusion, glucose dyshomeostasis, inflammation, oxidative 
stress, and neurotoxicity (Daulatzai, 2015); all of which are consistent with the previously noted 
observations of Chen et al. (2017b) and Maresky et al. (2019).  In addition, Narkiewicz and Somers 
(1997); (2003) concluded from their review that this sympathetic nerve response to hypoxia and 
hypercapnoea, carries over into the wakefulness period, albeit they were unable to explain why.   
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2.6 Impact of OSA on cerebral perfusion during wakefulness 
2.6.1 OSA and Cerebrovascular homeostasis 
A central question relevant to the current study is: Does OSA influence cerebral vascular homeostasis 
during the wakefulness period?  There are two offshoots to this question based on global cerebral 
perfusion or regional cerebral perfusion.  Global cerebral perfusion regulation is dominated by pressure 
and chemical drives, with the autonomic nervous system also playing a role through the extensive 
sympathetic enervation of the cerebral vasculature (Gulbenkian et al., 2001; Macey, 2015).  Regional 
cerebral perfusion on the other hand, is closely linked to changes in neuronal activity (Macey, 2015).   
Although the links between severe sleep apnoea and impaired regional cerebral perfusion during sleep 
are well established (Chen et al., 2017b), those links, whilst awake are not well understood and only a 
few studies have addressed this important question (Baril et al., 2020; Beaudin et al., 2019; Beaudin et 
al., 2017; Castello‐Branco et al., 2020; Innes et al., 2015; Ponsaing et al., 2018; Shiota et al., 2014).  
Moreover, even fewer studies have addressed the impact of OSA on global cerebral perfusion.  A search 
of Embase using as key words “OSA and global cerebral perfusion”, “Obstructive Sleep Apnoea and 
global cerebral perfusion” and “Sleep apnea and global cerebral perfusion” revealed only two relevant 
entries (Jensen et al., 2018; Macey, 2015).   
The study by Jensen et al. (2018) concluded that OSA does impact global cerebral perfusion during 
induced hypoxemia.  They found that: (1) hypoxia increased global cerebral perfusion in controls, but 
not in OSA patients, and (2) CPAP treatment normalised global cerebral perfusion response to hypoxia 
similar to controls.  The other entry by Macey (2015) is a commentary covering the drivers of global 
cerebral perfusion that he records as high sympathetic tone, reduced metabolic demand that he suggests 
dominate over elevated PaCO2. 
But, with respect to regional cerebral perfusion, several researchers have explored the relationship 
between sleep apnoea and an impaired cerebral perfusion while awake.  Meyer et al. (1987) used two 
processes – Xenon-133 inhalation method, and the stable Xenon computerized tomography – to 
demonstrate that patients with severe sleep apnoea had reduced cerebral perfusion in grey and white 
matter during both sleep and while awake.  More recently, Joo et al. (2007) Baril et al. (2015); Innes et 
al. (2015), Nie et al. (2017), Shiota et al. (2014) Yadav et al. (2013) and Chen et al. (2017b) also found 
that OSA impacted regional cerebral perfusion during wakefulness.  This despite the majority of people 
with OSA being able to breathe normally while awake and being capable of precise ventilatory control 
with little variation from the norm (Dempsey et al., 2010).  Joo et al. in their single photon emission 
computerized tomography (SPECT) study of 27 patients with severe sleep apnoea, observed regional 
cerebral perfusion patterns were altered compared to the flow patterns of their non-apnoeic controls.  
Baril et al. (2015), also using SPECT imaging, detected decreased regional cerebral perfusion in the 
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grey matter of people with severe sleep apnoea but not in people with mild or moderate sleep apnoea 
(See also Shiota et al., 2014).  Nie et al. (2017), likewise found regional cerebral perfusion was reduced 
in patients with severe sleep apnoea, but in their study, they used arterial spin labelling, as did studies 
by Innes and colleagues (2015), and Chen et al. (2017b).  Innes et al. (2015) found regional cerebral 
perfusion was decreased in their cohort of participants with either moderate or severe sleep apnoea 
when compared to their controls as did Chen and colleagues. The cerebral regions where blood flow 
was reduced are tabulated in Table 2-2.   
These results converge to the conclusion that regional cerebral perfusion whilst awake is decreased in 
people who have severe sleep apnoea.  Nonetheless, the question regarding the impact of moderate OSA 
on regional cerebral perfusion remains open.  The first study to definitively compare regional cerebral 
perfusion in people with moderate OSA was by Baril et al. (2015).  In their SPECT study, their cohort 
of 14 patients with moderate OSA did not differ with respect to regional cerebral perfusion from their 
controls (n = 20).  This they attribute to the AHI not being high enough to breach a threshold above 
which pathology would occur.  Otherwise, the only other studies to include people with moderate OSA 
were those by Chen et al. (2017b); Yadav et al. (2013) and Innes et al. (2015).  These three studies 
found regional cerebral perfusion was reduced in the apnoeic group when compared to the non-apnoeic 
group, but these results were in cohorts of both moderate and severe apnoeics, which obfuscates the 
effect of just moderate OSA on blood flow.   
Interestingly, although the studies by Innes et al., Chen et al., and Yadav et al. all used arterial spin 
labelling and found regional cerebral perfusion changes in their moderate/severe cohorts, the brain 
regions where the changes were found, differed (See Table 2-2 and Figure 2-5).  Nonetheless, a review 
of the regions where changes in cerebral perfusion did occur revealed that three of the seven studies 
reviewed, showed reduced cerebral perfusion in the parahippocampal gyrus.   Joo et al. (2007) and Nie 
et al. (2017) both found reduced cerebral perfusion bilaterally, while Innes et al. (2015) found reduced 
cerebral perfusion unilaterally in the right hemisphere. 
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Table 2-3.  Studies and their level of OSA severity, impact on cerebro homeostasis and cerebral regions 
where cerebral perfusion was reduced. 
Study  Scan 
type 
OSA severity Affected cerebral regions 
Joo et al.  
(2007) 
SPECT Severe Bilaterally in the parahippocampal gyri. 
Unilaterally in the left lingual gyrus. 
Yadav et al. 
(2013) 
ASL Moderate/severe Bilaterally near the corticospinal tracts, 
pontocerebellar fibres, and superior cerebellar 
peduncles. 
Unilaterally in the right medial lemniscus, right 
midbrain, right red nucleus, and left dorsal fornix/stria 
terminalis, left inferior cerebellar peduncle, and left 
tapetum. 
Shiota et al. 
(2014) 
SPECT Severe Bilaterally in the right middle and superior frontal 
gyri.   
Baril et al 
(2015) 
SPECT Moderate and 
severe 
In the severe cohort only: Bilaterally in the post-
central gyri.  Unilaterally in the left inferior parietal 
lobules (supra marginal gyrus), and right praecuneus.   
Mild and moderate OSA groups showed no 
differences in regional cerebral perfusion compared to 
controls. 
Innes et al 
(2015) 
ASL  Moderate/severe Bilaterally in the cingulate gyri, paracingulate gyri, 
and in the subcallosal cortex.   
Unilaterally in the left frontal cortex, left putamen, 
right hippocampus, right parahippocampal gyrus, right 
temporal fusiform cortex, and right thalamus. 
Nie et al  
(2017) 
ASL Severe Bilaterally in the parahippocampal gyri. 
Unilaterally in the left cerebellum posterior lobe, left 
medial frontal gyrus and left temporal lobe. 
Chen et al. 
(2017b) 
ASL Moderate/severe Right putamen/insula, right cerebellum, left thalamus, 
right caudate, right medial, superior and inferior 
frontal gyrus, right superior temporal gyrus, right 
fusiform gyrus, left and right cingulate gyrus 
ASL: Arterial spin labelling magnetic resonance imaging, BOLD: Blood oxygen level dependent 
functional magnetic resonance imaging, SPECT: Single photon emission computed tomography. (Baril 
et al., 2015; Innes et al., 2015; Nie et al., 2017; Shiota et al., 2014; Yadav et al., 2013). 
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In conclusion, there is evidence that sleep apnoea has an impact on cerebral perfusion, not only during 
hypercapnoea/hypoxia events, but also during the wakefulness period, thereby reducing perfusion.  
Although some studies consisting of both moderate and severe sleep apnoea, along with those consisting 
of severe apnoeics demonstrated reduced regional cerebral perfusion, the one study that measured 
regional cerebral perfusion in a cohort of Moderate OSA, did not.  This raised questions of 
methodological weaknesses, first, although all studies reviewed found cerebral perfusion alterations 
attributable to sleep apnoea, the cause remains elusive (Cipolla, 2009; Durgan & Bryan, 2012; Urbano 
et al., 2008).  Second, no common cerebral region impacted by reduced cerebral perfusion has been 
described.  Even studies that used the same method of MRI arterial spin labelling, no common cerebral 
region was found. 
2.7 Cerebral perfusion and cognition 
Alterations in cerebral perfusion are acknowledged as important contributors to the cognitive 
dysfunction seen in some people with OSA (Jafari, 2018; Leeuwis et al., 2018; Prilipko et al., 2012; 
Sforza, 2012; Tarumi et al., 2015; Wolters et al., 2017).   For example, Chen et al. (2017b), reported an 
association between intracranial regional perfusion changes, systemic inflammation and impaired 
cognitive functioning in patients with OSA (40 ± 8 years).  Wolters et al. (2017) also found that 
hypoperfusion was associated with accelerated cognitive decline and an increased risk of dementia, an 
association they attributed to hypoxia in older adults (median age 61 years) without OSA.  Leeuwis et 
al. (2018) tested memory, executive functioning attention and language, and found a positive correlation 
between cerebral perfusion and executive functioning, attention, and memory in older adults (mean age 
71 years) also without OSA.  Furthermore, Tarumi et al. (2015) in a study of non-apnoeic adults (65 ± 
6 years).and Prilipko et al. (2014) in their study of patients (43 ± 8 years) with moderate and severe 
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 Figure 2-5.  Perfusion regions identified by the following colour coded studies: 
More specifically, Joo et al. (2007) concluded that the memory, spatial learning, executive functioning 
and attention deficits, observed in people with OSA could be explained by altered regional cerebral 
perfusion patterns in the bilateral parahippocampal gyri, right lingual gyrus, pericentral gyrus, and 
cuneus.  In addition, Chao et al. (2010) noted that reduced cerebral perfusion, particularly in the right 
precuneus, right inferior parietal cortex, right middle cingulum and right middle frontal cortex, was 
related to the progression of cognitive impairment in people without OSA. Alosco et al. (2013) in their 
study, not only noted that cerebral perfusion contributed to poorer cognitive function, particularly on 
tests of memory, and attention/executive function, they also found a specific association between 
cerebral perfusion of the frontal lobe and performance on a test of executive function.  This is an 
observation supported by Sforza (2012) who concluded that the frontal lobe is more vulnerable to 
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apoptosis because of hypoxemia than to excessive daytime sleepiness and sleep fragmentation, 
conditions more like to result in attention deficits. 
None of the aforementioned studies, however, demonstrated cause and effect, only an association 
between perfusion and cognition. 
Several studies have addressed possible reasons for the association between cerebral perfusion and 
cognition.  Daulatzai (2012) in discussing OSA and cognitive dysfunction noted that impaired oxygen 
delivery could result in altered neuronal homeostasis, induced pathology, and neuronal degeneration 
and death.  Gozal et al. (2001) found that two days of intermittent hypoxia was sufficient to impair 
spatial memory in rats.  Emamian et al. (2016) following their meta-analysis concluded that progressive 
changes in sleep quality and structure, changes in blood flow, changes in neurovascular and 
neurotransmitter cellular redox status and changes in neural regulation are contributing factors.  Other 
studies have attributed the pathogenesis of cognitive impairment to endothelial dysfunction (Hughes et 
al., 2013; Kelleher & Soiza, 2013; Vendemiale et al., 2013).  Yet Obasi et al. (2012) found no 
association between inflammation and endothelial dysfunction with cognition. 
2.7.1 The neuropsychological sequelae of obstructive sleep apnoea 
There is little doubt that severe OSA has a negative impact on cognition (Aaronson et al., 2014; Aloia 
& Arnedt, 2012; Beebe et al., 2003; Bucks et al., 2013; Chen et al., 2011; Idiaquez et al., 2014; Kylstra 
et al., 2013; Wen et al., 2012), with attention, vigilance, memory, and executive functioning, along with 
quality-of-life measures being affected (Sforza, 2012; Vaessen et al., 2015).  Yet, despite a plethora of 
quantitative empirical studies, including meta-reviews that have attempted to collate and summarize the 
neurobehavioural consequences of adult OSA, it remains difficult to determine the exact aetiology of 
the syndrome because of data heterogeneity.  While in part this may be reflective of the inherent nature 
of OSA, methodological issues are also a significant factor behind this.  For example, the various studies 
investigating the neurobehaviour of those with OSA have often focused on different cognitive domains 
that are frequently not uniformly defined or have used a variety of different methodologies (Bucks et 
al., 2013; Tsai, 2010).   
Nevertheless, phenomenological reports of cognitive dysfunction by people with OSA have in general 
been echoed in the empirical literature where it is widely accepted that severe OSA contributes to 
cognitive impairment (Bucks et al., 2013), mood disorders, and daytime sleepiness (Olaithe et al., 
2015a).  More specifically, reviews by Aloia et al. (2004); Beebe et al. (2003); Bucks et al. (2013); 
Fulda and Schulz (2003); Olaithe and Bucks (2013); (Sales et al., 2013); Wallace and Bucks (2013) 
collectively support the position that vigilance, executive functioning including working memory, and 
both delayed long-term verbal and visual memory are adversely impacted by OSA.  Most studies also 
found that language and psychomotor capabilities were not impaired, although the data for global 
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cognitive functioning, immediate long-term verbal and visuospatial memory, short-term memory, and 
visuospatial construction were equivocal.  This conclusion is summarized in Table 2-3, which collates 
a number of studies that have investigated the impact of OSA on cognition.  This table is substantially 
based on the meta-analysis undertaken by Bucks et al. (2013) to which has been added two subsequent 
studies (Olaithe & Bucks, 2013; Sales et al., 2013), both considered to meet the original inclusion 
criteria of Bucks et al. 
Nonetheless, while the conclusions reached above are reflective of most studies, the extant literature is 
still debating the presence and extent of those cognitive changes.  In particular, questions remain about 
the contribution of cognitive reserve, co-morbidities, the individual roles of excessive daytime 
sleepiness versus hypoxaemia, the impact of OSA severity, and the effects of OSA treatment (Lim & 
Veasey, 2010; Lim & Dinges, 2010; Sforza, 2012; Yaffe et al., 2011). 
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Table 2-4.  Effects of OSA on the domains of neurocognitive function. 
 OSA comparison studies (with norms or controls)  
   Meta-analysis Systemic reviews Number of comparisons with 



















Attention/Vigilance   C+ C+ NA NA C+ C+ NA 4/4 
Executive function   C+ C+, 
N+ 
NA C+ C+ C+ C+ 7/7 
 Working 
memory a 
 C- C+, 
N+ 
NA C+ NA C+ C+ 5/6 
Global cognitive 
functioning 
  C+ C-, N+ NA NA C- NA NA 2/4 
Language   C+ C-, N+ NA NA C- NA C- 2/5 
Memory Short-term  C- NA NA NA NA NA C+ 1/2 
 Immediate Verbal C- C-, N- C+, N+ NA NA C+ NA 3/6 
 long-term Visual C- C+, N- C-, N+ NA NA C- NA 2/6 
 memory Visuo-
spatial 
NA NA C+, N- NA NA NA NA 1/2 
 Delayed Verbal C+ C-, N+ C+, N- NA C+ C+ NA 5/7 
 long-term Visual C+ C+, N- NA NA C+ C+ NA 4/5 
 memory Visuo-
spatial 
NA NA C-, N- NA NA NA NA 0/2 
Psychomotor function   C- C+, N- NA NA C+ NA C- 2/5 
Visuospatial/construction   C- C+, N- NA NA C+ C- C+ 3/6 
Note.  NA indicates that this domain was not assessed in the review.  C+ indicates that on balance the authors considered that the OSA group was impaired 
when compared to controls.  C- indicates no difference between OSA group and controls.  N+ indicates that the OSA group was impaired when compared to 
normative data.  Conversely N- indicates it was considered that no difference existed between OSA and normative data.  a Although not reported separately by 
Bucks et al, working memory comparisons were able to be extracted from Beebe et al. (2003) and (Olaithe & Bucks, 2013).  (Table and data substantially came 
from Bucks, R.S., Olaithe, M., and Eastwood, P. (2013).
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2.8 The selection and use of neuropsychological tests 
2.8.1 Neurocognitive testing 
The results from neuropsychological tests administered to adult patients with OSA have demonstrated 
that inter-individual variability is complex and far from being straightforward (Aloia et al., 2004; 
Decary et al., 2000; Denotti et al., 2009; Sforza, 2012).  For example, from the review by Aloia of 37 
studies published between 1985 and 2002, impairment was found in only 3 of the 7 studies that tested 
global cognition, 6 of the 8 papers that tested attention and vigilance, 6 of the 9 that tested executive 
functioning, 7 of the 11 that tested memory, 4 of the 5 that tested construction and 4 of the 5 that tested 
psychomotor speed showed impairment. 
These mixed results, which are in part credited to methodological factors (Beebe et al., 2003), limit our 
ability to coalesce the OSA literature into a common theory and to develop a clear understanding of its 
sequalae (Aloia et al., 2004).  Those methodological concerns are addressed in the following sections. 
2.8.2 A review of cognitive test batteries for OSA 
A review of the literature revealed that there is no standardized test battery for the neuropsychological 
evaluation of OSA patients despite efforts otherwise (Bucks et al., 2013; Decary et al., 2000), and hence 
each selection must be rationalised.  There is also an inconsistent use of cognitive tests (Bardwell et al., 
2001; Bucks et al., 2013; Tsai, 2010), with different tests used to test the same cognitive function.  
Moreover, different researchers use the same tests to test different cognitive functions.  This makes 
comparison of test results between studies difficult.  This limits the ability to cross reference studies.   
The origin of the tests also brings into question their ecological validity that is, the generalisation of 
results to real life circumstances (Coolican, 2005). The ecological validity of objective measures of 
cognition is, according to Vaessen et al. (2015) notoriously low (see also, Burgess et al., 1998; Chaytor 
& Schmitter-Edgecombe, 2003).  Furthermore, most tests that have been used in OSA studies were not 
constructed to assess the apparent subtle effects of OSA, placing further doubt on their validity.  It has 
been assumed that the neuropsychological tests have sufficient sensitivity and specificity to identify the 
specific and discrete patterns of the neurobehaviour correlates of OSA (Antic et al., 2011; Quan et al., 
2006).  Moreover, objective cognitive functioning often correlates poorly with cognitive complaints 
and QOL measures (Daurat et al., 2010). 
Neuropsychological tests are sensitive to cognitive reserves (Lezak et al., 2004; Olaithe et al., 2015a; 
Tsai, 2010), yet cognitive reserves are not consistently recorded.  Cognitive reserve has been proposed 
as an important buffer of the impact of brain pathology on cognitive functioning (Reed et al., 2010).  
For example, in a case-controlled study of 46 patients with OSA and 36 normal controls who undertook 
the Raven’s progressive matrices intelligence test, high-intelligence OSA patients were no different to 
29 
 
high-intelligence controls in tests of attention and alertness; whereas OSA patients of mid-range 
intelligence were impaired  compared to mid-range-intelligence controls (Tsai, 2010).  Finally, not all 
studies have accounted for test-retest reliability (Aloia et al., 2004), which can result in the inappropriate 
interpretation of some tests.   
2.8.2.1 OSA severity criteria 
Inconsistent use of OSA severity criteria was identified by Aloia et al. (2004) who commented that it 
was a critical factor when reviewing the effects of OSA on cognition. While OSA severity is mostly 
measured by the AHI, some studies have only counted apnoeas (Aloia et al., 2004) while others have 
used the respiratory disturbance index (RDI) which has been used interchangeably with the AHI 
(Weaver & George, 2011). This is problematic as the RDI also includes, in addition to apnoeas and 
hypopnoeas, other respiratory effort-related arousals (Tsara et al., 2009). Moreover, not all studies have 
used the generally accepted OSA severity scale of normal ≤ 5, mild 5–14, moderate 15–29, severe ≥ 30 
(Verstraeten, 2007).  Another confounding factor was that the 1999 Chicago criteria used to identify 
OSA was changed in 2007 and became slightly more restrictive.  A further change to the criteria was 
made in 2012.  Although the impact of those changes was small, they nonetheless weaken between-
study comparisons.  Lastly, improvements have been made to the sensitivity of polysomnography 
recording equipment in recent years, which impacts comparisons with earlier results (Heinzer et al., 
2015). 
It is also possible that the AHI may, by itself, be insufficient to identify clinically significant cases.  
Clear evidence of a relationship between the severity of OSA as indexed by the AHI and the severity 
of mood and cognitive functioning has yet to be established (Bucks et al., 2013). Bucks et al.’s 
conclusion converges with an observation by Saunamaki and Jehkonen (2007) that although cognitive 
impairment usually worsens with disease severity, the relationship is not linear.  
2.8.2.2 Recruitment and method of controlling demographic factors 
This was another area criticized by Aloia and colleagues who noted that a lack of control over 
demographic factors make it difficult for cross-over studies.  Their concern is backed up by the 
inconsistent use of matched controls. Many studies used adjusted published norms while others used 
comparison groups and others used placebo groups (Saunamaki & Jehkonen, 2007) but, as noted by 
Tsai (2010), they are not necessarily comparable (Beebe et al., 2003).  
Another problematic area is in the recruitment of comparison groups.  In some studies, they were 
recruited from clinical referrals, whereas in other studies they were recruited from the general public. 
The results of cognitive tests from participants recruited from referrals are not necessarily consistent 
with those randomly selected from the wider public because of clinical factors, despite having the same 
severity rating based on AHI scores (Bardwell et al., 2001; Engleman & Douglas, 2004; Weaver & 
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George, 2011).  Many studies do not factor out comorbidities, such as for example, depression, anxiety, 
diabetes, and obesity.  It is commonsensical when carrying out neuropsychological testing that a patient 
with comorbid depression, for example, should not be assumed to be comparable to a patient without 
depression, albeit that they could have the same AHI score.  
Finally, it was noted by Beebe (2005) that the small sample sizes in many studies limits statistical power 
and risk Type II false negative errors being made. 
2.8.2.3 Treatment interval and compliance 
This was a further concern raised by Aloia et al.  In their review, only 11 of 17 CPAP treatment studies 
measured compliance levels (see also Kylstra et al., 2013) and only four studies examined the impact 
of compliance on cognition.   Intervention periods also varied between studies with a range of one week 
(Bardwell et al., 2001) to 12 months or more (Munoz et al., 2000).  Although individual compliance 
varied widely in the later study (from 0.4 to 10.95 h per night) it does not appear that anyone was 
excluded from the study because of it.  In the face of mounting evidence that treatment outcomes are 
correlated to compliance levels, it is important that compliance patterns are clearly enunciated and 
included in analysis (Aloia et al., 2004; Weaver & Grunstein, 2008). 
Some of these methodological concerns are specific to OSA research, while others apply across most 
research (i.e., sample size, inappropriate use of tests, failure to account for co-founding factors such as 
comorbidities and cognitive reserves, poor demographic records, disparate metrics and measures, acting 
in ignorance of standards and norms, etc.).  On the other hand, there are methodological issues that are 
more specific to OSA research, such as the lack of specific neuropsychological tests and overall 
acceptable test battery.  In addition, there is the additional problem of having to place reliance on the 
AHI to measure OSA severity that by itself seems incapable of consistently separating clinical patient 
groups.  Fortunately, at the individual study level, most of the concerns noted above are manageable 
using sound research practices. 
2.8.3 Tests for the neuropsychological testing of obstructive sleep apnoeics 
Building a test battery for the cognitive testing of OSA is an important project.  Listed below is a review 
of the cognitive tests identified in the literature to assess the five cognitive domains associated with 
OSA.  These five cognitive domains are: 
2.8.3.1 Attention and concentration 
Attention is a multifaceted domain involving concentration, divided attention, vigilance or sustained 
attention, and alertness with deficits in vigilance, attention, and psychomotor speed most consistently 
reported as impaired in OSA.  Moreover, there appears to be a dose-response effect with higher AHI 
scores associated with worse cognitive outcomes.  Nonetheless, although most studies of Moderate 
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OSA patients find impaired performance on at least one measure of attention, studies examining focused 
and divided attention performance have yielded mixed results (Jackson et al., 2011a). 
Typical tests of attention and concentration are: 
• Psychomotor Vigilance Test (PVT) – The traditional version of the PVT takes 10 mins to run 
and is often used in sleep studies as a measure of sustained attention.  It is reported as being 
sensitive to sleepiness and the effects of OSA and treatment (Wilde et al., 2007).  The PVT 
provides two measures: errors of omission and errors of commission.  
• Stroop Test – The Stroop test is a popular neuropsychological measure, particularly of 
concentration effectiveness.  It is available in a number of formats although the Dodrill version 
is the one recommended by Lezak et al. (2004). Only two trials are needed for the colour-word 
interference to manifest; also because it is the longest version it is considered to be the most 
sensitive (Lezak et al., 2004).  Test-retest reliability is reported as high for reaction times 
obtained during the card version (Strauss et al., 2005). 
• Trail Making Test (TMT) – The TMT is widely used as an easily administered 
neuropsychological measure of scanning and visuomotor tracking, divided attention, and 
cognitive flexibility.  The TMT is sensitive to a number of neurocognitive impairments and 
processes (Tombaugh, 2004).  The test is administered in two parts, A and B.  Part A is typically 
used as a measure of attention while Part B is used as a measure of executive functioning (Bauer 
et al., 2012).  Test-retest reliability for Part A is estimated at 0.78 (Cangoz et al., 2009). 
• Wechsler Adult Intelligence Scale Digit Span subtest (WAIS Digit Span) – The WAIS Digit 
Span is a popular neuropsychological measure reported in 17 out of the 21 studies reviewed.  
Although the WAIS Digit Span has a strong short-term memory component,  Lezak et al. (2004) 
consider it to be more strongly associated with attention.  There are two variants of the digit 
span: Digit Span forwards and Digit Span backwards.  While both have an attentional 
component and both depend on short-term memory, each involves different mental activities 
and each is differently affect by brain damage (Lezak et al., 2004).  Digit span is minimally 
impacted by age.  Test-retest reliability coefficients range from .66 to .89 depending on interval 
length and age (Lezak et al., 2004). 
2.8.3.2 Executive functioning 
Executive functioning is also multifaceted and complex (Aloia et al., 2004).  It includes: initiation, 
planning, purposive action, self-monitoring, self-regulation, and volition processes (Lezak et al., 2004).  
According to Saunamaki and Jehkonen (2007) (See also Engleman & Douglas, 2004), the most affected 
facets of executive functioning because of OSA are: working memory, phonological fluency, cognitive 
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flexibility, and planning.  Although Gagnon et al. (2014) suggests that all sub-domains of executive 
functioning are impaired, namely: inhibition, shifting, working memory, generating new information, 
and fluid reasoning, and problem solving 
Tests typically used to test executive functioning in OSA studies (Beebe & Gozal, 2002; Decary et al., 
2000; Gagnon et al., 2014; Saunamaki & Jehkonen, 2007) are: 
• Mazes – Maze tracing is a task designed to test planning and foresight skills and is sensitive to 
planning deficits.  It has also been reported as significantly correlating with physiological 
measures of frontal lobe dysfunction (Lezak et al., 2004).  Although the Porteus version can 
take as long as 15 min to complete, the WISC-R and the WISC-III both provide shorter and 
more easily administered versions that for most clinical purposes , according to Lezak et al. 
(2004), are a practicable and satisfactory substitute. 
• Raven Progressive Matrice – The Raven Progressive Matrice is a measure of reasoning skills.  
It has good test-retest reliability correlations in the range of .7 to .9.  However, its usefulness as 
a screen for brain damage is limited.  Can take up to 60 min to complete (Lezak et al., 2004). 
• Stroop Colour Word Test – Although primarily a test of attention and concentration (Lezak et 
al., 2004), it has been used as a measure of executive functioning because of the response 
inhibition element to the test (Olaithe & Bucks, 2013).   Furthermore, it is highly sensitive to 
frontal lobe lesions (Decary et al., 2000).   
• Tower of Hanoi/Toronto/London – All variants of the Towers test principally measure planning 
but also rely on working memory, response inhibition, and visuospatial memory for ideal 
performance (Lezak et al., 2004; Olaithe & Bucks, 2013).  Although very similar, the different 
tests do not measure exactly the same skills and the correlation between performance on the 
Tower of Hanoi and the Tower of London is low (r = .37) (Lezak et al., 2004)  Tower tests 
appear relatively robust to age and education differences up to 79 years.  However, participants 
older than 79 years are more impaired than those in their twenties and thirties. 
• Trail making Test B and B-A – The TMT Part B is used as a neuropsychological measure of 
executive functioning, particularly complex attention, planning, cognitive set shifting and 
response inhibition (Cangoz et al., 2009; Olaithe & Bucks, 2013).  It has a test-retest reliability 
estimated to be .67. 
• Verbal Fluency – Tests of verbal fluency measure organizational ability and in particular 
strategic thinking.  Age (over 70), education, and gender can influence performance. Test-retest 
reliability over an interval of 1 year for elderly persons was moderate to high (r = .7 to .71) for 
letters other than A which was lower (Lezak et al., 2004).   
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• Wechsler Adult Intelligence Scale Digit Span backwards subtest – This measure of 
neuropsychological functioning is a simple measure of mental tracking.  Mental tracking 
involves perception, and complex mental operations including scanning.  The Digits Backwards 
is reasonably robust to age.  It is sensitive to different brain disorders, but particularly, those 
originating in the left hemisphere due to frontal lobe damage (Lezak et al., 2004) 
• Wisconsin Card Sorting Task– Designed to measure abstract behaviour and shift of set, this 
neuropsychological measure has gained widespread popularity as a measure of frontal lobe 
functioning.  Nonetheless, Lezak cautions against using it in longitudinal studies because once 
solved, it becomes a measure of long-term memory (Lezak et al., 2004).  Furthermore, the 
WCST has been measured against the TMT Part B and found to be a less sensitive measure of 
cognitive flexibility and ability to maintain set (Bauer et al., 2012) 
2.8.3.3 Memory  
Results are mixed for the impact of OSA on verbal memory.  While Beebe and Gozal (2002) found no 
significant effect of OSA, this was in contrast to Wallace and Bucks (2013) who found that the ability 
to recall verbal information immediately after presentation is impaired in individuals with OSA 
compared to both controls without OSA and cognitive normative data.  Wallace and Bucks (2013) 
suggested that this may be due to methodological reasons involving the separation of verbal memory 
from short term memory, verbal learning, and cued recall, and because of the larger number of studies 
included in their review.    
Salorio et al. (2002) evaluated 28 adults with OSA and 24 controls aged from 28 to 60 year using the 
California verbal learning test.  The results indicate that the controls recalled more words than those 
with OSA during the first five trials indicating better word retention.  However, delayed recall and 
recognition trials remained intact.  This suggests that encoding rather than maintenance deficits are 
associated with OSA.  The importance of differentiating between recall and recognition was highlighted 
by Decary et al. (2000) who observed that recognition can be preserved in patients with frontal lobe 
dysfunction. 
Typical tests of verbal memory and learning include:  
• Rey Auditory-Verbal Learning Test (AVLT) – This test is sensitive to the effects of age over 
70 and gender.  However, it has good test-retest reliability with correlations ranging from .61 
to .86 during a one-month interval.  It has proven useful in delineating memory system deficits 




• California Verbal Learning Test (CVLT) – This test procedure is like the AVLT and is sensitive 
to age and gender.  It also has after a 21-day interval a good test-retest reliability coefficient of 
.82 for Total Trials albeit that Total Learning Slope and Total Repetitions were considerably 
lower (27 and 30 respectively).  It can differentiate between recall and recognition. 
• Hopkins Verbal Learning Test Revised (HVLT-R) – This is a shorter version of the CVLT and 
is similarly sensitive to age and gender.  It is easy to administer and score and is well tolerated 
(Lezak et al., 2004).  Its test-retest reliability is like CVLT with low coefficients for some facets 
of the test.  Nonetheless, this is still an ideal test for longitudinal studies as there are six 
alternative interchangeable forms available (Benedict et al., 1998).  However, Benedict et al. 
provide a note of caution; the HVLT-R may lack sufficient difficulty to discriminate young 
impaired adults from healthy adults.  Although the original HVLT lacked a delayed recall trial, 
the revised version proposed by Benedict et al. does. 
2.8.3.4 Visual Memory and Learning 
The impact of OSA on visual memory and learning are mixed.  Bucks et al. (2013) reported that the 
impact of OSA on short-term visual memory is equivocal, with one study finding impairment but the 
other not.  The results for long-term visual memory were also equivocal.  Four reviews found OSA 
impacted delayed visual long-term memory, but none found OSA had impacted immediate visual long-
term memory.  Nonetheless, 15 of 22 studies in this review measured visual memory and learning 
capability. 
Tests typically used to measure visual memory and learning are: 
• The Rey Osterreith Complex figure (Rey-O) – This popular test is sensitive to mild 
neuropsychological impairment in a variety of clinical populations.  Participants are first asked 
to copy the figure and then, 3 or 30 mins later, they are asked without warning to recall as many 
elements of the figure as they can.  Although an early age effect was evident for the 30-minute 
delayed recall, the age effect in the three- min delay recall scores did not become pronounced 
until the participants were in their mid-sixties.  Gender differences appear not to exist (Lezak 
et al., 2004).  Decary et al. (2000) reported that the Rey-O has a moderate test-retest reliability 
coefficient of 0.6.  Unfortunately, the test-retest interval was not reported.  Small (.21) to 
moderately large (0.7) effect sizes were obtained.  In a small study of 35 TBI patients (Wilde 
et al., 2007), a small effect (0.21) was obtained in the copy sub-test while a greater effect of (-
0.70) was found for the 30-min recall sub-test.  These results converge with those of Sales et 
al. (2013) who found differences between OSA participants and controls for immediate and 
delayed recall, but not for copy. 
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• Corsi Block-tapping Test – This is a neuropsychological test of visual memory.  The test 
consists of nine black blocks fixed randomly to a board.  The participant must copy the order 
in which the examiner taps the blocks.  Age effects are not apparent until after 60 when they 
become increasingly pronounced.  Gender differences appear to slightly favour men over 
women.  Moreover, education contributes to performance (Lezak et al., 2004).  Castronovo et 
al. (2014) found differences between OSA and controls at baseline and again at 3-months and 
1 year. 
2.9 Quality-of-life measures and OSA 
OSA has been found to reduce quality-of-life, marital harmony, work performance, health expenditure, 
and reduced participation in everyday activities (Engleman & Douglas, 2004; Vaessen et al., 2015), 
even when age and weight have been taken into account (Weaver & George, 2011).  OSA has also been 
found to contribute to a reduction in physical activity, which in turn, influences subjective ratings of 
impaired sleep, energy, and emotional lability (Verwimp et al., 2013).   Moreover, Dutt et al. (2013) 
assessed quality-of-life using the Sleep Apnoea Quality-of-life Index with 69 apnoeic people and 41 
healthy controls and found the apnoeic group had worse experiences across all four Sleep Apnoea 
Quality-of-life Index domains – daily function, social interaction, emotion and symptoms. Vaessen et 
al. (2015) undertook a systematic review of subjective measures of cognition and found concentration 
was commonly impaired as they suspected were memory and executive functioning, but a lack of a 
validated cognitive complaints questionnaire prevented firm conclusions being reached. 
Vaessen et al. (2015) also noted that the more people with OSA complain about sleepiness, the more 
likely they are to also complain about problems with attention, memory, and executive dysfunction (see 
also Tsai, 2010).  This conclusion aligns with a review by Weaver and George (2011) who reported that 
approximately 80% of people with OSA complain of both excessive daytime sleepiness and cognitive 
impairments and 50% have reported personality changes.  
Although the link between OSA and quality-of-life measures appears strong, the link between the 
severity of subjective cognitive complaints and degree of cognitive functioning, measured objectively, 
may at best be weak (Barbagelata-Aguero & Vizcarra-Escobar, 2013; Dutt et al., 2013; Iacono et al., 
2013; Vaessen et al., 2015; Verwimp et al., 2013; Weaver & George, 2011).  For example, Chen et al. 
(2012) found no significant correlation between objective severity measures of attention, memory, and 
executive function with subjective severity ratings of attention, vigilance, memory, learning, abstract 
thinking, problem solving, emotional control, and motivation.  This led them to conclude that people 
with OSA may not fully appreciate the degree to which they are cognitively impaired, especially that 
which relates to executive functioning.  This conclusion converges with those of Barbagelata-Aguero 
and Vizcarra-Escobar (2013) Dutt et al. (2013) and Iacono et al. (2013) who all independently noted 
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that a reduced health related Quality-of-life perception was evident across all ages in those with OSA, 
particularly in the older population, and that it did not necessarily correlate with OSA severity.  
Misperception of impairment is also supported by an observation of Vaessen et al. (2015) that cognitive 
complaints are likely to persist after successful CPAP treatment.  Taken together, these findings suggest 
that the complaints are more an indication of psychological distress and do not necessarily reflect 
clinical symptoms.   
Not surprisingly, subjective cognitive complaints have been shown to influence treatment compliance 
(Olsen et al., 2008; Wells et al., 2007) and have been linked to health services expenditure (Greenberg-
Dotan et al., 2007).  Importantly, quality-of-life measures have been shown to be sensitive to the effects 
of CPAP treatment.  Avlonitou et al. (2012) measured the quality-of-life status of 50 OSA patients (9 
women and 41 men) before and after six months of CPAP treatment using the Sleep Apnoea Quality-
of-life Index.  They were initially diagnosed using overnight polysomnography as being mildly, 
moderately, or severely apnoeic, based on conventional criteria.  Compliance was monitored 
electronically and over the six months, CPAP mean usage was 4.5±0.5 h per night.  Sleepiness was 
measured using the Epworth Sleepiness Scale, which showed a decrease over the six months.  
Furthermore, a comparison between quality-of-life indexes before and after CPAP treatment showed 
improvements in Sleep Apnoea Quality-of-life Index scores across all four domains – daily functioning, 
social interactions, emotional functioning and symptoms – regardless of severity and gender.  Similarly, 
an earlier study, by Smith and Shneerson (1995), used the SF-36 to measure quality-of-life pre and post 
six months CPAP treatment and found it to be sensitive to the effects of sleep disruption in people with 
OSA and a useful measure of treatment outcome.  
Overall, using quality-of-life instruments to profile the experiences of people with OSA does provide a 
useful patient perspective that is mostly reflective of objectively measured symptomology.  There is an 
important exception however, while cognitive complaints may acknowledge the existence of cognitive 
dysfunction, they do not necessarily align with performance levels.  Quality-of-life measures have been 
shown to influence health outcomes and to be sensitive to treatment effects.  Thus, despite quality-of-
life measures being exposed to criticism for reporting on what seems to be the matter, rather than what 
is, they can be an important and useful measure of patient experience. 
Quality-of-life, Health-related Quality-of-life, and Functional Status Questionnaires are oft-used 
instruments in the assessment of OSA, yet all three focus differently.  Whereas Quality-of-life is a 
measure of everyday living, incorporating elements of material and physical wellbeing; relationships 
with other people; social, community, and civic activities; personal development and fulfilment; and 
recreation (Burckhardt & Anderson, 2003), Health-related Quality-of-life is illness centric, with a focus 
on the domains affected by the illness.  On the other hand, the Functional Status Questionnaire 
characterizes a person’s capacity to fulfil life’s current roles.   
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According to (Weaver & George, 2011), these measures can be further categorized as either generic or 
disease specific.  Disease -specific measures of OSA include the Functional Outcomes of Sleep 
Questionnaire (Weaver et al., 1997) and its shorter version (Chasens et al., 2009), Calgary Sleep Apnoea 
Quality-of-life Index  (Flemons & Reimer, 1998), and OSA Patient-Oriented Severity Index.  However, 
as instruments incorporating disease-specific measures have only recently been constructed, much 
research has used the Medical Outcomes Study Short Form 36 (e.g., Canessa et al., 2011) or the 
Nottingham Health Profile (Engleman & Douglas, 2004).  The Medical Outcomes Study Short Form 
36  measures: physical functioning, mental health, psychological distress, psychological wellbeing, role 
functioning, social functioning, health perceptions, pain, and vitality (Ware & Sherbourne, 1992) and 
therefore can be considered a Health-related Quality-of-life measure.  Similarly, the Nottingham Health 
Profile also measures health factors – i.e. pain, energy, sleep, mobility, emotional reaction, and social 
isolation – and general living factors, which deal with problems regarding occupation, housework, 
social life, family life, sexual function, hobbies, and holidays (McDowell, 2006). 
2.10 Microsleeps and OSA 
The maintenance of alertness is important during many daily activities, sometimes being the difference 
between a safe conclusion to a task or not.  Consequently, reducing or eliminating microsleeps during 
continuous real-life tasks, such as driving, may improve safety.  Moreover, according to Poudel et al. 
(2018), sleep deprivation increases the propensity to microsleep.  Therefore, understanding the impact 
of OSA on microsleep is important, yet a search of Embase found only one paper has addressed this 
important question (Morrone et al., 2020). 
2.10.1 Behavioural Characteristics 
Microsleeps have been variously described.  Beck et al. (2010) used the term to refer to short periods 
of sleepiness or sleep between 15–30 s.  Anderson et al. (2010) referred to any lapse in responsiveness  
with eyes closed as a microsleeps whereas a lapse with eyes open is either visual attention or distraction. 
Levitt (1967) referred to microsleeps as short periods of slow-wave sleep.  Attempts have also been 
made to define microsleeps using strict EEG spectral changes regardless of other overt behavioural 
indications (Harrison & Horne, 1996; Lim & Dinges, 2008; Peiris et al., 2006).  Harrison and Horne 
proposed that microsleeps are indicated by spectral, topographical, and morphological changes, mainly 
by the predominance of EEG theta (4–7 Hz) activity.  However, as noted by Boyle et al. (2008), there 
is a difficulty in using only EEG spectral power because muscle and movement artefacts can hinder 
EEG interpretation and because EEG interpretation is inherently subjective.  Golz and Sommer (2008) 
noted that episodes of theta activity can occur without the necessary coincident lapse in responsiveness, 
which brings into question the validity of EEG spectral power change as being by itself a sufficient 
marker for a microsleep.  Peiris and colleagues, attempted to use EEG spectral power, normalized 
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spectral power and power ratios from the standard EEG bands to detect microsleeps but achieved only 
modest success.  Finally, Sommer et al. (2009) proposed a two-stage methodology for defining 
microsleeps.  The first stage involved the identification of overt behavioural indications of sleep, such 
as prolonged eyelid closures, slow rolling eye movements, head nodding, slow drifting head movements 
all of which are often followed by abrupt reactions.  These episodes were then assessed using EEG, 
EOG, and eye tracking bio-signals.  Overlaps were defined as microsleeps while non-overlaps were 
referred to as non-microsleeps. 
The microsleeps of interest in this study are arousal-related lapses of responsiveness characterized by 
clear overt behavioural signs of either drowsiness, or sleep and a coincidental response disruption (Innes 
et al., 2013; Peiris et al., 2007).  Unlike that proposed by Sommer et al. (2009) there is no requirement 
that specific EEG, EOG bio-signals be present, otherwise they have similar behavioural features.  
Accordingly, the behaviourally-defined microsleeps have been associated with widespread, increased 
bilateral activity in the frontal and parietal cortex, particularly the inferior frontal, pre-central, post-
central, and superior parietal cortex during fMRI studies (Poudel et al., 2014)  They have, by arbitrary 
definition, a duration of 0.5–15 s with lapses greater than 15 s being classified as sleep.  The behavioural 
signs are full or at least 80 % eyelid closure accompanied by clear indications of drowsiness – which 
may include prolonged eyelid closure, slow rolling eye movements, head nodding and slumped posture, 
all of which are sometimes followed by abrupt reactions – coincident with flat responses, where the 
subject has stopped responding to the task at hand.  These behavioural signs are based on the criteria 
used by Wierwille and Ellsworth (1994) to identify severe drowsiness.   
Microsleeps are thought to be the result of low arousal and attention levels being unable to counter the 
homeostatic drive for sleep, possibly because of low levels of bottom-up exogenous stimulation 
(Matthews et al., 2002; Poudel et al., 2008).  They were studied by Peiris et al. (2006) who during the 
early afternoon and under soporific conditions, tested the impact of a continuous, monotonous, 
visuomotor task on responsiveness.  In a cohort of 15 healthy, male, non-sleep-deprived volunteers, 
they unexpectedly found frequent lapses in a substantial proportion of those who participated.  Over 
two one-hour sessions, the average lapse rate – including tracking flat spots, video microsleeps (lapses 
evident by overt signs of drowsiness but no coincidental flat tracking response), and definite 
microsleeps – was 39.3 per hour (range 0–141.5 per hour).  Notwithstanding, that these figures were 
observed in seated participants in a quiet room Poudel et al. (2014) also found that microsleeps were 
common in non-sleep deprived participants, but who were positioned supine in a confined and noisy 
environment of a fMRI machine.  They tested 20 healthy young adults and found that the mean 
microsleep rate per hour was 79 per hour (range 0–190).  Of the 20 participants in this later study, 14 
had at least 36 microsleeps during the 50-min tracking task, two participants had 1 and 2 microsleeps 
respectively, while four participants had none.  They attributed the relatively high number of 
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microsleeps to several factors, which included the monotonous nature of the continuous visuomotor 
task, postprandial somnolence, and the supine position of the contestants.    
2.10.2 Neurophysiology of Microsleeps 
In their study, Poudel et al. (2014), combined both EEG and fMRI in a study that investigated 
microsleeps during a continuous task.  The neural blood-oxygen-level-dependent (BOLD) activity 
decreased bilaterally in the midbrain, thalamus, posterior cingulate, and occipital cortex along with 
small areas in the right prefrontal cortex and cerebellum during microsleeps that, with the exception of 
the occipital cortex, have been associated with OSA (See Table 2-2).  Conversely, activity increased 
strongly in the parietal regions encompassing the bilateral postcentral, superior parietal, and 
supramarginal cortices and increased less strongly in the bilateral inferior frontal, precentral, 
parahippocampal, insular, temporal, occipital, and fusiform cortices during microsleeps.  Poudel and 
colleagues also investigated the time course of the BOLD signal in the thalamus and superior parietal 
cortex, the two structures that showed the greatest decrease and increase respectively during 
microsleeps.  They found that thalamic BOLD activity started to decrease at or near the onset of 
microsleeps and mirrored the duration of the microsleeps with shorter microsleeps associated with a 
smaller amplitude decrease.  Similarly, the size of the BOLD signal from the right superior parietal 
cortex also mirrored the duration of the microsleeps and again the shortest microsleeps were associated 
with the smallest amplitude change.  Theta activity in the postcentral EEG correlated positively with 
the BOLD signal in the bilateral thalamus, basal forebrain, prefrontal, posterior cingulated, posterior 
parietal, and visual cortices (Poudel et al., 2014).   
While sleep deprivation is not necessary for the expression of microsleeps (Innes et al., 2010; Peiris et 
al., 2006), sleep deprivation has been found to increase microsleeps propensity (Beck et al., 2010; Boyle 
et al., 2008; Moller et al., 2006; York, 2005).  Innes et al. (2013) investigated intra-individual 
differences in microsleep counts when non-sleep deprived and when sleep deprived.  They reported that 
the number of microsleeps during a 20-min monotonous task increased following sleep-restriction 
(mean 11.4 vs 27.9, p = .03).  However, they found no evidence that the high rates of microsleeps 
observed in some of their non-sleep-deprived people were due to poor sleep quality, sleep disturbance, 
circadian type, irregular sleep patterns, low daily sleep duration, or poor sleep efficiency.  Yet Morrone 
et al. (2020), using the presence of theta rhythms without electroencephalographic or electromyographic 
artifacts to identify microsleeps, found that episodes of microsleeps during the Maintenance of 
Wakefulness test were more common in participants with OSA, which leaves open the question, does 
OSA increase our propensity for microsleeping? 
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2.11 Positive air pressure therapy for the treatment of OSA 
2.11.1 Positive air pressure therapy overview 
Positive air pressure (PAP) is the most common first-line treatment for OSA (Avlonitou et al., 2012; 
Bardwell et al., 2001; Buchanan & Grunstein, 2011; Durgan & Bryan, 2012; Maresky et al., 2019; 
Spicuzza et al., 2015; Waltz et al., 2016).  PAP therapy creates an air-splint to maintain patency of the 
upper airway (nose, nasal cavity and pharynx) during inhalation.  This air-splint is created by a positive 
pressure of 0–20 cm H2O.  This prevents the airway from collapsing during inspiration when negative 
pressure is transmitted from the lung to the airway.  In other words, the increased luminal pressure 
counteracts the normal negative air pressure during the inhalation phase of the respiratory cycle.   
Continuous positive airway pressure (CPAP), a popular form of PAP therapy has been found to (i ) 
prevent or reduce high blood pressure (Korcarz et al., 2016), (ii) attenuate OSA moderated  arrhythmias, 
(iii) benefit heart failure patients, (iv) reduce cognitive impairment, (v) attenuate sympathetic drive, and 
(vi) improve default mode and task-positive network responses (Maresky et al., 2019; Prilipko et al., 
2014).  Moreover, according to Spicuzza et al. (2015), CPAP treatment reduces the number of apnoeic 
events to normal or near normal counts (i.e., AHI < 5), improves sleep parameters, and improves 
nocturnal oxygen saturation levels from the first night of treatment.  However, the gains noted above 
for OSA patients have been found to be short-lived, with many symptoms recurring one to three days 
following CPAP disruption (see Table 2-4) (Spicuzza et al., 2015).  Also, despite CPAP being regarded 
as a highly efficacious treatment for OSA its effectiveness is limited by poor adherence with many 
patients refusing the offer of CPAP therapy, or do not tolerate it, or fail to use the CPAP devices properly 
(Donovan et al., 2015; Ip et al., 2012).  Adherence is important, because as pointed out by Donovan et 
al. (2015) the greater the CPAP usage, the greater the benefits.  Adherence has been linked to sleep 
apnoea severity with higher compliance in those with severe sleep apnoea compared to moderate 
severity levels  (Yetkin et al., 2008).  Adherence has also been linked to  higher daytime sleepiness 
(Singhal et al., 2016) and subjective sleepiness (Park et al., 2017).   
Auto-titrating positive airway pressure (APAP) has been shown to improve compliance (Smith & 
Lasserson, 2009) by 13 minutes per night compared to CPAP (Kennedy et al., 2019).  APAP differs 
from CPAP therapy by taking account of changes in airflow resistance when setting the air pressure, 
thereby accounting for changes in posture, and nasal congestion, whereas CPAP delivers a fixed 
pressure for the entire sleep period (Ip et al., 2012). 
Good adherence with PAP therapy has been defined as the use of PAP for four or more hours in 70% 
of nights in any given month (Avlonitou et al., 2012; Billings et al., 2020; Golombeck et al., 2019).  
The longer PAP is tolerated the better the clinical outcome.  Avlonitou et al. (2012), argue that PAP 
should ideally be used for 4.5 hours per night to obtain the full benefits.  Similarly, Spicuzza et al. 
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(2015) suggest that at least 5 hours usage per night is needed to improve quality-of-life for both patient 
and bed partner.  However, Gaisl et al. (2020), point out, there is still substantial benefit to be gained 
from even suboptimal PAP adherence, particularly for patients with moderate or severe sleep apnoea. 
Table 2-5.  Common symptoms associated with OSA (from Spicuzza et al. (2015). 
Nocturnal Diurnal 
Snoring  Excessive sleepiness 
Witnessed apnoeas Morning headaches 
Choking at night Depression/irritability 
Nocturia Memory loss  
Insomnia Decreased libido 
 
2.11.2 PAP and cerebral perfusion 
An aim of the current study is to explore the impact APAP has on cerebral perfusion when awake.  In 
a SPECT study, Shiota et al. (2014), found that patients with severe sleep apnoea (AHI 62.7 ± 22.4/h), 
who used CPAP for at least five hours a night for three or more months, showed a significant 
improvement in regional cerebral perfusion, particularly in the frontal regions whilst awake.  Foster et 
al. (2007) described that 4 – 6 weeks of CPAP therapy was sufficient to normalize the cerebral perfusion 
response to hypoxia in people with severe OSA.  In their study of eight male patients the cerebral 
perfusion response to a simulated hypoxic event was reduced by 42% compared to controls.  Following 
CPAP therapy, the hypoxic response was restored to normal levels.  They also demonstrated a dose-
response relationship: the change in the cerebral perfusion to hypoxia after CPAP was greatest in those 
with the more severe sleep apnoea.  That suggests those patients with more severe sleep apnoea benefit 
most from CPAP treatment, an observation supported by Shiota et al. (2014).  Castronovo et al. (2014) 
also suggests that CPAP therapy has a beneficial impact on the restoration of OSA-mediated lowering 
of cerebral perfusion but cautions that even one year of compliant CPAP therapy may be insufficient 
for cerebral perfusion to be restored to normal physiological levels.  In their study of 17 patients with 
severe sleep apnoea (AHI > 30) and 15 controls (AHI < 5) they measured white matter integrity using 
diffusion tensor imaging at baseline, after three months, and after one year of CPAP therapy. They 
reported decreased functional anisotropy values in several parts of the brain: a) the right hemisphere, at 
the level of subcortical white matter of the superior and inferior parietal lobe, which includes fibres of 
the superior longitudinal fascicle, b) at the level of deep frontal white matter corresponding to a portion 
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of the arcuate fascicle, c) in the left hemisphere in a large area of the subcortical white matter belonging 
to the superior parietal lobe containing fibres of the superior longitudinal fascicle, as well as the left 
inferior frontal gyrus, including fibres of the frontal portion of the uncinate fascicle.  Although there 
was limited change in white matter integrity at three months, the change was more notable after one 
year with ”… an almost complete reversal of white matter abnormalities …” for treatment-compliant 
patients (Castronovo et al., 2014; p 1). 
Maresky et al. (2019) in their small study of seven patients with MRI scans taken pre- and post-six-
months CPAP treatment, they showed an improvement in cerebral perfusion in patients with severe 
sleep apnoea (see Figure 2-6).  They argued that OSA creates a state of persistent oxygen deprivation 
that damages the cerebral vasculature (see also Urbano et al., 2008; Yadav et al., 2013).  Maresky et al. 
(2019) contention is that CPAP treatment neutralizes or improves the underlying hypoxia damaging the 
cerebral autoregulation process, thereby leading to improvements in cerebral perfusion.  Reichmuth et 
al. (2009) support this conclusion by, using transcranial Doppler ultrasound to demonstrate that CPAP 
treatment ameliorates impaired hypercapnic vasodilation in the cerebral circulation. 
 
 
Figure 2-6  Pre-treatment and post-treatment magnetic resonance imaging (MRI) perfusion scans were 
used to measure cerebral perfusion (LH)  and cerebral blood volume (RH) and delta whole-brain maps 
showing regional increases in cerebral perfusion and CBF velocity after CPAP treatment (from 
Maresky et al. (2019)). 
Not all studies have found improved cerebral perfusion after CPAP therapy.  In addition to the study by 
Waltz et al. (2016) that concluded CPAP treatment does not impact cerebral autoregulation, is that 
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conducted by Prilipko et al. (2014).   In their study of 23 males with moderate to severe sleep apnoea 
who were randomized to receive therapeutic or sub-therapeutic (sham) CPAP for two months, they 
found that although cerebrovascular reactivity was increased with CPAP therapy, there was no 
correlation between cerebrovascular reactivity and cerebral perfusion and no difference in regional 
cerebral perfusion between patients and controls.  Higher cerebrovascular reactivity has been postulated 
by Prilipko et al. (2014) to better maintain adequate perfusion in the presence of fluctuations in oxygen 
and carbon dioxide blood levels. 
The recommendation of the American Academy of Sleep Medicine is to treat moderate and severe sleep 
apnoea with CPAP therapy (Epstein et al., 2009).  Although many studies have investigated the impact 
of CPAP on mild-to-severe, moderate-to-severe, or severe sleep apnoea, no study has investigated only 
moderate sleep apnoea (i.e., 15 > AHI < 30) on cerebral perfusion. 
In conclusion, several studies suggest that CPAP therapy can restore cerebral perfusion when awake to 
near normal physiological levels.  Furthermore, an increased benefit from CPAP therapy is accrued in 
those with a higher levels of sleep apnoea severity.  However, with no studies involving only patients 
with Moderate OSA, the benefit of CPAP therapy for this category of patients remains to be answered. 
2.11.3 CPAP and brain function  
An aim of our research was to determine if APAP therapy can offset/prevent adverse effects which 
moderate OSA might have on brain function.  The Apnoea Positive Pressure Long-term Efficacy Study 
(APPLES) (Kushida et al., 2012) investigated this question via a six-month, randomized, double-blind, 
two-arm, sham-controlled, multicentre trial. With nearly 1,100 participants given either active (n = 556) 
or sham CPAP (n = 542) this was a powerful study.  The inclusion criteria for this study were a diagnosis 
of OSA, an AHI > 10, and be aged 18 years or more.   
The primary outcomes were three neurocognitive variables, each representing a neurocognitive domain: 
(1) Pathfinder Number Test-Total Time (PFN-TOTL), which assesses attention and psychomotor 
function; (2) Buschke Selective Reminding Test-Sum Recall (BSRT-SR), which assesses verbal 
learning and memory (L/M); and (3) Sustained Working Memory Test-Overall Mid-Day Index to assess 
executive and frontal-lobe function.  Secondary outcomes were seven neurocognitive and two 
sleepiness measures, the maintenance of wakefulness test (MWT) and the Epworth Sleepiness Scale 
(ESS) (Kushida et al., 2012). 
Kushida et al. (2012); (Kushida et al., 2006) confirmed that there was no difference in AHI at baseline 
between the two groups.  However, despite a significant improvement in AHI levels after two-months 
(p < .0001) and six-months (p < .0001) of active CPAP therapy there was only a mild transient 
improvement at two months in executive and frontal lobe functioning for those with severe disease.  
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Dalmases et al. (2015) found that elderly adults (65 years and older) with severe OSA improved episodic 
memory (between-group difference in change, 7.60; 95% CI, 1.66-13.55; p = .014) and short-term 
memory (between-group difference in change, 1.06; 95% CI, 0.10-2.01; p = .032) and in executive 
function (speed of mental processing, 5.74; 95% CI, 1.69-9.79; p = .007; mental flexibility, -47.64; 95% 
CI, -81.83 to -13.45; p = .008), whereas no changes were observed in the control group.  This was after 
three months of CPAP treatment.  Whether these were transient improvements was not established. 
Moreover, the total N for both groups was 33, which is considerably smaller than the APPLES study, 
albeit all of their subjects had been diagnosed with severe OSA. 
Ferini-Strambi et al. (2013) conducted a narrative review of the papers evaluating the impact of CPAP 
treatment on cognitive performance.  They found that in most studies they reviewed, attention/vigilance 
improved, but changes in global functioning, executive functioning, and memory only improved in 
about half of the studies.  This they attributed to a large variability in inclusion and exclusion criteria, 
study design, and duration of treatment.  Accordingly, they concluded that it was not possible to make 
definitive conclusions regarding the impact of CPAP treatment on cognition in OSA. 
Finally, a study by Maresky et al. (2019) concluded, that in addition to symptom resolution, CPAP 
treatment may allow for the healing of  OSA-induced brain damage by reversing the mechanisms 
underlying hypoxia, thereby increasing oxygenation.  This they report, likely limits reactive oxygen 
species production thus allowing for the activation of the brains repair mechanisms.  However the study 
by Maresky et al. only had seven participants and their results and conclusions need to be treated with 
caution. 
2.12 Arterial spin labelling  
2.12.1 Overview of the arterial spin labelling process 
Cerebral blood flow has traditionally been measured using techniques, such as positron emission 
tomography (PET), single photon emission computerized tomography (SPECT), computed tomography 
perfusion, and dynamic susceptibility contrast magnetic resonance imaging (see Fantini et al. (2016) 
for a review).  A common feature of many of these methods is reliance on the use of diffusible 
radioactive tracers that can exchange between the vascular compartment and the tissue of interest, and 
significantly, have to be exogenously administered (Petcharunpaisan et al., 2010).   
Arterial spin labelling (ASL) is a magnetic resonance imaging technique for measuring cerebral 
perfusion, which was developed by Williams et al. (1992) and does not use diffusible tracers.  Instead, 
it uses magnetic-labelled arterial blood water protons as an endogenous tracer (Ferré et al., 2013; 
Jezzard et al., 2018; Petcharunpaisan et al., 2010).  Accordingly, it is non-ionizing and a completely 
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non-invasive technique, making it ideal for longitudinal studies (Wintermark et al., 2005; Xu et al., 
2010). 
Furthermore, because blood water protons are the tracer, (i) ASL provides an absolute measurement of 
cerebral perfusion, (ii) any change in cerebral perfusion rates can be expressed in physiologically 
meaningful units rather than as a percentage change (Borogovac, 2012), (iii) the quick magnetization 
decay means the scan times can be relatively short, (iv) unlike techniques such as the blood oxygen 
level dependent procedure, which are considered to mainly express venous flow rates, ASL expresses 
arterial perfusion, and (v) is a reliable measure (Zhou et al., 2015).  Also, according to Borogovac 
(2012), arterial spin labelling has a higher spatial and temporal resolution than any other current 
technique; an observation partially disputed by Ferré et al. (2013) who reported that arterial spin 
labelling has a poorer spatial resolution compared to techniques such as computerized axial tomography 
perfusion scan.  Also, Ambarki et al. (2015) compared arterial spin labelling cerebral perfusion from 
young healthy adults (age range, 20–30 years) and from healthy older adults (age range, 65–80 years) 
using pseudo-continuous arterial spin labelling against flow rates from phase-contrast magnetic 
resonance images.  They found that arterial spin labelled blood flow is over-estimated in healthy young 
adults and under-estimated in the health older adults, bringing into question the accuracy of arterial spin 
labelled derived cerebral perfusion rates.  However, a study by Kaneta et al. (2017) investigating the 
performance of ASL against SPECT found substantial differences in visual assessments of Alzheimer’s 
disease between the two methodologies with lower cerebral blood flow attributable to ASL with a post 
labeling delay of 1.5 s. 
Another disadvantage of ASL is a low signal-to-noise ratio related to the subtraction of control images 
from labeled image.  Moreover, ASL has a limited spatial resolution (Ferré et al., 2013) and poor 
temporal resolution (Petcharunpaisan et al., 2010) that when combined with the low signal-to-noise 
ratio results in a low contrast-to-noise ratio.  As ASL is a subtraction technique, it is sensitive to subject 
movement.  Yet despite these disadvantages, ASL’s noninvasiveness and ability to quantitatively 
measure tissue perfusion make ASL an ideal technique for research and clinical studies 




 Figure 2-7.  Arterial spin labelling acquisition principles.  First the inflowing blood is labelled (A).  It 
is then given time to infuse the brain volume of interest (B), before the images are acquired (C).   
The basic ASL process is a differentiating technique in which two signal acquisitions are carried out: 
one with the labelling of arterial blood water protons interspersed with a control acquisition that is 
completed without the labelling process.  The labelling is done by inverting the blood magnetization 
using a combination of bursts of a 180-degree radio-frequency pulse and a field gradient in the direction 
of blood flow (Fantini et al., 2016).  This labelling process disrupts the magnetization of the blood 
water, subsequently reducing magnetic resonance signal strength and image intensity.  The labelled 
protons then migrate via arterial vessels to the brain tissue where they pass from the capillary bed to the 
extravascular space.  Control images, on the other hand, are acquired without arterial labelling.  Thus, 
the blood water protons are relaxed and in equilibrium.  By adding a delay between the labelling process 
and image acquisition, called post-labelling delay (see Figure 2-7, the labelled blood can reach the 
capillaries where it gives rise to the perfusion-weighted image.  Subtraction of the labelled acquisition 
from the control acquisition suppresses the static tissue signals and the remaining signal is a relative 
measure of perfusion proportional to cerebral perfusion (Ferré et al., 2013; Petcharunpaisan et al., 2010; 
Wolf & Detre, 2007). 
2.13 Summary 
Although there is much still to be learnt about the mechanisms controlling the maintenance of cerebral 
circulation in OSA (Durgan & Bryan, 2012), there is strong evidence that OSA interferes with the 
regulation of cerebral perfusion.  Most studies discussing the impact of sleep apnoea and its impact on 
cerebral perfusion while awake have either included moderate with severe, or just severe sleep apnoea.  
Only one study (Baril et al., 2015) has reported the impact of moderate sleep apnoea on cerebral 
perfusion – i.e., no significant difference from non-OSA. 
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Most studies exploring the impact of CPAP therapy on cerebral perfusion have found that CPAP therapy 
restored cerebral perfusion to near normal levels.  However, this benefit appears to be dependent on 
severity of sleep apnoea, with a greater benefit accruing to those with more severe sleep apnoea.  With 
no studies investigating CPAP or APAP therapy for patients with only a moderate level of sleep apnoea, 
the benefit of CPAP/APAP treatment for that group of patients also remains unresolved. Accordingly, 
research into the impact of treatment on Moderate OSA and on cerebral perfusion during the awake 
period will make a worthwhile contribution to the management of moderate sleep apnoea, the 
importance of which should not be underestimated. 
A useful tool for investigating the impact of sleep apnoea on cerebral perfusion is ASL.  Being a non-
invasive procedure, it is ideal for the investigation of perfusion in people who can tolerate the close 
confines of the scanner.  It is particularly useful for longitudinal studies (Ugur et al., 2005). 
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Chapter 3  Methods 
3.1 Introduction 
To investigate the impact of moderate OSA on cerebral perfusion, cognition, and other measures, a 
longitudinal, intervention study was undertaken in which APAP therapy was administered over six-
months to a cohort of participants with moderate OSA, whilst another cohort, also with moderate OSA, 
was monitored but were not treated.  A third group of participants without OSA, a control group, was 
also tested at baseline and again after approximately six-months to assess any test-retest confounds.  
Perfusion and cognition scores from all three cohorts at baseline were contrasted against each other and 
against scores taken at the end of an approximate six-month treatment period.  Test measures were 
compared between baseline and end-of-treatment for the treated cohort and compared to the cohort who 
were not treated but who, nonetheless, had a similar intervening period between baseline and follow-
up tests.  The methodology used is described in more detail in the following sections of this chapter. 
3.2 Participants 
Twenty-four participants with an AHI between 15 and 30 events per hour were pragmatically recruited.  
They formed the moderate OSA group that was subdivided into either a treated cohort (4 females, 9 
males), or an untreated cohort (6 females, 5 males).  It was intended that both these two cohorts would 
consist of 15 participants.  However, recruitment proved to be difficult due to lower-than-expected 
numbers presenting to the Christchurch Hospital Sleep Unit.   
In addition, data was collected from a further 7 participants with an AHI < 5, who constituted a control 
cohort.  It was intended to recruit 15 participants to form this group.  However, due to the high 
prevalence of mild OSA in the general population for this age range, only 7 participants – of which 4 
were female – met our requirements within the available time. 
3.2.1 Inclusion/Exclusion criteria 
Membership of the moderate OSA group required that participants had an AHI score between 15 and 
30 events per hour as described by Level II polysomnography.  They were also required to have been 
referred to the Christchurch Hospital Sleep Unit by their General Practitioner, and to be naïve to APAP 
or CPAP therapy.  
In addition to having an AHI < 5, membership of the control group was dependent on participants being 
asymptomatic of OSA (e.g., did not experience excessive daytime sleepiness, or report excessive 
snoring).  Furthermore, they were not patients of the Christchurch Hospital Sleep Unit, or who have 
previously consulted their General Practitioner about sleep related problems.  Control group members 
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were recruited from the general-public through word of mouth, and public presentations of this research 
project.  Some potential members in a list of voluntary research recruits, held by the Otago School of 
Medicine, were also approached. 
The inclusion criteria for both the OSA group and the control group were (i) be 18 – 80 years of age; 
(ii) have a usual bedtime between 9.00pm and 12.00am; (iii) a usual time in bed of 7 to 9 hours; (iv) 
have an understanding of verbal and written English; (v) not be receiving or have previously received 
OSA treatment; (vi) not have a history of physiological, psychiatric, or neurological disorders unrelated 
to OSA, which could affect sleep behaviour, fatigue, cerebral perfusion or brain structure such as 
chronic obstructive pulmonary disease, congestive heart disease, diabetes, heart failure, hypertension > 
150/90, migraine, myocardial infarction, stroke, previous brain surgery, stroke, and traumatic brain 
injury; (vii) not be taking medication that could impact cerebral perfusion (e.g., ACE inhibitors, nitrates) 
or cognition; (viii) not be willing or otherwise unable to remove metal that could be harmful to the 
participant during a MRI scan or could create MRI artefacts that negatively affect the quality of the 
scan; and (ix) based on current Sleep Unit criteria, not have any reason for urgent medical treatment.   
As a part of the screening process, information on the subject’s current neurological, psychiatric, and 
sleep status was obtained during personal interviews.  A copy of the questionnaire used can be found in 
Appendix A. 
Demographic and other personal information from all participants (age, ethnicity, PSQI, ESS, and SF-
36) were obtained via questionnaires. 
All participants were required to have a Level II polysomnography sleep test administered by the CDHB 
Sleep Unit.  This evaluation by the Sleep Unit ensured potential participants in the OSA group met the 
diagnostic criteria for a moderate level of OSA that, in addition to the presence of sleep disordered 
breathing, required the presence of other symptoms typical of the disorder but not necessarily excessive 
daytime sleepiness.  It also ensured that members of the control group were correctly placed.  Moreover, 
the Level II polysomnography test minimised the risk of comorbid sleep disorders such as REM sleep 
behaviour disorder (Kapur et al., 2017) confounding results that would have otherwise been fully 
attributable to OSA.   
3.2.2 APAP treatment 
Initially, members of the treated group were offered APAP therapy for six months.  Minimum 
compliance criteria included APAP usage for a minimum period of 4 hours on 5 nights per week 
(Catcheside, 2010).  All APAP users were asked to join ResMed myAir, a support facility provided by 
ResMed for new users of APAP equipment.  With their consent, adherence to APAP therapy was 
monitored via ResMed’s Airview .  Those participants who remained non-compliant after 30 days were, 
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with their understanding, withdrawn from the treated cohort and offered placement in the untreated 
cohort  if that became necessary.    
3.2.3 Recruitment 
Participants intended for our moderate OSA group were all recruited from patients of the CDHB Sleep 
Unit who had been previously assessed as having a moderate level of OSA and would not usually 
qualify for funded treatment with APAP.  They were initially approached by the Sleep Unit asking 
whether they would consider participating in this research project.  If the response was agreeable, the 
prospective participant was then approached by the co-ordinating investigator (RB) who informed the 
prospective participant of the study objectives, what involvement would mean, and posted out a 
participant information sheet, to facilitate an informed consent.  A copy of that information sheet for 
membership of the OSA group along with the information sheet for the control group are included in 
Appendix B.  Approximately one week later, the Co-ordinating Investigator contacted the prospective 
participant, enquired about participation, and completed the consent process.  Recruitment was 
anticipated to take approximately six to nine months, estimated on the number of referrals received by 
the Christchurch Hospital Sleep Unit at that time.   
It was decided to recruit most of the treated cohort first because it was anticipated that this would be 
the hardest cohort to fill due to the recognized high non-compliance rate for APAP treatment.  Initially, 
participants were not given a choice to which group they were to be assigned.  However, the drop-out 
rate in the first 10 recruits was 40%.  That rate was higher than could be afforded.  Subsequently, 
participants were offered a choice of participating in the APAP treatment or the untreated cohort the 
rationale being that those participants who opted for the treated cohort would be committed participants. 
  Those that had been placed in the treated cohort and who found within the first month they were unable 
to tolerate, or for other reasons did not wish to continue using the APAP equipment, were asked if they 
would consider returning in approximately six months as a member of the untreated cohort if required.  
This pragmatic approach, although less than ideal (Lurie & Morgan, 2013), was justified on the basis 
of limited recruitment opportunities to otherwise met our desired populations.  Patients recruited 
explicitly for the untreated cohort were not given a choice to which cohort they could join.” 
Participants intended for the control group were approached by the Co-ordinating investigator.  An 
initial contact was first made where study objectives were explained, and participation were told what 
would be involve.  As was the case for the OSA Group, a commitment to participate was not sought at 
this stage and an information sheet was posted out.  Again, approximately one week later a further 
contact was made and agreement to participate sought. 
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3.3 Apparatus and Tests 
3.3.1 Polysomnography. 
All participants undertook an overnight Level II polysomnography at baseline of at least six-hours.  
Sleep was monitored overnight in the participant’s home using a Nox Medical polysomnograph (Model 
Nox A1, Nox Medical, Reykjavík, Iceland).  Central and occipital EEG, ECG, bilateral EOG, submental 
and tibialis anterior EEG, and body position were recorded using a standard polysomnography montage 
as recommended by the American Academy of Sleep Medicine (AASM) (Berry et al., 2017). A nasal 
cannula/pressure transducer was used to measure nasal airflow, whilst oral airflow was measured using 
a thermistor.  Respiratory effort was measured using chest and abdominal piezoelectric belts.  A pulse 
oximeter (Nonin 3150 WristOx2, Nonin Medical Inc, Plymouth, Minnesota) was used to monitor 
oxyhaemoglobin saturation (Sao2).   
In addition, a detailed sleep history was taken (Epton et al., 2017).  This included duration and sleep 
fragmentation questions; questions relating to snoring and apnoea, restless legs/ periodic limb 
movements of sleep, and parasomnia; caffeine, alcohol and drug history; weight and weight gain; 
driving and work-related incidents; and upper airway surgical history. A focused examination was also 
performed on the nose, mouth, jaw and upper airway, including the Friedman classification of the 
oropharynx and tonsils (Friedman et al., 2002). In addition, the Berlin questionnaire and the Epworth 
Sleepiness score were administered. 
These tests were repeated six to seven months later for both the Treated and Untreated cohorts.  To this 
end, the Treated cohort were asked to refrain from APAP therapy on the night immediately prior to the 
second polysomnography.  Refraining from the use of APAP on the night of the polysomnography was 
not expected to disrupt the treatment regimen as an acceptable compliance for the treatment of OSA 
requires CPAP to be used on at least 70% of nights in any given month (Avlonitou et al., 2012). 
3.3.2 Magnetic Resonance Imaging  
3.3.2.1 Data acquisition 
High-resolution, anatomic images of the whole brain were acquired by Pacific Radiology on a Signa 
HDxt 3.0 T MRI Scanner (GE Medical Systems, Milwaukee, WI, USA) using an 8-channel head coil.  
This included a T1-weighted spoiled gradient recalled echo (SPGR) acquisition with: echo time of 2.8 
ms, a repetition time of 6.6 ms, inversion time of 400 ms, flip angle of 15 deg, acquisition matrix of 
256 × 256 × 170, field of view of 250 mm, slice thickness of 1 mm, voxel size of 0.98 × 0.98 × 1.0 
mm3, and a scan time of 5 min 3 s.   
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Whole-brain perfusion was measured quantitatively using a stack of spiral fast-spin-echo-acquired 
images prepared with pseudo-continuous Arterial Spin Labelling (ASL) with: static background signal 
suppression, a repetition time of 6 s, echo spacing of 9.2 ms, post-labelling delay of 1.525 s, labelling 
duration of 1.5 s, eight interleaved spiral arms with 512 samples at 62.5 kHz bandwidth, field of view 
of 240 mm, 30 phase-encoded 5-mm-thick slices, reconstructed in-plane resolution of 1.88 × 1.88 mm, 
five excitations, and a scan time of 7 mins giving 70 volumes (scan time/repetition time). The units 
were mL/100g/min. 
3.3.2.2 Scanner relocation 
In September 2017, the scanner was relocated from 16 St. Asaph Street, Christchurch 8014 to a new 
building at Forte Health, 132 Peterborough Street, Christchurch Central City Christchurch 8013, a 
distance of approximately 1.6 km.  To understand the impact of this shift on scan integrity, a test-retest 
study was completed prior to and post shift.  No evidence of any instability between structural T1 scans 
prior to and post shift was found.  Although MRI ASL was not as stable as the T1 scan between tests, 
there was no evidence of biased signal between locations, or of differences in signal variance. (Melzer 
et al., 2020) 
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Figure 3-1  GE Signa HDxt 3.0T MRI scanner located at Pacific Radiology, Forte Health, used for the 
MRI scans. 
3.3.2.3 Image pre-processing 
Both baseline and follow-up images were treated cross-sectionally as opposed to longitudinal within-
subject co-registrations.  Pre-processing of acquired ASL data is necessary before it can be analysed. 
Accordingly, both structural and perfusion MRI data were pre-processed using CAT12 
(http://dbm.neuro.uni-jena.de/cat12/) - a toolbox of SPM12 (Wellcome Trust Centre for Neuroimaging, 
University College London, UK; http://www.fil.ion.ucl.ac.uk/spm) - and custom MATLAB scripts 
(Mathworks, Natick, MA, USA) as follows.  Structural images were: (i)  bias corrected, tissue classified, 
and normalized using linear and nonlinear transformations (DARTEL) within a unified model; (ii) grey-
matter segments for each subject were modulated, thereby preserving actual tissue values locally by 
accounting for the amount of warping; (iii) an intracranial volume (ICV) mask, used to facilitate brain 
extraction, was calculated using the automatic reverse brain mask method, in which the SPM ICV brain 
mask in MNI space was inverse normalized to each subject’s space using the DARTEL-derived 
deformations and nearest neighbor interpolation (Hansen et al., 2015), (iv) modulated, normalized grey 
matter segments were smoothed with a 10-mm full width at half maximum (FWHM) Gaussian kernel 
to improve signal to noise ratio and to minimize the effect of any residual misalignment.   
Perfusion images were: (i) quantified, co-registered to the SPGR images, brain extracted (using FSL 
5.0.2 www.fmrib.ox.ac.uk/fsl), and normalized using the deformation fields generated during 
segmentation and normalization of the SPGR images.  (ii) Normalized perfusion images were smoothed 
with a 10-mm FWHM Gaussian kernel.  (iii) All images were visually inspected for completeness and 
alignment (see para. 3.3.2.4 and Figure 3-2).  (iv) A study-specific grey-matter mask, used to exclude 
non-grey matter contributions in subsequent analyses, was created by averaging the modulated, 
normalized grey matter segment from all subjects.  (v) Values < 0.10 were excluded from the mask, as 
were all slices inferior to the superior cerebellum as spiral artefacts were present in this area on perfusion 
images; (vi) periventricular white matter regions misclassified as grey matter (partial voluming) were 
manually excluded from the grey matter mask; (vii) grey matter segments were normalized without 
modulation and smoothed to investigate grey matter concentration.  
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Figure 3-2  From top-left and clockwise: Coronal, sagittal and axial views of a typical 
normalized/warped cerebral perfusion image before smoothing; as shown in SPM.   
3.3.2.4 Quality control 
The quantified CBF map for each participant was overlaid on the T1 weighted SPGR structural image 
and visually inspected for artefacts and errors in registration (Figure 3-3).  This was done by verifying 
if the outside contours of the brain were registered with the inside edge of the skull and if the space 
between the hemispheres was in the middle of the image. 
Figure 3-3.  Typical structural images, those on the on the left, overlaid with the quantified CBF 
images on the right.  The z, y, z, co-ordinates for both sets of images are the same at 123, 179, and 93 
respectively. 
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3.3.2.5 Statistical image analysis 
A general linear model (GLM) ANCOVA  was used to investigate baseline voxel-by-voxel differences 
between the control group and the Moderate OSA group in grey matter volume and concentration, and 
grey matter perfusion.  Age, sex, and BMI were included in the GLM as explanatory variables (EV), 
along with the voxel-dependent grey matter 4D file, for both the regional grey matter volume/ 
concentration and perfusion analyses. Furthermore, separate models with and without the additional 
EVs of drowsiness during the ASL scan and total grey matter perfusion were also run.  
To test the treated cohort, and separately the untreated/control group, for change over time, a GLM 
ANCOVA was used to investigate voxel-by-voxel differences in grey matter volume and concentration, 
and grey matter perfusion at baseline and follow-up.  Age, sex, BMI, and drowsiness were included in 
the general linear model as explanatory variabless.  In addition, APAP usage, i.e. average hours of use 
per night, was also included in the treated cohort test.  
There is mounting evidence (Cielo & Tapia, 2019; Kainulainen et al., 2020; Scott et al., 2014) that 
increased desaturation severity, and percentage of sleep time with saturation levels below 90% are better 
markers of OSA severity than AHI.  Accordingly, to test whether Total Time with oxygen saturation 
below 90 percent (ST90) was correlated with changes in regional cerebral blood flow, a general linear 
model (for regression) was used to investigate voxel-by-voxel correlations, with age and sex included 
as covariates. 
A permutation-based inference tool was used for nonparametric statistical thresholding (“randomise” 
in FSL 5.0.2; www.fmrib.ox.ac.uk/fsl).  For each contrast or regression, the null distribution was 
generated over 5,000 permutations and corrected for multiple comparisons using family-wise error rate 
(threshold-free cluster enhancement corrected p<0.05).   
3.3.3 Eye-video recording during the ASL scan 
3.3.3.1 Eye-video capture 
Eye-video, used to rate participant drowsiness (see 3.3.3.2 ), was captured during the ASL sequence 
using a Visible Eye system incorporating a fibre-optic camera (Avotec Inc., Stuart, FL, USA).  The 
video-capture software recorded 352 × 288-resolution eye-video at 25 fps.  The participant looked at a 
blank screen.  During the ASL sequence the participant was instructed to “keep your eyes open except 
for blinks.”  Also, background music was turned off.  Although the quality of the screenshots was low 
(e.g., see Figure 3-4) the resolution was sufficient for the identification of full or partial eye closures, 
eye blinks, and saccadic eye movements that informed an observer’s subjective assessment of 
drowsiness.   
Figure 3-4  A screen shot of a typical frame from the eye video recording used to rate drowsiness 
levels during the ASL procedure.  
3.3.3.2 Eye-video rating of drowsiness 
Each participant’s 7-min eye video, recorded during their ASL scan, was visually rated for signs of 
drowsiness by an experienced rater (RB).  Drowsiness was rated in accordance with the visual scoring 
method proposed by Wierwille and Ellsworth (1994).  This rating system is based on observable 
personal characteristics including eye blinks, eye closures, and saccadic movement.  The rating system 
has 5 levels of drowsiness on an analogue scale of 0 to 100 (not drowsy = 0, slightly drowsy = 25, 
moderately drowsy = 50, very drowsy = 75, and extremely drowsy = 100).  Level of drowsiness was 
rated first as an average over each min, which were subsequently collated into an overall average rating 
across the 7 min.  Following the lead from a previous study (Innes et al., 2015), the drowsiness rating 
was done by a single experienced rater (RB).  Poudel et al. (2012) noted that interrater reliability of the 
visually rated drowsiness scores is extremely high with the average raters intraclass correlation 
coefficient = 0.95, using a 2-way mixed effects model.  Poudel, Innes, and Jones also reported that the 
visually rated drowsiness scores were strongly correlated with the mean percentage eye-closure in both 
rested (r = 0.75, p = .002), and sleep-restricted subjects (r = 0.86, p = .002). 
3.3.4 Constant Positive Airway Pressure 
Constant positive airway pressure therapy provided to the treated cohort (see 3.2.2 was administered 
through an Airsense 10 auto set using either an AirFit N30 full face mask, or an Airfit N20 nasal mask 
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(ResMed Ltd., Bella Vista, New South Wales, Australia).  The settings for the APAP machines are 
listed in Table 3-1.   
Table 3-1.  APAP settings used in this study. 
Setting Value 
Mode Autoset 
Maximum pressure 15.0 cmH2O 
Minimum pressure 5.0 cmH2O 
Response Soft 
Ramp time Automatic 
Start Pressure 4.0 cmH2O 
Expiratory pressure relief On 
EPR type Ramp only 
EPR level 3.0 cmH2O 
Humidity level 4 (range 1 to 8, 1 being low) 
APAP usage was objectively recorded by the APAP machine and reported directly to ResMed via the 
internet, where available, otherwise usage was recorded onto an integrated secure digital card that is 
subsequently downloaded.  Patient details, the days used, the hours it was used, APAP machine setting 
including mode, minimum pressure, maximum pressure, and expiratory pressure relief settings were 
recorded.  Therapy settings including median pressure, leaks, number of apnoea and hypopnoea events 
per hour, and Cheyne-Stokes respiration average duration were also recorded.  From this collected 
information 180-day compliance reports were collated for each participant in the treated cohort. 
Reported were the number of days APAP was used for four or more hours, the number of days where 
APAP was used for less than four.  Total hours used over the 180-day period, average usage per night 
over the 180-day period, average usage over the days used, median usage over the days used.  An 
example of a compliance report can be found in Appendix E. 
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3.4 Neurobehavioural tests 
Cognition was measured at baseline and again at follow-up.  This involved each participant completing 
a battery of cognitive tasks that was based on analyses by Beebe et al. (2003); Bucks et al. (2013); Fulda 
and Schulz (2003); Olaithe and Bucks (2013); (Sales et al., 2013); Wallace and Bucks (2013); Weaver 
and George (2011); and framed within the heuristic model of OSA neurobehaviour proposed by Beebe 
(2005).  It was designed to cover five domains of cognition: attention/concentration, executive 
functioning, learning and memory, speed of processing  and visuospatial  (Decary et al., 2000; Lezak 
et al., 2004).  This battery of cognitive tests along with the sequence of completion, and the 
neurocognitive domains which each test measured, is listed below.   
Table 3-2.  Cognitive tests undertaken at baseline and at the 6-month follow-up. 
Order of 
completion 
Proposed Neuropsychological test Neurocognitive 
domain 
Sub-domain 
1 Rey Complex Figure (Copy) (Osterrieth, 
1944; Rey, 1941) 
Visuospatial 
construction 
2 Rey Complex Figure (Immediate recall) Executive function Planning 
3 Verbal Fluency Test (FAS) (Borkowski 
et al., 1967). 
Executive Verbal Fluency 
4 Verbal Fluency Test (Category) Executive Verbal Fluency 
5 Digit Span (Forwards, Backwards, and 




6 Stroop (Colour patch, and Word) 
(Stroop, 1935). 
Attention Concentration 
7 Stroop (Interference) Executive 
functioning 
Inhibition 
8 Symbol Digits Modality Test (Smith, 
1973) 
Speed of Processing 
9 California Verbal Learning Test (Part 1) 
(Delis et al., 1987). 
Memory Long-term Verbal 
10 Rey Complex Figure (Delayed recall 30 
min) 
Memory Long-term Visual 
11 Trail Making Test A (Reitan, 1958). Attention Concentration 
12 Trail Making Test B Working Memory 
13 California Verbal Learning Test (Part 2) Memory Long-term Verbal 
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14 Judgement of Line (Benton et al., 1994). Visuospatial 
construction 
17 2D Tracking task Attention Concentration 
18 PVT (Dinges & Powell, 1985). Attention Sustained attention 
3.4.1 Microsleep and Psychomotor Vigilance Task (PVT)  
3.4.1.1 Experimental Setup and Equipment 
The microsleep and PVT assessments were conducted in a room measuring approximately 5.5 m x 3.2 
m. The room had no windows and, for the purpose of this study, was lit by a single 40-watt incandescent 
light bulb during the test sessions.  Ventilation was provided by an air conditioning unit with the room
temperature set at 22 C.
The participant’s workstation consisted of a small desk that faced a blank wall.  It held the stimulus 
visual display unit.  The participant sat in a chair placed in front of the workstation with the floor-
mounted joystick located between their legs approximately in line with their knees.  Approximately 700 
– 800 mm in front of and facing the participant was the stimulus visual display unit.  The top of the
screen was approximately level with the participant’s line of sight.  To the left of the participant, and
out of their line of sight was located the researcher’s workstation which contained the stimulus
computer, researcher’s visual display unit, keyboard, and mouse.
The stimulus visual display unit was a 17-inch LCD flat screen colour monitor manufactured by 
ViewSonic (Walnut, California, USA).  It had a screen resolution set at 1024 x 768 px and was refreshed 
at 60 Hz. 
3.4.1.2 Test program 
A Delphi-based computer program SMCTests™ generated the 2D pseudo random visuomotor tracking 
task used in the identification of microsleeps.  It also generated the stimulus used in the PVT.  The 
SMCTests™ program was run on a desktop computer employing a Windows platform.  The computer 
generated and displayed the target disk used in the tracking task (the red disk in Figure 3-9), and 
sampled the joystick response, which it then displayed as the response disk to provide visual feedback 
to the participant  of their tracking performance (yellow disk Figure 3-9).  During the PVT, the program 
generated the start of a PVT trial by randomly displaying a counter in the centre of the screen that 
showed in ms the time since the beginning of the trial (see Figure 3-11).  The program also stopped the 
counter when the off on button was pressed on the joystick, calculated reaction times for each PVT trial, 
and displayed that time on the screen for 1.0 sec to provide feedback on the PVT response.  Lastly, the 
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program stored the stimulus and response data from both the tracking and PVT tasks as Matlab 
‘.mat’‘.txt’ files for offline analysis. 
3.4.1.3 Eye-video recording 
The eye-video-recording used in conjunction with tracking response data to identify microsleeps, was 
made using a Complementary Metal Oxide Semiconductor (CMOS) pin-hole camera, model MO-S408-
3T-C, supplied by Misumi Electronics Corporation (Chungho City, Taipei Hsien, Taiwan, ROC).  This 
small camera was attached to the microphone boom of a headset worn by the participant during the 
microsleep task and adjusted so a recording of the participant’s left eye could be made. 
The video recording was captured through a Winfast VC100 XP video in capture card, (Leadtek, 
Taipei), and supported by VirtualDub version 1.10.4,  a video capture/processing utility for 32-bit and 
64-bit Windows platforms licensed under the GNU General Public License (Computer Software, 2012)
(Retrieved from https://sourceforge.net/projects/virtualdub/files/virtualdub-
win/1.10.4.35491/VirtualDub-1.10.4.zip/download).  VirtualDub uses an Audio Video Interleaf (AVI)
format with a ‘.avi’ filename extension for its movie files and has a capture rate of 50 fps.  For the files
to be used by SyncPlayer ™ the AVI format has to be converted to Quicktime h264 ‘.mov’ format using
a MatLab Conversion Script.  A video frame showing a typical view of a participant’s eye taken during
the tracking task is shown in Figure 3-5.
Figure 3-5  A typical eye video of a phasic/transient eye-closure used in conjunction with tracking 
response data to identify microsleeps. 
3.4.1.4 SyncPlayer™. 
Off-line analysis of the microsleep task was through SyncPlayer ™.  SyncPlayer is a software program 
written for previous microsleep studies (Buckley et al., 2014; Poudel et al., 2010).  It was used to 
synchronize and display via two separate windows; video recordings of the participant’s eye in the 
SyncPlayer window along with a graphical representation of the tracking data in the multiple signals 
window.  SyncPlayer uploaded the screen coordinates for both the response and target disks and 
displayed the x and y-axes of the response signal overlaid on the target signal.  It calculated and 
displayed the resultant speed of the response signal overlaid on the target signal and the tracking error 
(Figure 3-7).   
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Figure 3-6.  Shown are the four response signals to a typical microsleep.  Flat tracking response is 
readily seen for both the X and Y axes.  Along with the zero speed indicate the absence of joystick 
movement.  The result is an increase in tracking error evident in the bottom graph.  
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Figure 3-7.  Screen shot of the SyncPlayer™ window showing the Multi-signal data view window on 
the left, along with the SyncPlayer window on the right where marked events are recorded.   
In addition to its display function, the program has a function that allows the recording of seven markers 
used in the definition of a microsleep.  The seven markers are listed in Table 3-3 below and were those 
used previously by Poudel (2010).  Each mark locates the event by recording the associated video frame 
number. 
Table 3-3.  Description of the seven markers used to record an event.  Each mark is made by recording 
the associated video frame number. 
Marker Identity Marked Event 
Marker 1 Start of poor or flat/incoherent tracking including start of rise in error, or start of 
speed ~ 0 
Marker 2 50% of full eye-closure (where available) based on either video recording or 
VEOG. 
Marker 3 Start of full eye closure (where available) based on either video recording or 
VEOG. 
Marker 4 Completion of full eye closure (where available) based on either video recording 
or VEOG. 
Marker 5 50% of eye open (where available) based on either video recording or VEOG. 
Marker 6 Full eye open (where available) based on either video recording or VEOG. 
Marker 7 End or poor or flat/incoherent tracking including end of flat spot, start of speed > 
0, or start of coherent tracking. 
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3.4.1.5 Floor-mounted joystick 
The floor-mounted joystick shown in Figure 3-8 was purpose built by the Department of Medical 
Physics and Bioengineering, Canterbury District Health Board, New Zealand for a previous study.  It 
has a lateral movement of approximately 30o from the vertical in all directions, which for the average 
person meant, at the hand position, a circle of movement with a radius of 225 mm.  On top of the 
joystick is the response button for the PVT stimulus (see Figure 3-8).  It was used to respond to the 
PVT stimulus.  Its position on top of the joystick was readily accessible by the participant using their 
thumb.  To activate the switch the participant was required to depress the switch approximately 0.5 mm 
which required them to exert an approximate force of 6 N to overcome the switch’s inherent resistance. 
As necessary, the hand rest, integrated into the joystick, could be adjusted to accommodate different 
hand sizes. 
Figure 3-8  The floor-mounted joystick.  This joystick is positioned immediately in front of the seated 
participant such that they can utilise the full circle of movement without obstruction from their upper 
legs and knees.  The height of the joystick and the collar used as a hand rest can be adjusted to suit the 
user.  The button used to respond to a PVT trail is shown located on top of the joystick where it can be 
easily activated by the thumb.  Also shown is an adjustable collar that serves as a hand rest. 
Stimulus response button 
Adjustable hand rest 
Adjustment for length 
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3.4.2 Microsleep testing 
Testing for microsleeps involved assigning a monotonous repetitive tracking task the nature of which 
would facilitate the identification of ‘no response’.  During this task, eye behaviour is observed. 
Microsleeps are defined as brief periods – longer than 0.5 s but less than 15 s – where there was no 
motor response coincidental with eye closure and other indications of sleep, i.e. head nodding (Poudel 
et al., 2008). 
3.4.2.1 Tracking Task 
The tracking task was the same as that developed by Poudel and colleagues for the detection of 
microsleeps (Poudel et al., 2008).  Its suitability is reflected by its monotonous nature, which is 
conducive to microsleeps; the ability to detect, identify and measure motor performance with high 
temporal accuracy; that both eye behaviour and head movement could readily be videoed; and 
performance metrics could readily be synchronized with both EEG and the video data with millisecond 
accuracy.   
During this task, the participant was required to use a floor-mounted joystick to voluntarily track for 30 
min a moving target that tracks, without any ‘flat spots’, across a visual display unit in a 2-D 
pseudorandom manner – i.e., the target was always moving with a minimum speed.  Tracking 
performance was recorded at a sampling rate of 60 Hz by the SMCTests™ program for later analysis. 
Any lack of visuomotor responsiveness becomes evident due to either incoherent tracking or the 
presence of response flat spots attributable to a lack of joystick movement.   
The moving target was a yellow disc with a diameter of 7.8 mm.  It had a trajectory period of 30 s that 
was repeated 60 times to extend the task to a 30-min period (Figure 3-9).  The trajectory prescribed by 
the target disk was defined by summing seven sinusoids with frequencies evenly spaced between 0.033 
to 0.231 Hz for both the vertical and horizontal vectors of the target.  Poudel et al. (2008) considered a 
bandwidth of 0.231 Hz provides a moderately challenging task during baseline tracking, and a specific 
set of random-phase shifts in the vertical and horizontal components results in a trajectory that is largely 
unpredictable.  It also results in a target with a velocity range of 63–285 pixels per second.   Feedback 




 Figure 3-9  2-D continuous pursuit tracking task.  The trajectory of the target (c), traced by the yellow 
dot, was the result of summing seven sinusoids in two dimensions (a and b).  The red dot is the response 
cursor and provides visual feedback to the performer (from Poudel et al., 2008). 
3.4.2.2 Event Classification 
Microsleeps were identified and classified using a visual rating protocol developed by Innes et al. 
(2010), which in turn was based on the work of Peiris et al. (2006).  It involves a visual inspection of 
the recorded synchronized response and video data to identify a set of predefined characteristics.  The 
microsleep events were rated by an expert rater familiar with this rating procedure (RB).  
Where flat or incoherent tracking was observed for more than 500 ms, but less than 15 s, and full or 
partial eye closure (>80%) accompanied by clear behavioural indications of drowsiness, it was recorded 
as a microsleep. 
The distinction between a microsleep and sleep based on duration is arbitrary but, according to Poudel 
(2010), they are considered physiologically different because the recovery of responsiveness time is 
much shorter in a microsleep.  Therefore, events longer than 15 s, which would otherwise have met the 
criteria for microsleep, are sleep episodes.   
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Figure 3-10  Example of flat tracking as displayed by SyncPlayer.  The top two lines show the x-axes 
of the target track (smooth line) and the response (flat line).  The next two lines are the y-axes.  Partial 
eye closure occurred at 551.7 s coincidental with the beginning of a flat response.  Full eye closure 
occurred at 552.7 s.  Eyes began to open at 555.6 s and were fully opened 300 ms later at 555.9.  This 
was immediately followed by a saccade to the target.  Motor response began at 556.4 s. 
3.4.3 Psychomotor Vigilance Task 
The psychomotor vigilance task (PVT) used in this study is similar to the standard PVT proposed by 
Dinges and Powell (1985).  It is a reaction-based task of ten minutes that requires a participant to 
respond to a visual stimulus, which appears randomly with an inter-stimulus period of 2–9 s.  The 
stimulus used in this study was a numeric counter in the middle of the stimulus visual display unit that 
changed at each screen refresh (60 Hz) and displayed the time in ms since its appearance (Figure 3-11).  
The stimulus continued to change until the push-switch on top of the joystick was activated.  The 
stimulus – i.e., the time taken to respond – then remained visible for a further 500 ms to provide 
feedback to the participant on their performance for that trial.   
Since being proposed by Dinges and Powell (1985), the PVT has become a standard assay of attention, 
particularly in sleep studies (Ratcliff & Van Dongen, 2011; Veasey et al., 2002).  During the PVT, 
several trials are completed in which the participant reacts as quickly as possible to a stimulus.  This 
reaction time can be partitioned into two parts; time due to task demands, i.e., time required to physically 
complete the task, and time due to attention requirements.  An implicit assumption of the PVT is that it 
is the variability in attention, not task demands, that results in reaction times exceeding an arbitrary 500 
ms threshold (e.g. Belenky et al., 2003; Dinges & Powell, 1985). 
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3.4.3.1 Event Classification 
The identification of a PVT lapse was objective using system recorded data.  This was the time taken 
to recognize the stimulus plus time taken to depress the response button located on the top of the 
joystick.  By convention, reaction times in excess of 500 ms following the presentation of the PVT 
stimulus are considered to be lapses of attention (Anderson et al., 2010; Belenky et al., 2003; Chee & 
Choo, 2004; Graw et al., 2004; Loh et al., 2004; Ratcliff & Van Dongen, 2011; Van Dongen et al., 
2003).  In this study we have conformed to this convention and adopted the ubiquitous 500 ms as the 
threshold for determining the presence of an attention lapse. 
 
 
Figure 3-11  A screen shot of the PVT task as it appears on the stimulus VDU.  The white number is the 
stimulus for the PVT.  It first appears as a zero and then counts upwards in ms until the push-switch 
button on top of the joystick has been pressed.   
3.5 Procedure 
3.5.1 Polysomnographic testing 
All participants were required to have their OSA severity status assessed by a Level II Polysomnography 
prior to undergoing MRI or cognitive testing (see section 3.3.1  The process required the participant to 
attend an appointment at the Christchurch Hospital Sleep Unit where a sleep technologist, registered by 
the Board of Registered Polysomnographic Technologists (BRPT), (New York, Washington), placed 
the electrodes and sensors necessary for the polysomnography test.  The participant then went home set 
up for a night polysomnography undertaken in their own bed. In general terms this would mean going 
to bed and arising at their normal times that needed to be at least six hours. The following morning, the 
participant returned the recorder to the Sleep unit for analysis. 
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The polysomnography sleep records were scored manually in accordance with American Academy of 
Sleep Medicine guidelines (Berry et al., 2017) by a registered polysomnographic technologist employed 
by the Sleep Unit.  The Level II polysomnography provided: sleep statistics i.e., sleep period, total sleep 
time, sleep efficiency, sleep onset, etc.  The polysomnography also reported, sleep staging, ie, the 
amount and, percentage of total sleep time spent in the sleep stages. sleep summary, arousal statistics, 
position analysis, periodic limb movement analysis, pulse statistics, oximetry statistics, and respiratory 
indices – including the AHI score used to determine group membership eligibility (see Appendix D for 
an example of a sleep report).   
In addition to the polysomnography, all participants undertook a series of tasks that included an MRI 
scan, cognitive tests including a PVT, and a microsleep study.  The polysomnography was to be 
completed and scored prior to the commencement of the remaining tests.  However, due to Sleep Unit 
staff workloads, in some instances this did not happen, but every reasonable effort was made to ensure 
that the time between all baseline, or follow-up tests did not exceed 4 weeks.   
3.5.2 MRI ASL Process 
3.5.2.1 MRI data acquisition 
All participants underwent a series of MRI protocols at baseline and again following an intervening 
period of approximately six months.  All MRI scans were scheduled for an afternoon session.  Each set 
of scans took approximately 30 minutes to complete.  Participants were asked to arrive 15 minutes prior 
to their appointed time where they were met by the Co-ordinating Investigator, briefed on the procedure, 
and asked to provide their written consent.   
The sequence of scans at both baseline and follow-up included an initial localizer scan followed by a 
T1-weighted spoiled gradient recalled echo structural scan (T1 SPGR), and then the pseudo-continuous 
ASL (PCASL).  All scans were conducted by registered MRI technologists and clinically reviewed by 
a Registered Radiologist.  No participant had to be withdrawn from participating in the study because 
of clinical concerns arising out of the scans or because of unusable MRI scans. 
3.5.2.2 Observer Rating of Drowsiness 
During the ASL sequence, a video recording of the participant’s left eye was made from which a 
subsequent subjective drowsiness assessment was made by the Co-ordinating Investigator.  To facilitate 
this process, the MRI Technologist instructed the participant to keep their eyes open, except for normal 
blinks, during the ASL procedure.  Furthermore, during this procedure, background music was muted. 
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3.5.3 Cognitive test procedure 
Cognitive testing was undertaken at the New Zealand Brain Research Institute rooms.  The cognitive 
tests applied in this study are listed in Table 3-2, along with the neurocognitive domain investigated.   
To ensure homogenous circadian phasic and tonic arousal levels, all cognitive testing sessions were 
scheduled to begin at 1:00 PM.  Participants were instructed to eat a normal lunch, but to avoid coffee.  
Testing took approximately three hours to complete of which the PVT test and Microsleep testing took 
45 mins.  Cognitive testing was done in a bright, naturally lit room measuring approximately 3m x 2.5m 
that contained a single desk separating the participant from the Co-ordinating Investigator (RB), who 
administered the tests.  This room, in the New Zealand Brain Research building, Christchurch, was in 
a quiet part of the building away from most noise.   
The session began with the participant completing a Beck Depression Inventory (BDI ii) (García-Batista 
et al., 2018), the PSQI questionnaire (Buysse et al., 1989), the Epworth Sleepiness Scale (Johns, 1991), 
and the health-related quality-of-life SF12 form (Huo et al., 2018).  Following the completion of those 
four surveys the participant next completed the battery of cognitive tests in the order listed in Table 3-2.   
At the completion of the Judgement of Line task, participants were allowed a 10 min rest period.  They 
were then taken into a separate room, which housed the continuous tracking task used to measure 
microsleeps, and PVT set-up.  Here they completed the 30-minute continuous tracking task and the 10-
minute PVT task. 
3.6 Statistical considerations 
3.6.1 Statistical power and effect 
GPower (Faul et al., 2007) was used to calculate the minimum effect size that our analyses were 
powered to observe.  Power calculations required the following inputs: type of statistical test to be used, 
alpha level (0.5), whether the test would be one or two tailed, the participant numbers (n = 30 for 
moderate OSA and n = 15 for treated, untreated and controls) and desired power level, which by 
convention, we used 80% ("Article Summaries for May 2015 Psychosomatic Medicine, Volume 77, 
Issue 4," 2015; Howell, 2007).  Furthermore, according to Brysbaert (2019), an effect size of d = .4 is a 
good first estimate of the smallest effect size of interest in psychological research.   
The following power levels were calculated:   
1) To determine if there were regions in the brain which showed lower cerebral perfusion in people 
with moderate OSA compared with controls at baseline, a t-test (independent groups) with n = 
30 vs n = 15 provides 80% power to observe an effect size of 0.80 or greater (alpha level 0.05, 
one-sided). 
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2) To determine if there are regions in the brain which show lower cerebral perfusion in people
with moderate OSA after 6 months of APAP treatment compared with people with moderate
OSA who have not had treatment, a t-test (independent groups) n=15 vs n=15 will provide 80%
power to observe an effect size of 0.93 or greater (alpha level 0.05, one-sided). This is the least
powerful comparison.
3) To determine if there are regions in the brain which show higher cerebral perfusion in people
with moderate OSA after 6 months of APAP treatment compared with their cerebral perfusion
at baseline prior to treatment, a t-test (dependent sample – intraindividual comparison) with n
= 15 vs n = 15 provides 80% power to observe an effect size of at least 0.47 or greater (alpha
level 0.05, one-sided).
4) To determine if there is an overall effect of group and APAP-treatment on microsleeps, an
ANOVA (repeated measures, within-between interaction) includes three groups of n = 15 with
two measurements should provide 80% power to observe an effect size of 0.24 or greater (alpha
level 0.05), which is less than generally acceptable. (Brysbaert, 2019).
Given that statical power of 80% is generally acceptable (Page, 2014), then the power of the study 
would be adequate even for the least powerful comparison our study design allowed.   
3.6.2 Overview 
This was a longitudinal quantitative study to investigate the impact of OSA on cerebral perfusion, 
cognition, microsleeps and quality of life measures.  It involves the collection of cerebral perfusion data 
and cognitive functioning scores at baseline and again after an intervention period of approximately 
six-months. It also involved for those in the moderate OSA group a follow-up polysomnography.  This 
second sleep study was done off APAP so that we could get an indication of any change in AHI over 
that of 6 months earlier at baseline. If APAP was purely a symptomatic treatment, we would have 
expected no change, unless there was an actual deterioration in the underlying condition of sufficient 
magnitude as to be detected after only 6 months.   
Following the six-month intervention period during which the treated cohort was provided with 
APAP therapy, the treated cohort underwent a second set of tests that consisted of polysomnography, 
ASL, cognition, and microsleeps with polysomnography, ASL and cognitive/microsleep tests done on 
separate days.  Participants used APAP on the night immediately prior to their ASL, cognitive, and 
microsleep tests.  On the night of the polysomnography test, they were instructed not to use it. 
Moreover, in all instances, the second polysomnography was not undertaken on nights immediately 
prior to the other tests.  Accordingly, in those instances where the polysomnography preceded the other 
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tests, treated participants were instructed to continue using APAP on subsequent nights until the other 
tests were completed (i.e., ASL, cognition, microsleeps). 
Kribbs et al. (1993) found that just one night off nasal CPAP was sufficient to reverse all of the sleep 
and daytime alertness gains derived from CPAP Similarly, Weaver and Sawyer (2010) found that even 
one night off CPAP was sufficient for the return of symptoms and other manifestations of OSA. 
Furthermore, CPAP withdrawal has been shown to led to an immediate recurrence of sleep apnoea with 
increases in apnoea index, arousal index and oxygen desaturation (Grunstein et al., 1996).  
Refraining from APAP on the night of the polysomnography was not considered to disrupt the treatment 
regimen, as an acceptable compliance for the treatment of OSA requires CPAP to be used on at least 
70% of nights in any given month (Avlonitou et al., 2012). 
Of interest, was the impact of APAP therapy on perfusion, cognition, microsleeps, and quality of life 
from the treated cohort compared to the results from the untreated cohort.  To control for  possible 
practice effects that can occur in a longitudinal study (Caruana et al., 2015), a control group without 
OSA was established and subjected to the same assessments with the exception of the second 
polysomnography that was not required from the control group. 
3.6.3 One-tailed tests 
One-tailed tests 
Both one-tailed and two-tailed tests were used in this study.  Where one-tailed tests were used, this was 
on basis of there being no conceivable mechanism for a significant difference being in the direction 
other than that hypothesized, otherwise two-tailed tests were used (Coolican, 2005).     
3.6.4 Significance level and p-values 
The significance level applied to statistical tests is α = .05.  Fisher (1990) nominated 0.05 as a threshold 
of significance early in the 20th century.  It is a value typically used in social sciences (Coolican, 2005; 
Moran, 2003). However, the usefulness of a p-value has being questioned because it is prone to being 
miss- or over- interpreted, leading to serious methodological errors and misinterpretations 
(Panagiotakos, 2008).  Yet, despite the criticisms made, all agree that the significance level for a test 
should be decided before the data are viewed and compared. 
With respect to multiple comparisons, there is an increased risk of making a type I error unless a 
correction is applied to the p value.  Frequently in social science studies, the Bonferroni correction has 
been employed.  However, several papers have criticized the Bonferroni correction as being too severe 
(Columb & Sagadi, 2006; Moran, 2003), as it can substantially increase the risk of committing a type 
II error.  Benjamini and Hochberg (1995) proposed a methodology to avoid this criticism by controlling 
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the expected proportion of errors among the rejected hypotheses which they called the false discovery 
rate (FDR).  Nonetheless, where the measurements are independent the Bonferroni correction is 
accurate.  However, measurements of CBF, both global and regional, involve multiple comparisons of 
adjacent voxel that are not independent.  Accordingly, where multiple comparisons of perfusion are 
made in this study, an FDR corrected p value was used (Benjamini & Hochberg, 1995; Columb & 
Sagadi, 2006).   
3.6.4.1 Measures 
Five measures were analysed in this study.  These measures are shown in Table 3-4, along with their 
source – i.e., the task that produced them – and their application. 
Table 3-4  Measures, their source, and application. 
Measure Task Source Application 
Primary Demographic measures. Participant interviews, 
Polysomnography. 




perfusion at baseline 
and follow-up. 
MRI ASL scans. To understand how controlling 




perfusion at baseline 
and follow-up. 
MRIASL scans. To understand how controlling 
moderate OSA affects 
perfusion rates. 
Difference between 
cognition scores at 
baseline and follow-up. 
Cognitive tests 
including the PVT test 
To understand how controlling 
moderate OSA affects 
cognition. 
To understand how changes in 
cerebral perfusion affects 
cognition. 
Difference between 
microsleep scores at 
baseline and follow-up 
Microsleep task To understand how controlling 
moderate OSA affects 
microsleep rates. 
Secondary Microsleep duration Tracking and dual tasks To test if either task 
differences or microsleep 
frequency impact microsleep 
duration 
Tracking error Tracking and dual tasks To test task differences and to 
determine if motor skills 
reflect microsleep frequency 
Reaction time PVT and dual tasks To test task differences and to 
determine if motor skills 
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Measure Task Source Application 
reflect the frequency of 
attention lapses 
3.6.5 Research questions and statistical tests 
Following confirmation that the data is parametric using normality testing feature of SPSS, unpaired t-
tests shall be used to determine differences in microsleeps and cerebral perfusion at baseline between 
controls, people with moderate OSA who are treated, and people with moderate OSA who are untreated. 
Otherwise, nonparametric statistical methods shall be used such as the Mann-Whitney U test, and the 
Wilcoxon Signed Ranks test. 
Questions that give understanding to the make-up of the three cohorts that comprising the two main 
groups (moderate OSA and control) along with the research questions arising from the six hypotheses 
stated in the introduction along with the statistical test are tabulated below Table 3-5. 
Table 3-5  Hypotheses and research questions along with their proposed statistical test 
Hypothesis and research questions Proposed statistical tests 
Do group demographics between the 
moderate OSA group and the control group 
differ at baseline? 
To test for group differences in age Mann-Whitney U 
test was used. 
To test for gender differences a Chi square test was 
used. 
Do cohort demographics between the treated 
cohort, the untreated cohort differ at 
baseline? 
To test for group differences in age Mann-Whitney U 
test was used. 
To test for gender differences a Chi square test was 
used. 
Does the mean PSQI score between the 
moderate OSA group and the control group 
differ at baseline? 
To test for group differences a Student t-test was used 
Does the mean ESS score between the 
moderate OSA group and the control group 
differ at baseline? 
To test for group differences in ESS a Mann-Whitney 
U test was used. 
Does the mean Montreal SF-36 score 
between the moderate OSA group and the 
control group differ at baseline? 
To test for group differences in SF-36 a Mann-
Whitney U test was used. 
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Hypothesis and research questions Proposed statistical tests 
Does the moderate OSA group experience 
reduced cerebral perfusion while awake 
compared to the control group? 
Mean baseline global perfusion of the moderate OSA 
group will be tested using an independent samples t-
test (one-tailed) to determine if it is lower than the 
mean perfusion from the control group as 
hypothesized. 
Regional perfusion for the moderate OSA group and 
the control group will be tested at baseline using 
FSL’s Randomise independent samples t-test script.  
This is a non-parametric permutation inference tool 
used in neuroimaging studies (Winkler et al., 2014). 
Are the Cognitive scores of the moderate 
OSA group less than the scores from the 
control group? 
Baseline cognitive scores from each task for the 
moderate OSA group will be tested to determine if it 
is lower than the cognitive scores from the control 
group as hypothesized, using an independent sample 
t-test.
Does the Moderate-OSA group experience 
more microsleeps than the control group? 
Baseline microsleep counts from the Moderate-OSA 
cohort and the control cohort will be tested using 
Mann-Whitney U.  
Is the mean cerebral perfusion, experienced 
by the treated cohort at baseline, increased 
following six-months of APAP therapy?  
Differences in the mean global perfusion scores of the 
treated cohort at baseline and follow-up will be tested 
using a paired sample t-test. 
Differences in the regional perfusion scores of the 
treated cohort at baseline and follow-up will be tested 
using FSL’s Randomise paired samples t-test script 
with AHI, drowsiness, age, sex, and gCBF as co-
variates.   
Is the mean level of cognition, experienced 
by the treated cohort at baseline, improved 
following six-months of APAP therapy? 
A paired samples t-test will be undertaken to 
determine if the mean cognitive score at follow-up is 
higher than the cognitive score at baseline. 
Is the mean count of microsleeps, 
experienced by the treated cohort at baseline, 
reduced following six-months of APAP 
therapy? 
A paired samples t-test will be undertaken to 
determine if the mean microsleep count at follow-up 
is reduced compared to the count taken at baseline. 
Are measures of ODI, ST90, arousal time, 
and BMI better correlates of global cerebral 
blood flow than AHI?  
Measures of AHI, ODI, ST90, arousal time, and BMI 
will be correlated with global cerebral perfusion. 
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3.6.6  Effect sizes of OSA on cognition 
Table 3-6 (Stranks & Crowe, 2016) lists the effect sizes for 13 cognitive domains.  Using meta-
analysis, Stranks and Crowe investigated the cognitive functioning of 811 patients in 19 studies prior 
to them receiving any treatment.  OSA severity ranged from mild to severe with seven studies being 
mild to severe, seven studies being moderate or severe and 5 studies being severe only. 
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Table 3-6  Summary statistics for the effects of OSA (listed in order of decreasing weighted negative 
effect size) on each domain of cognitive functioning. 
Cognitive domain Number of 
studies 
Cohen's d 95% CI lower 95% CI upper 
Non-verbal memory 7 −0.79* −0.97 −0.60
Concept formation 4 −0.78* −1.12 −0.45
Psychomotor speed 7 −0.70* −0.92 −0.49
Construction  7 −0.69* −0.86 −0.51
Executive function 12 −0.64* −0.70 −0.48
Perception  1 −0.61 −1.30 0.07 
Motor 
control/performance 
6 −0.60* −0.74 −0.46
Attention 14 −0.57* −0.66 −0.47
Speed of processing 11 −0.52* −0.69 −0.35
Working memory  8 −0.41* −0.61 −0.22
Verbal memory  10 −0.39* −0.50 −0.28
Verbal 
functions/language 
3 −0.38* −0.73 −0.03
Verbal reasoning 11 −0.36* −0.51 −0.22
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Chapter 4  Results 
4.1 Introduction 
Subject demographics, clinical and polysomnographic measures, brain structure imaging, along with 
measures of global and regional cerebral perfusion, cognition, and microsleep counts were recorded at 
baseline and repeated following an approximate seven-month intervention period.  During that time, 
the treated cohort undertook a course of APAP therapy.  A summary of the research questions and 
hypotheses addressed is listed in Methods 3.6.3. 
4.2 Research participants 
The study design was based on 15 members being recruited for the treated cohort, 15 members for the 
untreated cohort and 15 members for the control group.  One hundred and eleven prospective 
participants were approached.  The final numbers recruited were: 
• 13 members in the treated cohort,
• 11 members in the untreated cohort of which four came from the treated cohort on evidence of
non-APAP compliance, and
• 7 members in the control group.
The total number was 31 of which the moderate severity group had 24 participants.  
To determine if a bias had been introduced into the Untreated cohort because of those who could not 
tolerate OSA being recruited, their individual results were compared against those results from the other 
remaining seven members of the Untreated cohort.  Comparing the mean and standard deviation for 16 
measures of sleep, cognition, microsleeps and QOL taken at baseline showed that in 17 of 64 instances 
was 1x SD was exceeded and in only one instance was 2x SDs exceeded, this being for microsleeps. 
4.2.1 Recruitment and exclusions 
Two flow charts show where recruits for the moderate severity group and control group were excluded 
and the reasons why. 
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Figure 4-1.  Recruitment results for the moderate sleep apnoea group.  Note that the medical reasons 
were not related to any of the studies interventions. 
CDHB patients with initial diagnosis of 
moderate OSA and who had agreed to 
be contacted re participation 
N = 78 
Number who declined participation due 
to: 
• Lack of interest = 5
• Reason not given = 6
N = 11 
 Number who agreed to initial 
screening. 
N = 67 Number excluded due to: 
• Language = 2
• AHI < 15 or > 30 = 29
N = 31 
Number subsequently lost due to: 
• MRI intolerance = 2
• CPAP intolerance = 2
• Loss of interest = 6
• Medical reasons = 2
N = 12 
Number with confirmed moderate-
severity OSA who completed 
Baseline tests. 
N  36
Number who completed Follow-up 
tests. 
N = 24 
Number in the Untreated cohort. 
N = 11 
Number in the Treated cohort. 
N = 13 




Figure 4-2.  Recruitment results for the control group. 
4.3 APAP Compliance  
4.3.1 Usage 
APAP compliance was monitored in the treated group.  The mean number of days between beginning 
APAP therapy and the follow-up MRI scan was 200.3 days (SD = 23.3, range 191 – 259).  The mean 
number of days between beginning APAP therapy and the follow-up cognitive tests was 205.6 days 
(SD = 23.9, range 192 – 270). 
 
 
Number of potential controls 
contacted re participation. 
N = 33 
Number who agreed to initial 
screening. 
N = 26 
Number with AHI < 10 who 
completed Baseline tests. 
N = 21 
Number who declined 
participation due to: 
• Lack of interest = 2 
• Time commitment = 5 
N = 7 
 
 Number excluded following level 
2 polysomnography due to: 
• AHI > 10  
N = 5 
 Number lost due to: 
• Lack of commitment = 4 
• Medical = 1 
• Scheduling = 2 
• Withdrawal of consent = 2 
N = 9 
 Number with AHI 5 < AHI < 10 
N = 5 
 Number with AHI < 5 
N = 7 
Number who completed Follow-up 
tests. 
N = 12 
Control Group 
80 
The percentage of days APAP was used over the 180-day period preceding the follow-up cognitive 
testing was 90.8% or 163.5 days (SD = 17.9).  Nightly use over the same 180-day period was 6.08 hr 
(range = 3.97–7.88 h).  On the other hand, because of scheduling differences between tasks, APAP 
mean usage over the 180-day period preceding the MRI scan was 91.8% or 165.3 days (SD = 14.2 days).  
Nightly use over the 180 days immediately prior to the MRI scan was = 6.13 h (min 4.73 h, max 7.87 
h).  There was no difference in either the number of days APAP was used (t(12) = -1.18, p = .259), or the 
nightly hours used (t(12) = -0.92, p = .378) for the two periods.  All treated cohort members met 
compliancy requirements on the day of their ASL scan and cognitive/microsleep tests. 
Following the recommendation by Aloia et al. (2004) to compare APAP usage with cognitive results, a 
Pearson's product-moment correlation was run.  There was no statistically significant correlation 
between hours of APAP use and cognition, r(11) = .24, p = .423 (see Figure 4-9). 
Figure 4-3  Scatter plot of the treated cohort’s (n = 13) standardized total cognitive score plotted 
against their APAP usage (expressed as hours of use).   
4.3.2 Therapy 
Over the 180-day treatment period preceding follow-up cognitive testing, the mean AHI for those 
receiving APAP therapy was 3.68 events per hour (range = 1.1–8.9) with a median of 2.6 (see chart of 
individual scores in ).   
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Figure 4-4  Average AHI events per hour for the treated (n = 13) and untreated (n = 11) cohorts 
during the 180 days prior to their follow-up cognitive test. 
4.3.3 APAP machine retention. 
At the conclusion of the data collection phase, those participants in the treated cohort were generously 
offered the APAP machines by ResMed who provided them for the study.  Of the 19 machines assigned 
to participants three were returned with the 16 remaining machines being retained.  Eleven of the 12 
comments addressing that offer, expressed a willingness by the recipients to continue using the 
machines despite this study not being able to demonstrate an improvement in cerebral perfusion, or 
cognition, or microsleeping.  Comments by those retaining the machines indicate a benefit was found 
in sleep quality for both the wearer and bed partner (see comments in ). 
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Table 4-1.  Comments received by 12 participants on being asked if they wanted to retain the APAP 
machine they were prescribed for their use. 
APAP recipient comments 
“Now that I have the correct fitting mask, I'm happy to keep it and continue using 
it.  I'm grateful to ResMed for their generous offer and fully accept the terms on 
which I assume ownership.” 
“Thanks. I’ll keep the machine.  I’m also happy to participate in any future tests and 
have a couple of friends who could also be interested in being ‘guinea-pigs’.” 
“I appreciate ResMed offering me to keep the machine.  I am obliged to keep using 
it at my wife’s instruction.  Apparently, I snore the house down if I don’t.” 
“I am still using the machine so would like to keep it. Thanks” 
“I’d rather keep the machine please.” 
“If at all possible, I would like to keep the APAP machine. I am still using it almost 
every night and both my wife and I feel that I sleep better when I am using it 
(hopefully it is still doing me some good).” 
“I am using the APAP nightly and getting great benefit from it.  I am no longer tired 
during the day and feeling quite rested after a night’s sleep. Very keen to hang onto 
it.” 
“I'm still using the APAP machine, and feel like I'm getting some benefits from it, 
so I will gratefully hang on to it.” 
“I would like to keep the APAP machine.” 
“Ok thanks for that, I am still using the machine and would like to keep doing so as 
I am sure it is helping me.” 
“Thanks for the kind offer, but I’m trying new medication so will return the 
machine.” 
“I continue to use the machine with very good effect. My average nightly sleep time 
is slowly creeping up to the six-hour mark and I am very grateful!  I bought a new 
nose-only mask which suits me better. At the rare times I don't use it, I remember 
what a complete pain it is to wake in a panic to start breathing again.  So, thank you 
for this and the opportunity to keep the machine. My head is very much clearer each 
day and I have the luxury of waking naturally each morning.” 
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4.4 Test-retest intervals 
This was a repeated-measures longitudinal study in which the intended interval between test-retest was 
to be approximately 180 days.  However, because limited access to the MRI scanner did not always 
align with subject availability, the mean interval between the MRI test-retest across all cohorts was 
231.9 days, (Min = 171, Max = 434), while the mean interval between the cognitive and microsleep 
tests was 241.0 days (Min = 192, Max = 349).  Note that in all instances the microsleep test was 
completed on the same day as the cognitive tests.  At baseline, the mean number of days between the 
MRI scan and the cognitive tests was 23.2 days (Min = 1, Max = 232). 
Follow-up intervals:  The difference in time intervals between the three cohorts, treated, untreated, and 
control, were explored using a boxplot and the Kruskal-Wallis H test.  The boxplots of the test-retest 
interval times for the three cohorts across MRI scans and the cognitive/microsleep tests are shown in 
Figure 4-5, followed by Kruskal-Wallis H test results in Table 4-3. 
Figure 4-5.  Interval in days between MRI scans and cognitive/microsleep tests at baseline and follow-
up for the three cohorts. 
Of the three cohorts, the highest level of variability and the largest intervals between tests and scans 
were in the untreated cohort (see Table 4-3). In one instance, it took 434 days before the follow-up MRI 
scan could be completed.  Nonetheless, to determine if there was a difference in the test-retest interval 
between baseline and follow-up tests, a non-parametric Kruskal-Wallis H test was run.  It showed that 
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the test-retest intervals for the three cohorts were not significantly different for either MRI, or 
cognition/microsleep.   
Table 4-2.  Cognitive and microsleep tests, and the MRI Scan intervals between baseline and follow-
up.   
Cohort N Median 
(days) 
IQR Kruskal-Wallis H Test 
Cognitive/microsleep Interval Treated 13 235 58.5 
Untreated 11 245 54 
Control 7 231 43 χ2(2) = 3.87, p = .145 
MRI Scan Interval Treated 13 213 49.5 
Untreated 11 224 64 
Control 7 210 42 χ2(2) = 1.49, p = .474 
Overall, the treated, untreated and control intervals between baseline and follow-up for 
cognition/microsleep (median = 236.0 days, IQR = 53.0) were longer than those for MRI scans (median 
= 214.0, IQR = 43.0).  Nonetheless, the interval difference between the two sets of tests was not 
statistically significant (Z = 1.21, p = .228).   
4.5 Polysomnographic results 
4.5.1 Apnoea Hypopnoea Index 
Research participants were approached for possible participation in this research based on a two-
channel, level III polysomnography, performed as a screening study for clinical indications.  Those that 
agreed to participate underwent a further baseline level II polysomnography.  As summarized above, 
five patients had a higher AHI on polysomnography than with the screening test and as a result were 
excluded.  The baseline descriptive data for the participants included in the moderate sleep apnoea and 
the control group are shown in Figure 4-6 and tabulated in Table 4-4. 
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Figure 4-6.  Apnoea hypopnoea count per hour for the three cohorts taken at baseline.  The boxplots 
show maximum and minimum values along with both upper and lower quartiles as well as median 
score. 
The AHI difference between the moderate group and the control group at baseline was significant (t(29) 
= 10.90, p = <.001, d = 5.35) however the difference in AHI was not significantly different between the 
treated cohort and the untreated cohort (t(22) = 0.41, p = 0.689, d = 0.16) 
Table 4-3.  Group/Cohort AHI statistics taken at baseline. 
Group/Cohort N Mean 
AHI 
SD Minimum Maximum 
Moderate sleep apnoea 24 21.72 4.49 15.6 29.9 
Treated 13 22.07 4.47 16.3 29.9 
Untreated 11 21.30 4.70 15.6 27.8 
Control 7 2.46 2.07 0.2 4.9 
 
The two cohorts treated and untreated, that constituted the group with moderate OSA, underwent a 
second level II polysomnography following an intervention period of 6–7 months (Table 4-5).  The 
control group did not have a follow-up polysomnography test.  It must be noted that APAP treatment 
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was to be suspended during the night of the polysomnography.  However, in three instances (participants 
001, 002 and 077), APAP was used the night of the repeated polysomnography testing contra to 
instructions.  Accordingly, those subject’s follow-up polysomnography results, i.e., AHI, oxygen 
desaturation index, arousal count and total time below ST90 were excluded from analysis.  Also, two 
untreated participants declined to undergo a second polysomnography (Participants 028, 089) and one 
untreated subject was unable to get a booking with the Sleep Unit within the studies funding cut-off 
date (Participant 093). 
Table 4-4.  Moderate sleep apnoea group AHI statistics at follow-up. 
Cohort N Mean 
AHI 
SD Minimum Maximum 
Treated 10 17.92 13.29 5.9 49.7 
Untreated 8 25.56 10.19 14.9 40.5 
Figure 4-7 shows the relationship between baseline and follow-up AHI for the treated and untreated 
cohorts.  Four participants from the treated cohort and one subject from the untreated cohort had an 
AHI at follow-up which would reduce their OSA severity category from moderate to mild.  One subject 
from the treated cohort, and three participants from the untreated cohort had AHIs at follow-up which 
increased their OSA severity level to severe.  The member of the treated cohort whose AHI score 
increased from 26.3 to 49.7 at follow-up had good compliance with an average daily use of 5 h, 46 min 
for 168/193 days.  However supine sleep increased markedly from 0% at baseline to 70.6% at follow-
up which may have accounted for the increase. 
The follow-up polysomnography was also compared to the baseline polysomnography to see if any 
pathological factors had arisen over the intervening months that could impact AHI results.  There were 
none.   
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Figure 4-7.  Individual AHI scores for the treated (n = 10) and untreated (n = 9) cohorts at baseline 
and follow-up.  Only the treated members who did not use their APAP machine on the night of the 
polysomnography are shown.  The control group did not do a follow-up polysomnography hence the 
absence of a line plot for that group.  Boxplots show maximum and minimum values along with both 
upper and lower quartiles as well as median score. 
4.5.1.1 AHI differences between groups and between baseline and follow-up 
At baseline, the AHI in the moderate group was higher than the AHI in the control group (t(29) = 10.91, 
p < .001), and at baseline AHI did not differ significantly between the treated and the untreated cohorts 
(t(22) = 0.41, p = .686, two tailed). 
A Pearson correlation across all moderate sleep apnoea participants indicated there was a positive 
association between AHI at baseline and again at follow-up (r(19) = 0.50, p = .030).  However, follow-
up AHIs from either the treated cohort (t(9) = 1.22, p = .253), or the untreated cohort (t(7) = -1.03, p = 
.336) were not significantly different from baseline AHIs (see Table 4-6). Three participants in the 
treated cohort were excluded because they used the APAP machine on the night of the follow-up 
polysomnography contra to the study design.  
88 
Table 4-5.  AHI scores for the treated and untreated cohorts at Baseline and at follow-up 
Moderate sleep 
apnoea  
Baseline AHI Follow-up AHI 
Treated N = 10 M = 23.44 SD = 4.17 N = 10 M = 18.92 SD = 12.64 
Untreated N = 8 M = 22.69 SD = 4.75 N = 8 M = 25.56 SD = 10.20 
4.5.2 Arousal Counts 
The number of arousals per hour of sleep for the moderate OSA group and the control group were 
recorded during their baseline level II polysomnography.  The difference in arousal counts between the 
two groups were tested for equality using the nonparametric Mann-Whitney U test for two independent 
samples which found a difference between the moderate group (median = 13.1) and the control group 
(median = 8.4), U = 38.5, z = -2.15, p = .029, r = 0.39 using an exact sampling distribution for U.  
However, there was no significant difference in arousal counts between baseline and following APAP 
treatment for the treated cohort, using the non-parametric Wilcoxon Signed ranks test, 
(z = -0.53, p = .638 two-tailed, r = 0.11).  This result is reflected in Figure 4-8.  With respect to the 
treated cohort, the small difference between arousal counts at baseline compared to the follow-up counts 
indicates that APAP treatment does not have a lasting therapeutic impact on arousal counts beyond the 
night of treatment.   
In keeping with expectations, arousal counts decreased in 8 of the 13 instances for the treated cohort, 
whilst 3 of the 8 untreated cohort members decreased arousal counts.  Furthermore, as can be seen, 
there are large variances in scores for both cohorts in both directions. 
The outlier at follow-up (54 arousals per hour) was the same participant whose AHI score at follow-up 
increased markedly.  Evident at the individual level is the marked heterogeneity of counts within and 
between participants 
The participants were requested to cease APAP treatment on the night of the repeat sleep study, so 
changes in arousal counts during APAP usage cannot be inferred. 
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Figure 4-8.  Arousal counts per hour at baseline and follow-up for the treated (n = 13) and untreated 
(n = 8) cohorts.  The control group did not do a follow-up polysomnography. 
Arousal counts were plotted against AHI for all participants (Figure 4-9).  A Pearson correlation test 
between the two factors confirmed a positive correlation between AHI and arousal counts (r(31) = 0.38, 
p = .036) – as the AHI increased so did the arousal count. 
This positive correlation indicates that the moderate sleep apnoea group had a tendency towards more 
arousals during sleep than the control group which can be seen in Figure 4-9.   
With respect to the treated cohort, the almost zero difference between arousal counts at baseline 
compared to the follow-up counts indicates that APAP treatment does not have a lasting therapeutic 
impact on arousal counts beyond the night of treatment.   
There was no difference between baseline and follow-up arousal counts for the treated and untreated 
cohorts.  However, there was considerable individual differences with two treated members increasing 
their arousal counts significantly at follow-up.  It is noted that that the member with the greatest increase 
in arousal count at follow-up also had the greatest increase in their follow-up AHI count. 
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Figure 4-9.  Arousal counts and apnoea/hypopnoea index scores at baseline for treated (n = 13) and 
untreated (n = 11).  The fitted line indicates a positive correlation between the two factors. 
Correlations between arousal counts, Epworth Sleep Quality results, Pittsburgh Quality-of-life indices 
and Medical Outcomes study, including all eight subtests, were tested using the Pearson correlation test.  
Only arousal counts and Pittsburgh Quality-of-life scores were moderately correlated (r(31) = 0.37, p = 
.039).   
4.5.3 Oximetry – ST90  
SpO2, also known as oxygen saturation, is a measure of the amount of oxygen-carrying haemoglobin 
in the blood relative to the amount of haemoglobin not carrying oxygen.  Time spent with peripheral 
oxygen saturation levels below 90% was measured during the polysomnography at baseline and at 
follow-up for the two cohorts that constitute the moderate sleep apnoea group, and at baseline for the 




Figure 4-10.  Total oxygen saturation time spent below 90 percent for the two cohorts that constitute 
the moderate sleep apnoea group, and the control group, all at baseline.   
The median baseline value for the control group was 12.2 (IQR = 27.6), which was slightly, but not 
significantly higher (U = 70.00, z = -0.66, p = .532) than the median value for the moderate sleep apnoea 
group (Median = 11.8, IQR = 28.4.  
Spearman’s rho was used to correlate Total time ST90 against arousal counts, ESS, behavioural 
microsleeps, drowsiness, global cerebral perfusion, PSQI and SF-36 at baseline (Table 4-7).  None of 
the correlations were significant. 
Table 4-6.  Spearman’s rho correlations between ST90 against AHI, arousal, ESS, microsleeps, global 
cerebral perfusion, PSQI, and SF 36. 
  AHI Arousa
l 
ESS MSleep gCBF PSQI SF-36 
ST90 rs .27 0.03 0.27 0.25 -.02 0.20 -0.10 
 p .144 .895 .135 .173 .920 .275 .584 
Spearman’s rho was also used to calculate the correlation between ST90 and composite cognitive score 
at baseline.  The result approached significance (rs(30) = -0.33, p = .07) with a negative correlation 
indicating that greater time spent with reduced oxygen while asleep is associated with a lower cognition 
score when awake. 
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Baseline and follow-up counts for ST90 when SP02 fell below 90% are presented in Figure 4-11.  The 
treated member (participant 013) whose SPO2 count went from 20 at baseline to nearly 30 at follow-up 
and the untreated member (participant 091) score went from just over 2% to 20% had their scores 
checked for data entry eerrors and conformed as correct.  Their scores were also compared with their 
cognitive scores.  Participant 013 had an overall cognitive score of 0.57 SD while participant 091 had 
a follow-up score for cognition at -0.09 SD and was the lowest of the follow-up scores for the untreated 
cohort.  A review of the five cognitive domains showed that participant 91 had the lowest “speed of 
processing” score (-1.79) and scond lowest “executive function” score of -1.57 SD.  It is also worth 
noting that the participant with the second highest overall cognitive score at follow-up also had a 
moderately low ST90 score of 1.2%.  The participant with the highest cognitive score at follow-up did 
not have an oximetry test done at follow-up.   
Figure 4-11  Total saturation time below 90% (min) for the treated (n = 13) and untreated (n = 11) 
cohorts at baseline and follow-up.  An increased score indicates a worsened state. 
4.5.4 Correlation between AHI and other measures 
Spearman correlations indicate that AHI was positively associated with arousal counts, ESS, and PSQI 
scores, but not with Microsleeps, or SF-36 score at baseline (Table 4-7).  However, because the SF-36 
instrument is more than a measure of sleepiness, the possibility needed to be explored that some of the 
items constituting the SF-36 might obfuscate valid associations.  Accordingly, the correlations between 
AHI and each of the eight items that comprise the SF-36 (i.e., physical functioning, role-physical, bodily 
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pain, general health, vitality, social functioning, role-emotional, and mental health) were calculated 
(Table 4-8). 
Table 4-7.  Spearman-rho correlations between AHI and number of arousals, ESS, Microsleep counts, 
PSQI scores and the SF-36 ratings.   
  Arousal ESS Micro- 
sleeps 
PSQI  SF-36 
AHI rs .36 * .58 ** .11 .43 * -.09 
 p .048 .001 .554 .015 .630 
Note:  N = 31 in all instances. 
*Correlation significant at 0.05 level, ** correlation significant at 0.001 level  
 
Table 4-8.  Spearman-rho correlations for AHI against the eight SF-36 items.   














AHI rs -0.24 0.05 0.27 -0.36 -0.37 -0.29 -0.32 -0.32 
 p .099 .405 .071 .023* .021* .055 .039* .041* 
* Correlation significant at 0.05 level (1-tailed).  ** Correlation significant at the 0.01 level (1-tailed). 
 
Thus, while the overall score for SF-36 was not significantly correlated with AHI, when the SF-36 is 
broken into its component parts, four of the components were significantly associated with AHI – 
General Health, Vitality, Role Emotion, and Mental health.  That is, an increase in AHI is associated 
with poorer health, loss of vitality, increase in emotional problems, and poorer mental health.   
4.6 Clinical Results 
4.6.1 Body Mass Index (BMI) 
To understand the BMI profiles of the moderate sleep apnoea and the control groups, BMI data were 
collected from all participants at the time of their sleep study.  Because the control group did not have 
a follow-up sleep study, only one set of BMI data collected at baseline was available for that group.  
Otherwise, two sets of BMI data were available for the two cohorts that made up the moderate sleep 
apnoea group. 
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A boxplot of the BMI scores showing the distributions for the two cohorts that constitute the moderate 
sleep apnoea group and the control groups at baseline is shown in Figure 4-12. 
Figure 4-12.  Body mass index scores at baseline for the three cohorts.  Box plots show maximum and 
minimum values along with both upper and lower quartiles as well as median score. 
A Mann-Whitney U test found there a difference between the BMI scores for the moderate sleep apnoea 
group (mean rank = 18.29) and the control group (mean rank = 8.14) (U = 29.00, z = -2.60, p = .006). 
Differences between follow-up and baseline BMI scores within the treated and untreated cohorts were 
tested using the Wilcoxon Signed Ranks test.  The BMI median scores for the treated cohort at baseline 
and follow-up were 27.7 and 28.6 vs 30.2 and 31.8 for the untreated cohort.  However, the differences 
were not significant (z = -0.13, p = .918, and z= -1.12, p = .313, for treated and untreated cohorts 
respectively) indicating there was no significant change in a person’s BMI score during the period 
between baseline and follow-up tests.   
4.6.2 Drowsiness during the arterial spin labelling scan 
The drowsiness of all participants, as proposed by Wierwille and Ellsworth (1994), was rated during 
the ASL sequence of the MRI scan both at baseline and at follow-up.  The correlation between 
drowsiness during the MRI scan and AHI was not significant (rs(31) = 0.31, p = .850 two-tailed). 
 Drowsiness ratings taken at baseline during the MRI scan by AHI at baseline.  
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The distribution of drowsiness levels between the two groups, moderate sleep apnoea and control, were 
tested for differences using the Mann-Whitney U test.  This showed that the moderate sleep apnoea 
(Median = 13.5) and the control group (Median = 7.0) were not significantly different (U = 65.5, z = -
0.88, p = .391).  These two results suggest that drowsiness levels during ASL cannot be primarily 
attributed to OSA status. 
A scatter plot of drowsiness levels during the ASL scan and global cerebral perfusion reveals, at most, 
a weak correlation between these two factors (Figure 4-13), (rs(31) = -0.32, p = .083). 
Figure 4-13.  Scatter plot with fitted line of “drowsiness” levels by “global cerebral blood flow” at 
baseline for all three cohorts.. 
4.6.3 Epworth Sleepiness Scale 
Longer-term sleepiness for all participants was subjectively estimated at baseline and again at follow-
up using the ESS instrument, in which a higher score indicates greater sleepiness.  The distribution of 
baseline scores for the treated, untreated and control cohorts are shown in Figure 4-14   
The median ESS score of the moderate group at baseline was 13.00 (IQR = 6, which was higher than 
that for the control group of 7.00 (IQR = 8).  (U = 13.00, z = -3.37, p < .001, d = 1.51).   
To determine if APAP treatment had any influence over ESS scores, the treated cohort ESS scores at 
follow-up were compared to the cohort’s baseline scores using a Wilcoxon Signed-Rank test.  This 
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showed that APAP treatment of at least six months resulted in an improvement in ESS scores for this 
cohort (median = 8.0, IQR = 4.0 and median = 13.0, IQR = 4.0 respectively, z = -2.94, p = .003)   
Conversely, there was no difference in self-reported sleepiness between baseline and follow-up in the 
untreated cohort (median = 14.0, IQR = 5.0 and median = 13.0, IQR = 8.0 respectively, z = -1.01, p = 
.312) [Figure 4-14].   
Attributing the improved ESS result following APAP treatment to a test-retest effect can be discounted 
because there was no difference in the follow-up and baseline results in the untreated cohort which 
would have been expected if a test-retest effect existed. 
Evident in Figure 4-14 are the number of treated participants who improved their ESS score, some quite 
markedly.  However, for the untreated and controls the overall shift in the ESS was not so large, albeit 
that even in those two cohorts there were some large individual changes in both directions.  Again, the 
heterogeneity of the scores both within and between participants is evident. 
Figure 4-14  Epworth Sleepiness Scale scores at baseline and follow-up for the treated, untreated and 
control cohorts (n = 12, 11, 7 respectively).  The smaller the Epworth Sleepiness Scale number the 
better the sleep. 
4.6.4 The Pittsburgh Sleep Quality Index  
The PSQI was completed by all participants at baseline and again at follow-up.  Figure 4-15 shows the 
distribution of baseline scores for the moderate sleep apnoea group and the control group where a higher 
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score is an indication of poorer sleep quality.  The group with moderate OSA had a mean PSQI score 
of 15.29 (SD = 3.59), whereas the control group’s score was 12.14 (SD = 0.86).  The Kolmogorov-
Smirnov test of normality indicated that the PSQI scores followed a normal distribution (D(24) = 0.16, p 
= .140, and D(7) = 0.26, p = .149, respectively).  Accordingly, the baseline differences in PSQI scores 
were tested using the parametric independent-samples t-test.  This test found that the scores for the 
group with moderate OSA and the control groups were different (t(29) = 2.18, p = .019, one-tailed, d = 
0.94).   
Figure 4-15.  Global Pittsburgh Sleep Quality Index scores for the three cohorts taken at baseline.  A 
high score indicates a worse result. 
The group difference in PSQI scores was also reflected in a moderate positive correlation between AHI 
and PSQI scores (r(31) = 0.48, p = .003, d = 1.09)  (Figure 4-16).  However, with respect to the baseline 
PSQI scores between the treated cohort (M = 15.69) and the untreated cohort (M = 14.82), there was no 
significant difference (t(22) = 0.59, p = .564, d = 0.25).   
Comparisons between baseline and follow-up showed that the treated cohort had a better PSQI at 
follow-up (See Table 4-10).  In contrast, there was a trend for the untreated cohort to have a worse score 
at follow-up.  However, the results show that the PSQI scores for the control group did not change.   
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Figure 4-16.  Total PSQI scores and AHI at baseline for the three cohorts.  The lower the score the 
better the result. 
 
Table 4-9.  Mean PSQI scores for the three cohorts, treated, untreated, and control, at baseline and at 
follow-up along with SD values and t-tests.   







Treated 13 15.69 (3.82) 14.23 (3.19) .046 0.44 
Untreated 11 14.82 (3.43) 16.27 (3.61) .070 0.35 
Control 7 12.14 (2.27 11.57 (2.15) .103 0.55 
Of interest was whether there was an interaction between the three treatment categories and 
baseline/follow-up as suggested in Figure 4-17.  A 2x3 ANOVA found that the interaction between 
treatment category and order of PSQI tests i.e., baseline/follow-up, was not significant, F(2, 52) = 1.20, p 
= .309, partial ŋ2 = .041. 
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Figure 4-17.  Plot of baseline and follow-up PSQI scores for the treated (n = 13) and untreated (n = 
11) cohorts and the control group (n = 7).  A higher score is an indication of poorer sleep quality. 
At the individual levels, it was evident there were large movements in some individual scores (Figure 
4-17).  For example, one treated participant had an improved standard score of 5.94 at follow-up, whilst 
another had an improved score of 3.95.  Yet one treated participant was worse at follow-up with a z 
score of -3.06.  Overall, nine of 13 treated participants (69%) improved their PSQI score, while only 
three participants of the 11 members of the untreated cohort  (27%) improved their result.  With respect 
to the control group, five participants improved, one stayed the same, and one got worse. 
4.6.5 Medical Outcomes Study 
The Medical Outcomes Study 36-item short-form health survey (Ware & Sherbourne, 1992), was 
completed by all participants at baseline and again at follow-up.  A higher score indicates a better health 
state.  Figure 4-18 shows the distribution of mean scores for the moderate sleep apnoea group and the 
control group taken at baseline where the median SF-36 score for the control group is higher than the 
score for the moderate sleep apnoea group.  Descriptive statistics for each of the eight items that make 
up the SF-36 can be found in Table 4-11  
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Figure 4-18.  The distribution of median scores from the SF-36 Health Survey for the moderate sleep 
apnoea and the control groups measured at baseline where the higher score indicates better health 
status.  This is the median score of the eight items that constitute the survey.   
4.6.5.1 SF-36 baseline results 
The Mann-Whitney U was used to test for group differences between moderate sleep apnoea and 
control, across the eight items comprising of the SF-36.  The results from those tests are tabulated in 
Table 4-11 in which at baseline, the overall quality-of-life measure for the moderate sleep apnoea group 
was not as good as that of the control group.  At the item level, this was true for: Physical Functioning, 
General Health, Vitality, and Social Functioning.   Conversely, the mean ranking of scores for Role-
Physical, Bodily Pain, Role-Emotion, and Mental Health were not different across the two groups. 
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Table 4-10.  Group test summary (moderate sleep apnoea and control) of the eight items that comprise 
the SF-36 Health Survey including the Median score at baseline. 
SF-36 Item Moderate group Control group 




Physical Functioning 74.0 25.0 90.0 10.0 .024 * 0.76 
Role Physical 75.0 50.0 100.0 25.0 .043 * 0.66 
Bodily Pain 74.0 29.0 51.0 43.0 .108 0.47 
General Health 59.5 33.0 92.0 23.0 .002 ** 1.17 
Vitality 50.0 24.0 70.0 25.0 .021 * 0.78 
Social Functioning 87.5 47.0 100.0 0.0 .024 * 0.76 
Role Emotion 83.3 58.0 100.0 0.0 .062 0.51 
Mental Health 74.0 35.0 80.0 32.0 .107 0.44 
SF-36 Total 68.57 22.43 80.38 12.0 .018 * 0.83 
* Significant at p < .05, ** significant at p < .01
4.6.5.2 SF-36 follow-up results 
The overall SF-36 descriptive statistics for the treated cohort at baseline and at follow-up are shown in 
Table 4-12  
Table 4-11.  Descriptive statistics for SF-36 for the treated cohort at baseline and at follow-up. 
Treated cohort N Mean SD 
Baseline 13 66.09 17.09 
Follow-up 13 76.31 15.45 
Treated cohort baseline and follow-up overall SF-36 mean scores were tested using paired samples t-
test and were found to be different (t(12) = -1.98, p = .035, one-tailed, d = 0.58).  The one-tailed t-test 
was justified on the basis of our hypothesis that APAP treatment would lead to an improved score. 
The separate item scores comprising the SF-36 were also tested to determine which, if not all improved 
because of APAP therapy.  The separate item results of paired samples t-tests for the treated cohort are 
102 
 
tabulated in Table 4-13 which shows that Vitality, Role-Emotional, and Mental Health were improved 
at follow-up, whilst for all other items there were no significant changes.  
Table 4-12.  T-test results from the treated cohort.  Tested were the mean differences between pre- and 
post-treatment scores of the eight items, which comprise the SF-36.   
SF-36 Item Test Statistic T(12) p Value (One-tailed) Cohens d 
Physical Functioning -0.30 .384 0.11 
Role-Physical -1.40 .094 0.39 
Bodily Pain -0.90 .199 0.25 
General Health -0.62 .273 0.17 
Vitality -2.03 .033 * 0.56 
Social Functioning -0.39 .353 0.11 
Role-Emotional -2.74 .009 ** 0.76 
Mental Health -2.02 .033 * 0.56 
* Significant at p < .05, ** significant at p < .01 
 
To determine if a test-retest effect obfuscated any change, the difference in the scores between follow-
up and baseline for the untreated/control cohorts combined were also tested (any significant difference 
must be attributable to a possible test-retest order effect).  The mean scores were 71.22 (SD = 18.19) at 
baseline and 73.85 (SD = 20.27) at follow-up.  This difference was not significant (t(17) = -1.06, p = .153 
(one-tailed).  However, when the improvement in the treated score is compared to both the untreated 
and control group scores at baseline and follow-up both the treated and control group scores improved 
while the untreated score did not (see Figure 4-19).  The sameness in improvement for the treated cohort 
and the control group shown in the plot strongly suggests the improvement in the treated cohort is the 
result of a test-retest effect.  However, any firm conclusion cannot be made because the large variation 
in individual scores evident, could obfuscate true results. 
At the individual level, 46% of treated participants improved over the treatment period whilst 2% 
improved in the untreated cohort and 43% of controls improved.  With the exception of one treated 
participant and one untreated participant who had z-scores of 2.55 and -1.79 respectively, the 




Figure 4-19  -Three items in the SF-36 for which the improvements were statistically significant for the 
treated cohort.  They are Vitality, Role-emotional, and Mental health, measured at baseline and again 
at follow-up for the three cohorts.  (In all cases a higher score indicates an improved result.  At follow-
up, the population in each cohort was treated = 13, untreated = 11, and control = 7. 
4.6.6 Demographics 
The demographics of the moderate sleep apnoea group and the control group, along with the 





Table 4-13.  Group demographics for control and Moderate OSA groups as well as the two cohort, 
Treated and Untreated, that comprise the moderate OSA group. 





Control  AHI <5 7 4  62 years (42–73) European 7 
OSA  AHI 15–29 24 10  59 years (32–72) European 23 Maori 1 
Asian 1 
 Treated 13 4  59 years (43–69) European 12 Maori 1 
 Untreated 11 6  62 years (32–79) European 11 Asian 1 
 
The median age difference between the two groups was not statistically significant (Z = 0.92, p = .365, 
exact two-tailed).  Also, the mean rank ages of the two cohorts that make up the moderate group were 
not significantly different (Z = 2.32, p = .820, exact two-tailed).  Furthermore, there was no significant 
difference between the female-to-male ratios in the moderate group and in the control groups (χ2(1, N = 
31) = 3.84, p = .250).  Finally, there was no significant difference between female-to-male ratios in the 
treated and untreated cohorts (χ2(1, N = 24) = 1.39, p = .100). 
4.7 Global cerebral perfusion  
4.7.1 Global cerebral perfusion 
To ensure the appropriateness of parametric testing of global cerebral perfusion using an independent 
samples t-test, the distributions from the moderate sleep apnoea group and from the control group were 
subjected to the Kolmogorov-Smirnov and the Shapiro-Wilk tests of normality.  The results indicated 
that parametric t-test could be used.  
Moderate sleep apnoea and control group perfusion rates were measured to establish if a difference in 
global perfusion existed between the two groups at baseline.  Any group difference in baseline global 
perfusion would need to be quantified to establish if APAP had an intervention effect.  The mean global 
perfusion and distribution for the two groups at baseline are presented in Figure 4-20.  Differences were 
tested using the student’s t-test.  There was no difference in global perfusion scores between the 
moderate sleep apnoea group and the control group at baseline (mean 49.26, vs 48.73, t(30) = 0.126, p = 
.899; d = 0.06).   
Global perfusion was not correlated with AHI ( r (50) = -0.14, p = .34) and as can be seen in Figure 4-20 





Figure 4-20  Global cerebral blood flow plotted against Apnoea Hypopnoea Index at baseline for the 
three cohorts. 
4.7.2 The effect of APAP treatment on global cerebral perfusion 
To determine if APAP treatment changed global cerebral perfusion, a paired samples t-test was 
conducted between baseline and follow-up results for the treated cohort.  This showed that baseline 
global cerebral perfusion (M = 51.64, SD = 8.56) and the follow-up result (M = 48.56, SD = 7.42) were 
not significantly different (t(12) = -1.53, p = .150 (two-tailed, d = 0.36).  That is, there was no 
improvement in global cerebral perfusion. 
The difference in baseline and follow-up mean global cerebral perfusion rates for the two cohorts not 
treated (untreated cohort and control group combined) were also tested.  A significant difference would 
be an indication of some intervening factors that may have obfuscated any change in the treated cohort.  
Again, the difference was not significant (M = 47.34, vs 45.24, t(17) = -1.21, p = .242 two-tailed), 
indicating that there was no order effect between baseline and follow-up testing on global cerebral 
perfusion rates. 
A line graph (Figure 4-22 showing the individual change in gCBF for the treated and untreated cohorts 
at baseline and follow-up.  Cohen’s d for the Treated cohort between baseline and follow-up was 0.38, 
Cohens d for the Untreated cohort was 0.11.  Figure 4-21 shows that 4 of 13 treated cohort members 
improved their gCBF rates, and 5 of 9 untreated cohort members improved.  Large variations in 
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individual scores are evident with z-scores ranging from 1.27 to -1.87 in the treated cohort and from 
1.51 to -2.03 in the untreated cohort.    
Figure 4-22  Global cerebral blood flow values for the treated and untreated cohorts at baseline and 
follow-up. 
4.7.3 Global cerebral perfusion and other OSA indices 
Correlations between global cerebral perfusion and arousal counts, ESS scores, PSQI scores, 
Microsleep counts, and the SF-36 score were calculated using Spearman-rho, Table 4-14.  None of the 
correlations were statistically significant, albeit that the correlation between global cerebral perfusion 
and arousal counts unexpectedly approached significance (p = .064). 
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Figure 4-23  Arousal counts and global cerebral perfusion at baseline for all participants.   
 
Table 4-14.  Spearman-rho correlations between global cerebral perfusion, other indicators of OSA, 
and sleep quality measures at baseline.   
  Arousal 
counts 
ESS results Microsleep 
counts 




rs 0.34 -0.22 0.07 0.11 -0.13 
 p .064 .226 .725 .552 .495 
* Correlation significant at 0.05 level (2-tailed).  global cerebral perfusion: global cerebral 
perfusion 
 
The number of days separating the polysomnography, from which the arousal count was obtained, and 
the MRI scan was 77.2 (SD = 71.3).  To determine if this could have obfuscated the relationship between 
global cerebral perfusion and arousal counts, a Pearson’s partial correlation was run.  It showed that the 
relationship strengthened slightly rpartial(29) = 0.37 vs rs(29) = 0.34, and became statistically significant 
(see Table 4-14).  Conversely, the mean number of days separating the day the ESS, Microsleeps, PSQI 
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and SF-36 were done, and the day of the MRI scan was 23.2 (SD = 42.9).  This interval had no material 
impact on the statistical significance of the correlations, albeit that the correlation between arousal 
counts and global cerebral perfusion became significant (Table 4-15). 
Table 4-15.  Pearson’s partial correlation accounting for the length of time separating the tests. 
  Arousal 
counts 
ESS results Microsleep 
counts 




rpartial 0.37 * 0.17 0.13 0.06 -1.8 
 p .042  .369 .487 .736 .353 
* Correlation significant at 0.05 level (2-tailed). (global cerebral perfusion: global cerebral 
perfusion) 
4.7.4 Global cerebral perfusion and cognition 
Baseline measure of global cerebral perfusion was compared to cognition using Spearman’s rho and 
was found not to be significant across the moderate OSA and control groups for any of the cognitive 
domains tested or for the overall composite cognitive result (See Table 4-16).  A scatter plot of global 
cerebral perfusion and composite cognition score is shown in Figure 4-24 where the heterogeneity of 
the data is evident. 
Furthermore, the composite cognitive score and the scores from the five domains tested for the moderate 
OSA group and the control group did not differ at baseline (see 4.11.1   
Table 4-16.  Spearman’s rho correlation results for global cerebral perfusion, the five cognitive 
domains tested and the composite cognitive test result. 
 Attention Executive 
function 






rs(31) 0.20 -0.08 -0.20 0.07 0.15 0.09 





Figure 4-24  Global cerebral perfusion and cognition at baseline for the three cohorts  
4.8 Regional cerebral perfusion 
4.8.1 Regional cerebral perfusion 
Differences in regional cerebral perfusion rates between the moderate sleep apnoea group and control 
group were tested at baseline.  Using threshold-free cluster enhancement analysis between participants, 
with AHI, age, sex, and global cerebral perfusion as explanatory variables along with the voxel 
dependent grey matter, no differences were found in regional cerebral perfusion after multiple-
comparisons correction.  Moreover, using the four explanatory variables of AHI, drowsiness during 
ASL, sex, and age, as used by (Innes et al., 2015) there were still no differences between the moderate 
OSA group and the controls (p > .05).   
Differences in regional cerebral perfusions between the treated cohort at baseline and at follow-up were 
also tested as above.  Figure 4-25  shows a positive effect of APAP therapy on regional perfusion in 22 
axial views taken from the treated cohort.  No statistically significant regions of improved cerebral 
perfusion were identified, however, two clusters of voxels (right cerebral cortex/cingulate gyrus region, 
and the right angular/supramarginal gyri (Harvid Oxford cortical structure map; Figure 4-26) 
approached significance (p < .10).  In addition, no significant differences were found in regional 
cerebral perfusion between the baseline and follow-up for the untreated and the control group combined 











 Figure 4-25  These three multi-sliced-axial views of the human brain come from the group analysis of 
the treated cohort, untreated cohort and the control group.  They show differences in regional cerebral 
perfusion at follow-up over baseline.  The measurement used is the students t-statistic where 
orange/yellow represents regions of the brain where changes in perfusion were had increased at follow-
up, whilst blue represents regions where changes in perfusion had decreased.  The larger differences 
are represented by the colour yellow or green, red and blue represent small changes.  There were no 
statistically significant regions of difference.  
With respect to the ASL difference between follow-up and baseline for the treated cohort, the peak t-
test score was 4.06 – the peak t is the highest t-score of a defined cluster of voxels, in this case the whole 
brain. This set of values was similar to that found in the studies by Baril et al. (2015) that ranged from 
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3.6 to 5.4 (n = 33), Baril et al. (2020) that ranged from 3.9 to 4.6 (n = 36), Innes et al. (2015) whose 
peak t values ranged from 3.9 to 5.4 (n = 38), and Nie et al. (2017) whose peak t scores ranged from 2.4 
to 6.0 (n = 60).  Nonetheless, the difference was not significant (p = .09, d = 1.13). 
Figure 4-26  This corrected probability map of the treated cohort with age, sex, body mass index, and 
drowsiness as explanatory variables shows the location of two regions where differences in cerebral 
perfusion between baseline and follow-up approached significance.  These are in the right cerebral 
cortex/cingulate gyrus region, and in the right angular/supramarginal gyri (Harvid Oxford cortical 
structure map). 
4.8.2 ST90 
ST90 was regressed against perfusion rates to determine if it could differentiate cerebral regions 
between moderate OSA and controls.  However, threshold-free cluster enhancement analysis, with age 
and sex as co-variates, found no significant differences (p > .05). 
4.8.3 Regional cerebral perfusion regions of interest from a previous study 
Baseline perfusion data from three regional clusters, previously found by Innes et al. (2015) to have 
significant perfusion differences, were tested for differences between the moderate sleep apnoea and 
the control groups from this study.  Those regions are: (1), bilaterally, the paracingulate gyrus, anterior 
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cingulate gyrus, and subcallosal cortex, including the left putamen and left frontal orbital cortex (2) the 
right-lateralized, posterior temporal fusiform cortex, parahippocampal gyrus, and hippocampus and, 
(3). the right thalamus.   
Multiple-comparisons correction using threshold-free cluster enhancement analysis did not show any 
of those three regions of interest having significant perfusion differences between the two groups in this 
study (p > .050).  
Table 4-17.  Participant demographics and clinical measures from the study by Innes et al. and our 
study, 
Innes et al. (2015) This study 
OSA n (female) 19, (2) 24 (8) 
Control n (female) 19 (4) 7 (4) 
OSA mean age (range) 57yr, (41–70) 58yr, (32 – 79) 
Control mean age (range) 50yr, (41 – 81) 61yr, (42 – 73) 
OSA mean BMI (range) 29.3, (22.9 – 37.5) 30.2, (22.6 – 37.5) 
Control mean BMI (range) 27.5, (2.0 – 32.6) 24.5, (22.7 – 25.9) 
OSA mean AHI (range) 30, (15 – 53) 22, (16 – 29) 
4.9 Cerebral perfusion normalization quality 
Part way through data collection, the MRI scanner was relocated.  To demonstrate the quality of the 
ASL procedure following that shift, normalisation processing of perfusion data, cerebral brain perfusion 
images, in subject space, from four participants are provided (Figure 4-27).  These four participants 
were selected because their baseline scan was done prior to the scanner being relocated to its current 
site, whilst their follow-up scan was done at the new location, thus permitting a visual comparison of 
the ASL data pre- and post-relocation.  The images, post-relocation, appear similar in quality to those 
taken pre-relocation, thereby supporting the contention that there was no degradation of scan quality 
because of the shift that may have obfuscated any differences in baseline group regional perfusions. 
Moreover, the images are representative of the overall quality of the ASL procedure and the underlying 
data.  They show that the scans are complete with good structural separation evident.  There was no 
evidence of degraded scan quality taken overall that could have obfuscated any differences in baseline 
group regional perfusions. 
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In addition, the Cat 12 pre-processing steps produce an image quality report at the 
segment/normalisation stage.  For both pre- and post-move, 65% were assessed as B, 33% assessed as 
B- and 2% as C+.  Although these ratings are internal to the software program, they do indicate a level
of consistency across results.
Figure 4-27  Normalized cerebral perfusion images from four participants pre-MRI scanner relocation 
(left-hand images) and post-relocation (right-hand).  The three slices in each sequence come from z = 
30, 50, and 70 co-ordinates, and are taken in subject space. 
4.10 Microsleeps 
The number of microsleeps that occurred during the microsleep trial for each participant were collected 
at baseline and again 6–7 months later at follow-up.   
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4.10.1 Microsleep counts. 
The counts of microsleeps are shown in Figure 4-28).  There was a wide variability in the counts.  One 
subject experienced 126 microsleeps during the 30-min trial, with a mean microsleep duration of 6.6 s 
(min = 0.9 s, max = 109. 7 s).  Conversely, 18 of the 31 participants had no microsleeps at baseline and 
19 of 26 participants had no microsleeps at follow-up.  A review of individual counts found that the 
untreated subject who experienced 126 microsleeps at baseline had 8 counts at follow-up.  Conversely, 
another untreated subject experienced 56 microsleeps at baseline, and 59 at follow-up. 
Figure 4-28  Microsleep counts during the 30 min trial.  Shown are the baseline and follow-up counts 
for the three cohorts, treated (n = 13), untreated (n = 11) and controls (n = 7 at baseline with the data 
from two treated cohort members lost at follow-up, one untreated cohort member lost at baseline and 
follow-up and one control member lost at follow-up).   
An independent samples Mann-Whitney U test was applied to the distributions of microsleep counts 
for moderate sleep apnoea (median = 0.5) and control groups’ (median = 0.0), which showed no 
significant difference (U = -1.29, p = .253, d = 2.1).  Moreover, a Kruskal-Wallis test of the follow-up 
microsleep counts also confirmed there were no significant differences in microsleep counts across the 
three cohorts, treated (Median = 0.0), untreated (median = 0.0) and control (median = 0.0), (χ2(2) = 2.68, 
p = .262).  
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Evident at the individual level was the heterogeneity of the data with one untreated participant reducing 
microsleeps between the two trials from 126 at baseline to 8 at follow-up.  However, most participants 
(N=22), had two or less microsleep episodes with 17 of that 22 having none. 
4.11 Cognition 
4.11.1 Baseline 
There was no difference in cognition – as measured by the mean, normalized and standardized test 
scores of Attention, Executive Function, Memory, Processing speed, and Visuospatial construction – at  
baseline between the moderate sleep apnoea group and the control group using the Mann-Whitney U 
Test (U = 119.0, p = .104, d = 0.62), nor was there a difference in cognition between the treated and the 
untreated cohorts (U = 68.0, p = .865, d = 0.08), or between the treated and control cohorts (U = 64.0, 
p = .157, d = 1.30)  These results are graphically represented in Figure 4-29 which shows the overall 
cognitive scores for each of the three cohorts at baseline, albeit that the control group overall had slightly 
higher cognitive scores than the two cohorts constituting the moderate sleep apnoea group. 
The five cognitive domains that constitute the overall cognitive score were tested for group differences 
at baseline using the Mann-Whitney U Test.  There was no significant difference between the moderate 
sleep apnoea group and the control group in any of the five cognitive domains.  However, two of the 
neurocognitive tests used in the assessment were significantly different.  These were the FAS part of 
the Verbal fluency test used to help assess Executive functioning, and the copy part of the Rey Complex 
Figure Test used to help assess Visuospatial Construction. 
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Figure 4-29  Median standardized cognitive scores at baseline for the moderate sleep apnoea group, 
which consists of the treated and the untreated cohorts, and the control group. 
Table 4-18.  Mann-Whitney Test results of the distribution of cognitive scores for each of the five 
cognitive domains used to assess overall cognition between those with moderate sleep apnoea and 







Attention Average overall 92.00 0.38 .729 
Digit Span (Forwards, and Backwards) 77.5 -0.31 .764 
Digit Span (Ordering) 75.0 -0.43 .695 
Stroop Colour-Patch 105.5 1.03 .317 
Stroop Words 117.0 1.57 .127 
Trail Making Test A 98.0 0.66 .532 
Executive 
functioning 
Average overall 118 1.61 .115 
Rey Complex (Immediate recall) 109.5 1.21 .234 
Stroop Interference 87.0 0.14 .908 
Trail Making Test B 96.0 0.57 .595 
Verbal Fluency (FAS) 136.5 2.49 .011* 
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Verbal Fluency (Category) 91.5 0.36 .729 
Memory Average overall 101.00 0.80 .444 
CVLT (Free Recall) 74.5 -0.45 .661 
CVLT (Short-Delay Free Recall) 87.0 0.14 .908 
CVLT (Long-Delay Free Recall) 64.5 -0.93 .365 
CVLY (Yes/No Recognition) 112.5 1.37 .182 
Rey Complex (Immediate recall) 109.5 1.21 .234 
Rey Complex (Delayed recall) 428 1.55 .121 
Speed of 
processing 
Average overall 112.5 1.35 .182 
Symbol Digits Modality Test 102.5 0.89 .391 
Stroop Interference 87.0 0.14 .908 
Stroop Words 117.0 1.57 .127 
Trail Making Test A 98.0 0.66 .532 
Visuospatial 
construction 
Average overall 119.0 1.65 .104 
Judgement of Line 89.0 0.24 .835 
Rey Complex (Copy) 133.5 2.34 .017* 
* Significant at p < .05 
4.11.2 Does APAP treatment of moderate sleep apnoea improve cognition? 
To test for an improvement in cognition following approximately six-months of APAP treatment the 
non-parametric Wilcoxon Signed Ranks test was used to test for differences between baseline and 
follow-up scores (see Table 4-19).  Although there was no difference in the composite cognitive score, 
when the five cognitive domains were tested separately, the memory domain was found to be different 




Table 4-19.  Wilcoxon Signed-Ranks test results for differences between baseline and follow-up 
cognitive domain scores for the treated cohort.   
Cognitive domain Wilcoxon z Effect size p (one-tailed) 
Attention -.66 -0.13 .265 
Executive Function -.77 -0.15 .233 
Memory -2.83* -0.55 .001 
Speed of Processing -1.01 -0.20 .170 
Visuospatial Construction -.18 -0.04 .446 
Cognition Overall -0.73 -0.14 .249 
 
Individual results fluctuate widely as can be seen in the lie chart Figure 4-30.  A feature of six charts 
that comprise this figure, is the variation in scores across all three cohorts with large improvements and 




Figure 4-30  Baseline and follow-up results for the five domains that made up the overall cognitive 
score these being attention, executive function, memory, speed of processing, and visuospatial 




To examine if the improved memory results reflected a test-retest order effect, the results from those 
participants not treated, i.e., the untreated cohort combined with the control group, also the untreated 
cohort, and the control group separately, were tested using the Wilcoxon Signed Ranks test.  Evident in 
Figure 4-31 is that the median score for all three cohorts improved between baseline and follow-up.  
However, only the treated cohort difference was significant even though the median score for the control 
cohort showed the most improvement at follow-up.  However, the control group had the greatest spread 
along with low numbers (n = 7) resulting in insufficient power to reach significance.  Yet the tighter 
spread at follow-up for the treated cohort meant the improvement in this cohort was significant.  Despite 
the lack of significance in the untreated and control cohorts, the higher follow-up scores across all three 
cohorts indicates a strong test-retest influence.  Accordingly, we reject the hypothesis that the treated 
cohort memory scores would change between baseline and follow-up. 




Table 4-20.  Wilcoxon Signed Ranks Test results for differences between baseline and follow-up for 
Memory overall and the six cognitive tests used in the assessment. 





Overall 0.2 0.9 -2.83 .001** 
CVLT Free Recall 1.4 2.0 -2.83 .001** 
CVLT Short Recall 0.0 0.7 -2.53 .004** 
CVLT Long Recall 0.0 0.7 -2.52 .004** 
CVLT Yes/No -1.0 1.0 -2.68 .002** 
Rey Complex Immediate 0.1 1.1 -1.50 .071 
Rey Complex Delayed -0.3 0.8 -2.03 .021* 





Overall 0.6 0.8 -1.16 .139 
CVLT Free Recall 1.7 2.1 -0.92 .196 
CVLT Short Recall 0.0 0.7 -1.73 .049* 
CVLT Long Recall 0.3 1.0 -2.06 .021* 
CVLT Yes/No 0.0 0.0 -0.07 .496 
Rey Complex Immediate 0.4 1.1 -0.85 .213 
Rey Complex Delayed 0.4 0.8 -0.62 .289 





Overall 0.3 1.4 -1.10 .164 
CVLT Free Recall 1.3 2.0 -1.37 .094 
CVLT Short Recall 0.0 0.7 -0.68 .281 
CVLT Long Recall 0.0 1.3 -1.48 .094 
CVLT Yes/No 0.7 0.0 -1.63 .094 
Rey Complex Immediate 0.6 1.6 -1.78 .047* 
Rey Complex Delayed 0.7 1.2 -1.10 .148 
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4.11.3 Psychomotor vigilance task 
Participants completed a standard 10 min Psychomotor vigilance task (PVT) as part of the cognitive 
test at baseline and at follow-up.  The PVT objectively assesses fatigue-related changes in alertness 
associated with sleep loss (Basner et al., 2011).  Therefore, it should provide a useful insight into a 
moderate apnoeic’s ability to sustain attention in comparison to controls.  It was not included in the 
combined cognitive test analysis because normative data was not available. 
Comparing the count of attention lapses, defined as a reaction time of 500 ms or more, there was no 
difference between those with moderate sleep apnoea and the control group (U = 81.0. z = -0.15, p = 
.908).  This result is reflected in the analysis of reaction times between the two groups that also showed 
no difference (U = 75.0, z = -0.43, p = .695). 
Individual counts are plotted in Figure 4-32.  This chart is characterized by large variance in individual 
scores with one member of the control group improving their score by 32 counts.  While most 
participants showed some improvement, one untreated and two treated participants had a poorer 
performance at follow-up compared with baseline. 
Figure 4-32    Psychomotor vigilance task (PVT) counts during the 10 min trial.  Shown are the baseline 
and follow-up counts for the three cohorts, treated (n = 13), untreated (n = 11) and controls (n = 7). 
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Chapter 5  Discussion 
Our study investigated global and regional cerebral perfusion, cognition, and microsleeps in people with 
moderate OSA before and following APAP therapy.  Overall, six hypotheses were formed, none of 
which were subsequently supported by the results of this study.  Initially our study hypothesized that 
cerebral perfusion and cognition would be reduced in people with moderate OSA and that microsleeps 
would be higher at baseline compared to participants without OSA.  However, we found no significant 
differences in either global cerebral perfusion, regional cerebral perfusion, cognition, or microsleeps at 
baseline between participants with moderate OSA and controls.  The next three hypotheses, largely 
contingent on there being a difference in cerebral perfusion at baseline between the moderate -OSA 
group and the control group, were that six months of APAP therapy would improve cerebral perfusion, 
cognition, and microsleeps.  Despite no significant difference in cerebral perfusion at baseline, the 
impact of 6–7 months of APAP therapy was nonetheless analysed in case the low population, 
particularly in the control group (n = 7), reduced the power of the between-subject t-test to identify 
regions of reduced cerebral perfusion at baseline.  However, in keeping with a lack of difference at 
baseline 6–7 months of APAP therapy (1) did not significantly alter cerebral perfusion, (2) did not 
improve cognition, and (3) did not change microsleeps.   
5.1 Cerebral perfusion 
5.1.1 Is cerebral perfusion reduced in people with moderate OSA severity? 
Cerebral perfusion is significantly distorted in severe OSA (Winklewski & Frydrychowski, 2013).  
Previous studies have found that global (Urbano et al., 2008) and regional cerebral perfusion (Chen et 
al., 2017b; Innes et al., 2015; Yadav et al., 2013) is reduced during the awake period in mixed cohorts 
of moderate and severe apnoeics. Whether this finding holds true for a cohort of people with just 
moderate OSA has yet to be clearly established. Only one other study has addressed this question and 
did not identify any regions of reduced cerebral perfusion in people with OSA of moderate severity 
(Baril et al., 2015).  Not finding an effect does not necessarily falsify a premise, it may just mean that 
the observations were not detailed enough or that the sample size was too small to identify differences.  
Given the high prevalence of moderate OSA (Heinzer et al., 2015) and the deleterious effect of the sleep 
disorder, one of the objectives of our study was to look more carefully at cerebral perfusion.  For 
example, is cerebral perfusion reduced, whilst awake, in people who have moderate OSA?  Also,  if we 
pay particular attention to people with moderate OSA (Ryan, 2019), given OSA severity increases with 
age (Aloia et al., 2004), we may be able to reduce the risk of downstream morbidities.  All of which is 
predicated on poor CBF leading to brain injury and ensuing problems as opposed to poor CBF occurring 
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with or after brain injury. Moreover, the fact that moderate OSA does not appear to impact cerebral 
perfusion could argue for this phenomenon not being a precursor to brain injury and cognitive problems. 
The results from studies that included both moderate -OSA and severe-OSA patients in their cohorts 
(Chen et al., 2017b; Innes et al., 2015; Yadav et al., 2013) raised the question that participants with 
moderate OSA would show regional hypoperfusion.  However, our study found no evidence to refute 
the null hypotheses that cerebral perfusion in those people with moderate OSA differ from controls 
either globally or regionally.  This remained so for regional cerebral perfusion even after considering 
AHI, drowsiness levels during an MRI scan, age, and sex as covariates. 
Of the seven studies reviewed that had investigated the impact of OSA on cerebral perfusion whilst 
awake (Baril et al., 2015; Chen et al., 2017b; Innes et al., 2015; Joo et al., 2007; Nie et al., 2017; Shiota 
et al., 2014; Yadav et al., 2013), only the study by Baril et al. (2015) directly addressed whether regional 
cerebral perfusion was altered in those participants with moderate of OSA.  In their SPECT study, Baril 
et al. (2015) found no significant difference between their cohort of 14 patients with moderate OSA and 
their cohort of 20 controls without OSA.  However, they did find a cerebral perfusion difference 
between their cohort of severe apnoeics and controls, as did all the studies reviewed that included 
patients with severe OSA.  This may suggest that the level of OSA severity is a determinant factor in 
the manifestation of the disorder, and that moderate OSA is associated with insufficient pathology to 
significantly reduce regional cerebral perfusion while awake. 
To confirm this premise, our study tested for cerebral perfusion differences in three regions that Innes 
et al. (2015) had described in their mixed cohort of people with either moderate or severe-OSA.  By 
selecting regions a priori, the number of multiple comparisons would increase the power of the t-test to 
detect differences and decrease a type II error.  The study by Innes et al. was selected because the 
methodologies were consistent with our study, and because of ease of access to local data.  They found 
cerebral perfusion differences in their cohort of people with either moderate or severe OSA (1) 
bilaterally in the paracingulate gyrus, anterior cingulate gyrus, and subcallosal cortex, including the left 
putamen and left frontal orbital cortex, (2) right-lateralized, in the posterior temporal fusiform cortex, 
parahippocampal gyrus, hippocampus, and thalamus.  However, our study of only moderate OSA found 
no change in perfusion in any of those regions of interest.   
Given the ASL procedures were the same in both the Innes et al. (2015) study and ours, the reason for 
the different result most likely had to lie either in demographic or clinical factors.  A comparison of the 
data between the two studies showed that they differed in number of controls and the male/female ratio, 
mean age of the controls, and BMI for the controls.  Overall, the level of OSA severity, as measured by 
the AHI, was higher in the Innes et al. study.  All these variables have been linked to differences in 
global cerebral perfusion (Chen et al., 2017b; Cosgrove et al., 2007; DuBose et al., 2018) and, therefore, 
either separately or combined, could be the reason for the different results.  It is also worth noting that 
127 
 
ASL scans are noisy and prone to artifacts (Hales et al., 2020) meaning that CBF measurements are 
inherently variable.  Nonetheless, our results are consistent with the premise that the pathophysiology 
of patients with moderate OSA does not significantly reduce regional or global cerebral perfusion whilst 
awake. 
Science’s understanding is quite advanced in the neurophysiology of cerebral perfusion, which is 
dependent on intracranial compliance, cerebral autoregulation, and sympathetic tone to maintain 
cerebral blood flow homeostasis, much is still to be understood.  Although cerebral autoregulation has 
been shown to be affected by severe OSA (Beaudin et al., 2017; Urbano et al., 2008; Waltz et al., 2016), 
the impact of moderate OSA was equivocal with no evident impact on the efficacy of cerebral 
autoregulation found.  This observation is supported by Waltz et al. (2016) who concluded that one 
month of effective CPAP treatment had no impact on cerebral autoregulation regardless of OSA severity 
levels (see also Beaudin et al., 2017).   
However, although studies of people with moderate OSA versus controls, like this study and Baril et 
al. (2015) could find no difference in cerebral perfusion rates, either globally or regionally other studies, 
which recruited participants with more severe OSA (i.e., Innes et al., 2015; Joo et al., 2007; Yadav et 
al., 2013), did find regional differences.   
Despite an incomplete understanding of the pathogenesis of OSA (Maresky et al., 2019) and how 
cerebral autoregulation works (Fantini et al., 2016), this study postulated that any adverse effect of 
moderate OSA on cerebral perfusion can be adequately compensated for by the normal homeostatic 
processes responsible for the maintenance of cerebral perfusion, such as intracranial compliance, 
cerebral autoregulation, and sympathetic tone (Macey, 2015).  This postulate is supported by the current 
study and that of Baril et al. (2015) and others (Chen et al., 2017a; Joo et al., 2007; Nie et al., 2017; 
Shiota et al., 2014; Yadav et al., 2013) that all tested either moderate/severe or severe and found cerebral 
perfusion was reduced, whereas the current study and that of  Baril et al. (2015) that tested cohorts with 
a less severe diagnosis of OSA, did not.  This evidence supports the hypothesis that the autoregulatory 
system can adequately manage disruptions to CBF caused by instances of mild or moderate OSA but 
not in severe instances of OSA.  This is further supported by the low correlation between AHI and 
gCBF in our study.  Accordingly, it is proposed that if the OSA is severe enough the autoregulatory 
system will break down and allow pathological changes to CBF to occur. 
Although global cerebral perfusion did not differ in our study between people with moderate OSA and 
controls, we went on to compare arousal counts, along with ESS, ODI, PSQI, microsleep counts, and 
SF-36 scores in case any of these variables were more sensitive to changes in cerebral perfusion than 
AHI.  Only arousal counts were found to be significantly and positively associated with global cerebral 
perfusion (rp = 0.37, p = .042). The significance of this finding is unclear as the exact role of arousal 
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levels on the pathogenesis of OSA, if any, has yet to be resolved (Eckert & Younes, 2014; Wali et al., 
2020; Yue et al., 2009).   
5.1.2 Does APAP therapy have an impact on cerebral perfusion whilst awake? 
Another objective of our study was to clarify whether PAP treatment would improve cerebral perfusion 
in those with moderate OSA during the awake period.  This objective was originally set contingent on 
finding a difference in cerebral perfusion at baseline between moderate OSA and controls, a difference 
subsequently not found.  Nonetheless, the question relating to whether PAP therapy improves cerebral 
perfusion whilst awake remains unresolved with several studies finding an enduring beneficial impact 
of PAP therapy on cerebral perfusion in patients with severe OSA (Kim et al., 2017; Maresky et al., 
2019; Shiota et al., 2014), while other studies found that PAP does not make a difference (Prilipko et 
al., 2014; Waltz et al., 2016).  The importance of this question lies in the financial cost of the treatment 
and because of the inconvenience and social cost of PAP usage, neither of which is trivial. 
Our study investigated whether 6–7 months of PAP provided as auto-titrating, a symptomatic treatment, 
would improve cerebral perfusion rates over baseline results using both within and between 
comparisons.  In line with expectations based on our finding of no difference in perfusion between 
people with moderate OSA and controls at baseline, our study found no changes in global or regional 
cerebral perfusion rates while awake within the treated cohort following 6–7 months of treatment.  This 
same result was found in the untreated cohort of people with moderate OSA.  Together these results 
suggest that cerebral perfusion remains unimpaired in people with a moderate level of OSA severity.   
These results differ from those of Kim et al. (2017).  Their study tested 30 male participants with severe 
OSA (AHI = 63.4 + 17.5) and 26 male participants without OSA (AHI = 3.99 + 1.5).  Compared to 
controls, those with severe OSA had a significantly lower rCBF.  Furthermore, six-months or more of 
CPAP treatment partially reversed rCBF in the limbic and prefrontal regions, with a complete reversal 
in the medial orbitofrontal, angular, and cerebellar regions.  Differences in rCBF between studies were 
considered by Kim et al. (2017) to be due to differences in clinical characteristics of patients in each of 
the studies, including level of disease severity.” 
Our study did not measure cerebral perfusion during actual PAP usage, so we cannot confirm that PAP 
prevented reductions in global and/or regional cerebral perfusion during PAP usage.  However, PAP 
treatment was effective in reducing OSA severity during treatment with AHIs dropping to a mean of 
3.68 (range 1.1–8.9).  Accordingly, the efficacy of PAP treatment for decreasing AHI is not in question. 
Moreover, internight variability of AHI has been found not to change significantly in people with 
moderate OSA over two nights of at-home polysomnography (Sforza et al., 2019).  Also, the AHI did 




Another objective of our study was to assess the impact of moderate OSA on cognition.  Despite a 
plethora of studies exploring the impact of OSA in general, or moderate and severe OSA, or severe 
OSA on cognition, this question, specific to moderate OSA only, has been little explored.  For example, 
a meta-analysis by Stranks and Crowe (2016) listed only one of 14 studies that had considered moderate 
OSA as a separate cohort (Kloepfer et al., 2009).  Kloepfer et al. found that procedural and declarative 
memory was impaired in that cohort.  Beebe et al. (2003) in their meta-analysis of 31 studies had no 
studies of only moderate OSA albeit, that studies by Engleman et al. (2000); Kim et al. (1997); Redline 
et al. (1997), and Monasterio et al. (2001) all considered mild and moderate severity. or mild and severe 
OSA.  Accordingly, the opportunity was taken in our study to specifically address the question: does 
OSA of moderate severity have an impact on cognition?   
To test cognition, five cognitive domains were tested: attention/vigilance (Aloia et al., 2004; Bawden 
et al., 2011; Decary et al., 2000; Harvey, 2019; Jackson et al., 2011b; Quan et al., 2006), executive 
functioning (Aloia et al., 2004; Bawden et al., 2011; Decary et al., 2000; Harvey, 2019; Jackson et al., 
2011b; Olaithe & Bucks, 2013), memory (Aloia et al., 2004; Bawden et al., 2011; Decary et al., 2000; 
Harvey, 2019; Jackson et al., 2011b), processing speed (Aloia et al., 2004; Harvey, 2019; Quan et al., 
2006), and visuospatial construction (Aloia et al., 2004). 
Our study found no difference in cognition between the moderate OSA group and the control group at 
baseline as reflected by the total aggregate score from the five domains tested.  Furthermore, none of 
the cognitive domains tested showed any differences between groups, including the PVT test (lapses 
and reaction times), which were analysed separately.  By comparison, several studies have found 
cognitive deficits (Aloia et al., 2004; Beebe et al., 2003; Bucks et al., 2013; Stranks & Crowe, 2016).  
However, the finding of cognitive deficits is not universal.  Other studies have reported an effect of 
OSA on psychomotor vigilant tasks.  Lee et al. (2010) found that performance on a PVT by participants 
with an AHI > 10 (mean PVT counts = 1.75) was not significantly different to the PVT counts by 
participants with an AHI < 10 (mean = 2.63). Sforza et al. (2004) on the other hand, found that vigilance 
performance could be impacted by OSA but only at AHI levels greater than 50.  With respect to 
executive functioning, language, memory, psychomotor functioning and construction, the results are 
less equivocal, with the review by Bucks et al. (2013) finding a number of studies in their meta-review 
linking OSA to cognitive deficits, as did Aloia et al. (2004).  The review by Aloia et al. (2004) also 
examined the association between cognitive status and OSA severity and noted that of the 11 studies 
they reviewed, 10 had a significant association between OSA severity and cognitive performance.  
Accordingly, they concluded that before cognitive deficits could manifest, some threshold of apnoea 
severity might require being breeched.  The lack of a significant difference in cognitive scores between 
those with moderate OSA and controls in our study is consistent with that premise. 
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When individual responses are reviewed, wide variability becomes evident across the five cognitive 
domains with extreme results occurring in executive functioning, speed of processing and visuospatial 
construction (see Figure 4-30 ).  Moreover,  
5.2.1 Does PAP therapy have an impact on cognition? 
We explored the hypothesis (Hypothesis 2) that cognitive performance would be impaired between 
controls without OSA and those with moderate OSA at baseline, and whether APAP treatment could 
improve cognition.  This was done in case variances within the baseline groups obfuscated a real 
difference between the two groups resulting in a false negative.  
At baseline, there was no difference in composite cognition between the moderate OSA group and 
controls, or between the treated and untreated cohorts, or between the untreated cohort and control 
group. This also extended to the five cognitive domains when tested separately at baseline.   
At follow-up, no improvement in the composite cognition score was seen in participants with moderate 
OSA who received six-months of APAP treatment.  However, when the five cognitive domains were 
considered separately, semantic and visual memory showed a statistical improvement in the four 
components of the CVLT tested – Free recall, Short delay recall, Long delay recall, and the Yes/No 
recognition test, all of which are measures of semantic memory (Lezak et al., 2004).  In addition, a 
statistical improvement was observed in the delayed recall trials of the Rey-Osterrieth Complex Figure 
test, a measures of visual memory (Lezak et al., 2004).   
The exact mechanisms behind statistical improvements in semantic and visual memory experienced by 
the treated cohort over the treatment period cannot be attributed to improved cerebral perfusion, which 
was not impaired at baseline in our study, and which did not change following APAP treatment.  
However, they could be attributable to improved sleep quality and quality-of-life, which improved.  
They could also be attributed to a test-retest effect for the CVLT and Rey-Osterrith complex despite 
some studies (Berry et al., 1991; Meyers & Meyers, 2008; Woods et al., 2006) reporting good test-retest 
characteristics for those tests.  Strong support for a test-retest effect comes from the observation in our 
study, that the median memory scores for all three cohorts were higher at follow-up with the greatest 
increase being in the control group, albeit the differences, apart from the treated cohort, were not 
significant, possibly because of the relatively low number of subjects a wide spread of the data in the 
control group.  It is of course possible that untreated OSA patients do not “learn” as well as do treated 
patients, and hence do not show a test-retest improvement.  However, the absence of differences in 
memory scores between the OSA group and controls at baseline indicates that memory was not impaired 
in people with moderate OSA at baseline and therefore would be unlikely to improve.  Consequently, 
it is concluded the statistical improvement seen in the memory score for the treated group is most likely 
attributable to a test-retest effect.  Also, the absence of any differences in memory scores between the 
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moderate OSA group and the control group at baseline would indicate memory was not impaired in 
people with moderate OSA and therefore would be unlikely to improve. 
These findings are comparable to that obtained in the APPLE study by Kushida et al. (2006).  In their 
large 6-month, randomized, double-blind, two arm, sham-controlled, multicentre trial found that only 
executive and frontal lobe function were impaired in those with severe OSA at two-months but not at 
six-months between the two arms of their study (sham or active CPAP).  They found no difference with 
respect to attention and psychomotor function and learning and memory.  However, this weak impact 
on cognition does not appear to be attributable to AHI per se, but to the severity level of oxygen 
desaturation.  Kushida et al. (2012) found that after adjusting for level of education, ethnicity, and 
gender, there was no association between AHI and neurocognitive performance.  However, they did 
find that the severity of oxygen desaturation was weakly associated with worse neurocognitive 
performance on some measures of intelligence, attention, and processing speed. 
5.2.2 Does global cerebral perfusion have an impact on cognition? 
Leeuwis et al. (2018) in their study involving a cohort of 452 participants (214 Europeans, 151 South 
Asian, 87 African Caribbean) from the SARE study (Tillin et al., 2012) used 3T pseudo-continuous 
arterial spin labelling to estimate whole-brain, haematocrit corrected CBF.  They also measured global 
cognition and three cognitive domains (memory, executive functioning/attention, and language).  They 
found higher cerebral blood flow was associated with higher cognitive performance on executive 
functioning, attention, and memory, but not language. 
Nonetheless, in our study, baseline measures of global cerebral perfusion and composite cognitive score 
or its five domain scores were not correlated because of small effect sizes and small population of 7 for 
the control group (Brysbaert, 2019).  The composite cognition score had an r = 0.09, while attention 
had an r = 0.20, followed by visuospatial cognition with azsn r = 0.15.  On the other hand, memory had 
a negative effect size of  r = -0.02 and executive functioning an r of -0.08, albeit none of these 
correlations were significant.  Compared to a meta-analysis of cognitive scores and effect sizes (Stranks 
& Crowe, 2016), attention and executive functioning were both outside their 95 percentile ranges, while 
memory was within.  Stranks and Crowe did not specify an effect size for visuospatial construction. 
Despite the absence, of an impairment in either cerebral perfusion or cognition at baseline between 
moderate OSA group and the control group, we were still able to explore, at least to a limited extent, 
the question of an association between perfusion and cognition. 
5.3 Microsleeps 
Our study tested the number of microsleep people with moderate OSA had during a 30min monotonous 
task.  Microsleeps are obtrusive lapses of responsiveness that are driven by sleepiness levels and can 
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occur in both sleep and non-sleep-deprived people (Innes et al., 2010; Peiris et al., 2006; Poudel et al., 
2014).  They differ from Harrison and Horne’s definition (1996) which is EEG based.  Microsleeps, as 
defined by Peiris et al. are thought to emanate from a homeostatic drive for sleep/rest and a complex 
interaction between the brain’s arousal and attention systems (Buckley et al., 2014).  Given the link 
between OSA with sleep loss in general and thus an increased homeostatic drive for sleep, microsleep 
counts can be expected to be higher in people with moderate OSA than in those people without OSA. 
Contrary to expectations, moderate OSA had no impact on the number of microsleeps that occurred.  
Our study counted microsleeps at baseline and at follow-up for the three cohorts; treated, untreated and 
controls.  We found no significant difference in microsleep counts between those with moderate OSA 
and controls.  This also extended post-treatment both within and between cohorts. Accordingly, we 
found no improvement in microsleep counts because of APAP treatment for those with moderate OSA. 
These results were surprising given the association between microsleeps and 1) sleep restriction and/or 
2) subjective sleepiness (Innes et al., 2013).  Our data indicates a wide variation in microsleep counts, 
with one participant experiencing 126 microsleeps during the 30-min trial, yet 18 subjects had none.  
The untreated person who experienced the high microsleep count, improved greatly over the 6–7 -month 
period and at follow-up had only 8 microsleeps. It is likely that this large variability in scores both at 
baseline, and between baseline/follow-up, reduced the power of the test to detect differences.   
Thirteen of our participants experienced microsleeps (42%) and 18 did not in a 30-min tracking task.  
This is less than the 70% of participants who, in a study by Poudel et al. (2014), had at a mean rate of 
79 microsleeps/hour during a 50-min tracking task.  However, another study in non-sleep-deprived 
participants (Buckley et al., 2014) found that 11 of the 23 participants (48%) experienced microsleeps, 
with an average count of 2.26 for the 30-min task.  Finally, a study by (Innes et al., 2013) investigated 
microsleeps in a non-sleep restricted cohort found that 9 of the 16 participants (56%) averaged 11.4 
microsleeps during a 20-min session.  Why fewer participants in the current study had microsleeps than 
the three above studies is not known.  The protocol used to classify microsleeps was the same in all 4 
studies but there were differences in tasks and/or conditions.  Task durations differed with Poudel et 
al.’s study lasting 50 min compared to the current study (30 min). Also, in both Innes et al.’s and Poudel 
et al.’s studies, the participants were lying supine in an MRI scanner, and the joystick was smaller hence 
smaller movements. In contrast, the tasks in both (Buckley et al., 2014) and the current studies were 
identical (30 min), participants were seated, and they controlled a floor-mounted joystick. 
Consequently, there was not a great difference in proportions of participants who had microsleeps – i.e., 
48% and 42% respectively. 
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5.4 Sleepiness and Quality-of-life measures 
At the conclusion of the data collection phase, participants in the treated cohort were offered to keep 
the APAP machines provided to them for the study.  Of the 19 machines allocated, three participants 
returned the machines and 16 retained them.  Eleven participants who provided feedback kept the 
machines despite our study not showing an improvement in cerebral perfusion, or cognition, or 
microsleeping.  Comments by those retaining the machines indicated a benefit in sleep quality for both 
the wearer and bed partner. 
The comments supported a subjective improved sleep quality and improved quality-of-life that were 
also reflected by improvements in Epworth Sleepiness Scores, PSQI, and the Medical Outcome Study 
SF-36 results.  Those results show that at baseline, the moderate OSA group experienced worse sleep 
and quality-of-life than the control group.  At the end of 6–7 months of APAP treatment, sleep and 
quality-of-life measures improved.  Improvements did not occur in the untreated cohort and control 
group. 
These improvements cannot be the result of any measurable changes in cerebral perfusion, which 
remained unchanged following APAP therapy.  They were also not correlated to ST90, another 
recognised covariant of OSA (Wali et al., 2020).  However, these improvements could be the result of 
a reduced AHI.  Although there was no enduring improvement in AHI as the result of 6–7 months of 
APAP therapy, nightly monitoring showed AHI levels did drop to non-apnoeic levels on the nights 
APAP was used (medium = 2.6), resulting in improved sleep architecture, sleep physiology and reduced 
fatigue the next day.  Also, in this study, improving PSQI scores were related to reduced arousal levels 
that were shown in our study to reflect AHI scores.  Another possibility is a placebo effect that is a 
beneficial health outcome resulting from a person’s anticipation that an intervention will help.  It is 
possible that due to a placebo effect, APAP users may actual or perceived improvements in subjective 
sleep and general quality-of-life that cannot be directly attributed to the APAP therapy itself. 
Despite the possibility of a placebo effect needing to be considered, the subjective quality-of-life 
improvements were associated with changes to OSA severity.  This highlights the importance of sleep 
quality in the manifestation of symptoms associated with OSA. 
5.5 Study design 
A primary purpose of our study was to understand the impact of PAP therapy over time on cerebral 
perfusion, cognition, and microsleeping in a cohort of apnoeics with moderate OSA.  At the time this 
study was commenced; it was not known just what the impact of moderate OSA would have on cerebral 
perfusion Baril’s (2015) study had not been published and two studies (Innes et al., 2015; Yadav et al., 
2013) had shown reduced regional cerebral perfusion in mixed cohorts of moderate and severe OSA.  
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Furthermore, the study by Innes et al., had not been able to find regions of reduced perfusion in their 
cohort of severe OSA and it was not until they combined both moderate and severe OSA that a 
significant effect was revealed.  Thus, feeling reasonably confident of finding an effect of just moderate 
OSA on regional perfusion we undertook a longitudinal study to compare perfusion at baseline with 
that after APAP intervention.  A key question with any longitudinal study is the length of time over 
which the study is conducted before baseline measures are repeated.  One of the determinants of that 
question, is the efficacy of the treatment, in this case how well OSA responds to APAP therapy.  Another 
determinant is the responsiveness of the pathology to the treatment, e.g., how quickly do OSA-related 
cognitive deficits respond to APAP treatment?  Also, it must be considered whether any of the functions 
being measured were impaired at baseline or whether the sample size was too small to enable the 
detection of differences. 
Constant positive airway pressure therapy is highly efficacious, with improvements in AHI scores 
during sleep often occurring on the first night of treatment (Sutherland et al., 2018).  Typically, 
symptoms return to pre-treatment severity levels following the cessation of treatment (Schwarz et al., 
2018; Young et al., 2013).  However, according to Kohler et al. (2011), two week CPAP withdrawal 
can lead to a rapid recurrence of OSA (on the second night), a return to subjective sleepiness, and is 
associated with impaired endothelial function, increased urinary catecholamines, increased blood 
pressure, and an increase in heart rate.  Consequently, it must be acknowledged that with-holding 
treatment on the night of the polysomnography could be detrimental to the patient’s health. 
Also, of importance, is the question: How long does PAP need to be used before an improvement in 
cognitive function can be documented?  Bardwell et al. (2001) demonstrated that one week of CPAP 
treatment was sufficient to improve overall cognition in their participants with severe OSA, albeit that 
none of the cognitive domains when tested separately were significantly improved.  Munoz et al. (2000) 
demonstrated CPAP-derived changes to daytime functioning after twelve-months of treatment.  Others, 
such as Canessa et al. (2011) and Castronovo et al. (2009), used a three-month intervention period to 
demonstrate improved cognition and daytime functioning respectively in severe apnoeics, as did Aloia 
et al. (2003), Gale and Hopkins (2004), and Zimmerman et al. (2006), whilst Joseph et al. (2009) and 
Kushida et al. (2012) based their longitudinal studies on a six-month intervention.  Overall, cognition 
may improve sometime between one-week or 12 months of treatment.   
The final determinant was the level of impairment at baseline.  If a dependent variable is not impaired 
at baseline, then treatment is not required.  In our study, it was reasonable to assume cerebral perfusion, 
cognition, and microsleeps would be impaired based on available literature at that time.  Accordingly, 
and noting that most of the studies mentioned above involved patients with severe OSA, we chose an 
intervention period of 6 months.  It was reasonable to expect those 6 months of APAP therapy would 
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provide sufficient time for the manifestation of cognitive and microsleep changes yet would not be too 
onerous for those participants who would be treated. 
5.5.1 Retest reliability 
A consideration in repeated measures studies is test-retest reliability.  Test-retest reliability is the 
degree to which test scores remain unchanged when measuring a stable individual characteristic on 
different occasions (Vilagut, 2014)   
The PSQI has a high retest reliability and a good validity for patients with primary insomnia according 
to Backhause et al (2002), as does the SF-36 (Anderson et al 1996 and Ruta et al. 1994).   
Melzer et al. (2020) undertook a study on test-retest effect of a relocation.  As part of that study, they 
also did a test-rest study at the new location which was 9 weeks apart; what they termed a within-site 
repeat.  They found little difference between scanner relocation and within-site results which appeared 
to have a negligible effect on variability of the global MRI metrics tested including cortical grey matter 
perfusion. 
With respect to microsleeps, Peiris et al. (2006) tested 15 male participant on two occasions spaced at 
least one week apart (mean 17, range 7-50).  They found there was no difference in the number of 
participants who experienced microsleeps, 5 vs.8, McNewman’s test p = .250.  Also there was only a 
marginal increase in rate of definite microsleeps, 10.8 vs 19.6 h-1, p = .085. In a repeated-measures 
design study, interindividual differences in microsleep rates have shown substantial agreement across 
two sessions (single-rater intraclass correlation (2,1) = 0.72, p<0.001) (Innes et al., 2013). 
Table 5-1  Cognition retest reliability 
Test Coefficient Reference 
CVLT 0.76 – 0.89 (Alioto et al., 2017) 
Digit Span  0.83 (Waters & Caplan, 2003) 
Verbal Fluency FAS 0.47 (Ross, 2003) 
Judgement of Line 0.84 – 0.90 (Spencer et al., 2013) 
Rey Complex figure 0.76 – 0.89 (Woodrome & Fastenau, 2005) 
Rey complex interrater o.80 – 0.99 (Woodrome & Fastenau, 2005) 
Symbol Digit Modality 0.70 (Pereira et al., 2015) 
Stroop 0.85 (Martínez-Loredo et al., 2017) 




Retest reliability coefficients were also obtained for the eight cognitive tests used in this study (Table 
2-6).  With the exception of the Verbal Fluency test, which was moderately poor, all had good retest 
reliability coefficients. 
5.5.2 Baril et al’s study 
The study by Baril et al. (2015) also investigated as a standalone group, patients with moderate OSA.  
Like this study, they found no significant difference in cerebral perfusion either global or regional in 
their cohort of moderate OSA when compared to their control group.  This raised the question, “what 
did our study add?”  Baril used SPECT to investigate regional perfusion in mild, moderate and severe 
OSA patients whereas this study used ASL to test for cerebral perfusion in moderate OSA.  Kaneta et 
al. (2017)  in their study which compared ASL with SPECT found that ASL with a post delay of 1.5 s 
produced a better-quality image overall than SPECT (84,9% vs 66.7%).  A comparison of Baril et al’s 
results to other SPECT studies showed that Baril’s findings were different with reduced perfusion found 
in the outer neocortex, which raised the question “what did they do differently to other studies?”.   
This study, on the other hand, used MRI ASL, and used an ASL protocol that in a previous study (Innes 
et al., 2015) had found perfusion changes in regions consistent with other studies.  Moreover, our 
intention to the very end was to recruit 30 participants with moderate OSA and 15 without OSA.  This 
would have given us more power than Baril et al. who recruited 14 participants with a moderate level 
of severity and 20 controls.  Finally, this study also sought to contribute to our understanding with 
respect to cognition and microsleeping, constructs not considered by Baril et al. 
In summary, these proposed differences show that this study should have complimented that of Baril et 
als., by using a supposedly better scanning protocol (Kaneta et al., 2017), proven methodology (Innes 
et al., 2015), having more power (n = 45 vs n = 34), and more coverage (cerebral perfusion, cognition 
and microsleeps).  The lower than desired participation in this study impacted the power of this study. 
5.6 Patient demographics recruitment and treatment allocation 
5.6.1 Recruitment and statistical power 
Final recruitment numbers were less than targeted because recruitment of participants with moderate 
OSA was much slower than anticipated.  In addition, several potential participants with moderate OSA 
on initial screening turned out to have more severe OSA on undergoing a formal Level II 
polysomnography sleep study to estimate their AHI at baseline.  Conversely several participants (n = 
5) had lower AHI scores thus placing them in the mild OSA category.  Recruitment of controls was also 
slower than expected as not many people were willing to commit for the six-month period of the study.  
Also, several participants without overt symptoms of OSA, were found to have OSA when tested 
formally for a place in the control group.  This included several participants placed in the mild OSA 
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category (n = 10).  Those factors, along with attrition from both the clinical and control groups during 
the six-month period, led to slow recruitment and the nonachievement of targeted numbers.  The less-
than-desired recruitment numbers meant there was an imbalance between controls (n = 7), and moderate 
OSA group with n = 13 in the treated cohort and n = 11 in the untreated cohort.  This imbalance has 
negatively impacted the power of the statistical tests.  For example, the power to detect an effect size 
of d = 0.4 (Brysbaert, 2019), with probability of an α = 0.05, and n = 24 and 7 for a two tailed Mann 
Whitney U-test for between moderate OSA and controls was between 22% and 68% depending on how 
well the two groups were matched.  What was hoped to be achieved apriori was a power between 33% 
and 83%; again, dependent on how well the two groups were matched. 
5.6.2  Treated or untreated cohort placement 
Ideally, this study design would have been a randomized controlled trial (RCT with a placebo treatment 
and subjects blinded to treatment allocation, as was done by Kohler et al. (2011).  However, Schwarz 
et al. (2018) cautioned that RCTs of CPAP usage in OSA are not only time consuming but their findings 
are often inconclusive or limited because of suboptimal CPAP adherence by CPAP-naïve patients with 
OSA.  In a RCT, participants would have been randomly assigned to the treated or untreated cohorts 
and those participants who found they could not tolerate APAP treatment placed in an “Intention to 
Treat” sub-cohort of the treated cohort.  However, that ideal design was beyond the funding/scope of 
this study.  Instead, it was decided to rely on the order patients presented to the Sleep Unit for placement 
in the two cohorts with the treated cohort mostly filled first.  Accordingly, moderate OSA participants 
were first assigned a place in the treated cohort.   
Several participants (n = 4) had difficulty adjusting to the intrusiveness of APAP therapy and did not 
reach ideal compliancy targets (four or more hours over 70% of nights in any given month, (Billings et 
al., 2020).  They were withdrawn from the treated cohort and provided there had been no more than 30 
days since they had begun APAP and with their consent were offered an interim placement in the 
untreated cohort.  This was done on the understanding that if recruitment for the untreated cohort was 
not met by conventional means, they would be asked to undergo the follow-up tests.  This decision was 
made knowing there was a possibility of bias being introduced into follow-up perfusion, cognition, ESS 
and microsleep scores, but countering those concerns were slow recruitment opportunities and 
additional sleep studies both of which we could not afford.  By now a substantial cost had been incurred: 
(1) they had completed all baseline tests including Level 2 polysomnography testing, (2) cognitive 
testing had been completed and, (3) they had undergone an MRI ASL scan.  Subsequently, four 
participants who could not tolerate APAP treatment were recruited into the untreated cohort.   
It is noteworthy that none of the treated participants who had been offered a choice of placement were 
non-compliant, whereas 40% of those that were not given a choice, were. 
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5.6.3 Participant demographics 
The problems with recruitment led to cohorts not being perfectly matched. Although there was no 
statistical difference in age or sex between the moderate OSA group and the control group or between 
the treated and untreated cohorts, there were differences in actual numbers, particularly in the ratio of 
female to male where there were more women than men in the untreated and control cohorts but more 
men in the combined treated and untreated cohort compared to controls.  Furthermore, the narrow range 
for the control group (22.7 – 25.9) that was much narrower than the range for the OSA group (22.6 – 
37.5) could be a potential confounding factor. 
Whether these differences are sufficient to result in biased findings is difficult to assess.  However, it is 
known that global cerebral perfusion is higher in women than in men but differences are less clear with 
respect to regional cerebral perfusion (Cosgrove et al., 2007).  Given the higher ratio of females to 
males in the control group compared to the moderate OSA group, this may have introduced a bias 
towards finding a difference – i.e., the possibility of a false positive..  However, the question regarding 
sex differences in cognitive performance is complex (Jäncke, 2018; Lezak et al., 2004).  In general, the 
literature tends to support better performance by women on verbal tasks and better performance by men 
on non-verbal and visuospatial tasks (Coltheart et al., 1975; Lezak et al., 2004; Schaie, 1994).  But, as 
pointed out by Lezak et al., this conclusion is controversial.  To overcome this controversy, our study 
used cognitive data that had been normalised for sex, age, and BMI, apart from the PVT task where 
normalised data was not available. 
5.6.4 Ethnic mix 
Recruitment of moderate sleep apnoeics was driven by referrals from the Sleep Unit.  Of those 79 
referrals, one was female Māori, three were male Māoris, and one was female Pacific Islander, one was 
female Asian, and one was male Asian.  Thus, by far, most participants were of European descent.  
When compared to the ethnic mix for Canterbury, European New Zealanders were over-represented 
while Māori and Pacific New Zealanders were under-represented in this study.  Of the 31 active 
participants, there was one female Māori, one male Māori and one male Asian, the rest being of 
European descent.  According to Mihaere et al. (2009), Māori, because of greater BMI and neck 
circumference, are more likely than non-Māori to report having OSA risk factors and symptoms and 
were 4.3 times more likely to have an AHI ≥ 15 (95% CI = 1.3–13.9) after controlling for sex and age.  
Thus, there should have been a greater number of Maori participants then was the case. 
A review of the exclusion criteria for this study noted that participants were required to have been 
referred to the Christchurch Hospital Sleep Unit by their General Practitioner.  Low referral numbers 
of Māori and Pasifika people from General Medical Practitioners probably accounts for the low 
representation.  Furthermore, according to Frith and Cant (1985), evidence from sleep clinics in New 
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Zealand suggest that Māori patients often present with more severe OSAS and therefore would be more 
likely to be ineligible for this study, as would be the case for Pasifika people (Frith & Cant, 1985). 
Table 5-2 Ethnicity mix for Canterbury and New Zealand for 2020/21. 
 Canterbury New Zealand 
Other 87.4% 76.7% 
Māori 9.8% 16.6% 
Pasifika 2.8% 6.7% 
5.7 Individual differences 
Individual differences were assessed at baseline and between baseline and follow-up differences.  To 
do this, z scores were calculated for all results.  An examination of the individual data was carried out 
to identify any underlying patterns or subgroups that may not have been evident from the group 
analyses.  Clear was the heterogeneity seen at the group level also occurs between and within individual 
participants.  Moreover, whilst much of the data showed individual and group differences, none 
revealed any striking subgroups of value that pointed towards useful phenotypes.  This also applied to 
two of the phenotypes –, minimal symptoms, and excessive daytime sleepiness – nominated by Ye et 





Chapter 6  Concluding summary and outlook 
6.1 Achievement of objectives 
Our study aimed to clarify the impact of moderate OSA on cerebral perfusion, cognition, and 
microsleeps before and after APAP treatment.  Previous studies had shown reduced cerebral perfusion 
and cognition in cohorts consisting of moderate and severe apnoeics, or severe apnoeics.  However, 
whether this would remain true for just moderate OSA was unresolved.   
To achieve this objective, we formed six hypotheses.  Three hypotheses were that moderate OSA 
adversely influenced perfusion, cognition, and microsleeping.  Our study, consequent to finding an 
influence, then hypothesized that APAP treatment would result in an improvement in perfusion, 
cognition, and microsleeps.  Despite these hypotheses being rejected, the main findings are informative 
and contribute to our understanding of cerebral blood flow and cognition in people with moderate OSA. 
6.2 Main findings 
In our study in which all participants had sleep apnoea of moderate severity, we found no evidence of 
reduced of reduced cerebral perfusion, either globally or regionally.  This concurs with the only other 
study which has investigated the effect of moderate severity sleep apnoea on cerebral perfusion (Baril 
et al., 2015).  The significance of our finding becomes apparent when the results from studies involving 
people with severe sleep apnoea are compared with the results of our work.  The finding by other studies 
of regional differences in cerebral perfusion in their participants with either moderate/severe OSA or 
severe OSA suggest that a certain level of obstructive sleep apnoea severity, as measured with AHI, is 
necessary before cerebral perfusion is impacted.  This conclusion is supported by findings that cerebral 
autoregulation is disrupted in cohorts with both moderate and severe OSA but which is maintained in 
people with just moderate OSA (Waltz et al., 2016).  The sympathetic nervous system seems to have 
little influence on cerebral autoregulation except under challenging circumstances (ter Laan et al., 
2013).  Accordingly, it is suggested that homeostatic processes (vasomotor, chemical, metabolic), 
responsible for maintaining cerebral perfusion within normal limits, are effective in people with mild 
or moderate OSA These processes seem to deteriorate in people with severe OSA resulting in 
pathological changes. 
These pathological changes can manifest as impaired cognition, which has been shown to be impacted 
by severe obstructive sleep apnoea (Kushida et al., 2012).  The impact of just moderate OSA on 
cognition has rarely been explored.  Studies that have explored its effects on cognition have produced 
ambivalent results (Aloia et al., 2004; Bucks et al., 2017; Kushida et al., 2012).   
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Our study found no difference in cognition between participants with moderate OSA and the control 
group at baseline.  Several important study factors may have led to this result, including small sample 
size, demographic differences, recruitment bias, differences in fatigue levels because of individual 
differences in personality/interest/motivation trait complexes, along with participant wellbeing 
(Ackerman & Kanfer, 2009).  However, steps were taken to limit these confounding factors, principally 
using normalised data, selection criteria and methodology that saw all participants tested at the same 
time of day and in the same sequence.  Moreover, recruitment was undertaken based on order of 
presentation to the Sleep Unit.  This would mitigate some recruitment bias as order of presentation 
would be somewhat random in terms of many demographic factors.  There was no placebo effect at 
baseline.  It is also possible that the sample size was too small to reach sufficient statistical power. 
There was also no difference found in cognitive scores between the treated cohort and the untreated 
cohort at follow-up.  Again, there are important study factors that could have contributed to this result.  
In addition to those mentioned above, there is also a placebo effect.  Kushida et al. (2012) managed this 
confound using a sham CPAP device, as have other studies (Baillieul et al., 2021; Pepin et al., 2016).  
However, this was not an option in this study because of cost.  Other studies investigating CPAP 
treatment and cognition have not used sham CPAP to manage any placebo effect.  These included 
Canessa et al. (2011); Castronovo et al. (2014); and Dalmases et al. (2015) and Xu et al. (2017) 
Our study also investigated the association between global cerebral perfusion and cognition.  No 
evidence of an association between those two measures was found at baseline, which is consistent with 
the absence of any reduced regions of cerebral perfusion.  This absence of any correlation between 
global cerebral perfusion and cognition also extended to the five sub-domains of cognition tested in this 
study.   
The absence of any difference in cerebral perfusion and cognition at baseline also extended to 
microsleeps.  Our study investigated the effects of moderate severity sleep apnoea on behavioural 
microsleeps.  Based on behavioural microsleep counts no difference in microsleeps was found between 
people with moderate OSA and controls at baseline or between baseline and follow-up in any of the 
three cohorts tested.  In our opinion the most likely explanation for the absence of a difference is the 
small cohort size, which meant we had insufficient power to detect differences.   
Our study also compared sleep quality measures using the Epworth Sleepiness Scale, PSQI, and 
Medical Outcomes Study with indicators of sleep apnoea severity levels such as AHI, arousal counts, 
cognition, global cerebral perfusion, microsleeps, and ST90 levels.  The AHI correlated best with 
measurements of sleep quality and quality-of-life indices. As the AHI increased, sleep quality and 
quality-of-life measures worsened.  Arousal counts correlated with the PSQI (rs = 0.37, p = .039) 
showing that as arousal counts dropped, sleep improved.  Otherwise, cerebral perfusion, cognition, 
microsleeps, and ST90 levels were not associated with changes in sleep and quality-of-life indices.  At 
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baseline, arousal counts were also correlated with AHI (rs = 0.38, p = .036) as was the PSQI (rs = 0.48, 
p = .003).  This correlation does not confirm a causation, however in the given setting of our study, it 
is most likely that the correlation between arousal counts and the PSQI was driven by obstructive sleep 
apnoea severity as measured by the AHI.   
Our study could not detect any impact of moderate OSA on cerebral perfusion or cognition.  Still 16 
(85%) out of 19 participants were keen to retain the APAP machines.  Given the low adherence rate in 
the general population for APAP compliance (Wolkove et al., 2008), this high retention rate suggests 
that the users gained benefits that were elusive to our measurements (Engleman et al., 1996).  A review 
of the comments justifying why the participant’s wanted to keep their APAP machines, all point to 
perceived improved sleep, and quality-of-life.   
On treatment with APAP, the Epworth Sleepiness Scale, PSQI, and the SF-36 all improved as expected.  
These results are supportive of treating, if not to improve cerebral perfusion or cognition, but to improve 
sleep and quality-of-life. 
To conclude: 
1) At baseline, no difference was found in global or regional cerebral perfusion between 
our participants with moderate OSA severity and our controls. 
2) Following 6–7 months of APAP treatment, no global or regional cerebral perfusion 
differences were detected. 
3) No difference in cognition was detected between our participants with moderate OSA 
and our controls. 
4) Following 6–7 months of APAP treatment, cognition did not improve. 
5) No association was found between cerebral perfusion and cognition at baseline. 
6) At baseline, no difference was detected in microsleep counts between our participants 
with moderate OSA and our controls.  
7) At baseline, Epworth Sleepiness Scale, PSQI, and SF-36 were worse in our participants 
with moderate OSA compared to our controls.   
8) Following 6–7 months of APAP therapy the Epworth Sleepiness Score, PSQI, and SF-
36 scores improved in the treated cohort.  
9) The main study limitations were sample size, especially the size of the control group, 




6.3 Review of hypotheses 
This study proposed six hypotheses.  Each is critiqued with the benefit of hindsight. 
(H1) Cerebral perfusion is reduced in moderate OSA:  It was hypothesised that cerebral perfusion in 
people with moderate OSA would be reduced while awake compared to perfusion rates in non-apnoeic 
people.  This hypothesis was based on previous observations of people with moderate-severe sleep 
apnoea that suggested reduced cerebral perfusion can occur in people with moderate OSA.   
We found no significant differences in cerebral perfusion when people with moderate OSA were 
compared to controls (the absence of a difference does not necessarily mean there was not a difference 
just that it was not found).  At the time this hypothesis was formed, we did not have the benefit of Baril 
et al.’s (2015) study who explored the same research question and reached similar results.   
H2)  Cognition is reduced in moderate OSA:  It was hypothesised that people with moderate OSA would 
have reduced cognition.  The rationale for this position were studies with participants that had mild and 
severe sleep apnoea, These studies would have also included moderate OSA and have found cognitive 
differences in both verbal and visual memory, attention, and spatial awareness.  Nonetheless, contrary 
to our hypothesis, when our participants with moderate OSA were tested, none of the five domains of 
cognition were reduced compared to our controls at baseline.   
Although this hypothesis was not supported by our findings, it was nonetheless, a valid question to ask 
as the relationship between obstructive sleep apnoea, severity and cognitive performance, according to 
Bucks et al. (2013) still needed to be resolved, and only few studies have investigated the impact of 
moderate OSA on cognition.  This research question is consistent with observations that cognitive 
impairment is associated with sleep apnoea severity (Aloia et al., 2004).   
H3)  Microsleeps is increased in people with moderate OSA:  Obstructive sleep apnoea is known to 
cause daytime sleepiness.  The mechanism is assumed to be due to arousals from sleep associated with 
sleep apnoea (Slater & Steier, 2012) although hypoxemia (Dewan et al., 2015)and inflammation 
(Kheirandish-Gozal & Gozal, 2019) cannot be discounted..  Microsleeps are thought to be influenced 
by drowsiness levels with greater microsleeps related to increased levels of drowsy (Innes, Poudel, & 
Jones, 2013; Poudel, Innes, Bones, Watts, & Jones, 2014).  It was hypothesized that the incidence of 
microsleeps would be higher in people with moderate OSA. 
This hypothesis was rejected because we found no difference in microsleep counts at baseline.  
However, the substantial variability in microsleep counts in the same cohort of participants with 
moderate OSA affected the power to detect differences, if any.  In retrospect, the population size of our 
study was insufficient to resolve this hypothesis. 
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H4)  Impaired cerebral perfusion in people with moderate OSA can be improved by APAP treatment:  
The effect of APAP treatment on perfusion in those with moderate OSA has not been adequately 
explained.  Our hypothesis was that APAP treatment would reduce OSA severity that in turn would 
improve cerebral perfusion.  Although this hypothesis was based on the premise that cerebral perfusion 
is impaired in people with moderate obstructive sleep apnoea, our study still explored the effect of 
APAP treatment on cerebral perfusion.  This study found that following 6–7 months of compliant APAP 
therapy, cerebral perfusion did not change.  This means we either did not detect a clinically meaningful 
difference in cerebral perfusion, or APAP therapy has no effect when the baseline perfusion level is 
within the normal reference range of 50 mL per 100g of brain tissue per minute. 
H5)  Impaired cognition in people with moderate OSA can be improved by APAP treatment:  The 
independent effects of cerebral perfusion on neurocognitive function in people with moderate OSA 
remain poorly understood.  Evidence from studies into cardiovascular disease suggest a positive 
correlation between cerebral perfusion and cognitive functioning.  Other studies have reported that 
cerebral perfusion is negatively impacted by OSA.  Accordingly, it was hypothesized that a reduction 
in OSA severity would improve cerebral perfusion and consequently, cognition. 
An underlying assumption of this hypothesis was that cognition would be different between moderate 
OSA and controls at baseline, an assumption that was subsequently found not to be the case.    
Nonetheless, the hypothesis was still useful as the results were consistent with not finding either a 
difference in cerebral perfusion or a cognitive difference at baseline thereby lending weight to the 
premises that moderate OSA does not have a significant effect on either cerebral perfusion or cognition. 
H6)  Increased microsleeps in people with a moderate severity level of OSA can be reduced by APAP 
treatment:  A frequent consequence of obstructive sleep apnoea is excessive daytime sleepiness which 
may increase the propensity for microsleeps. However, the relationship between behavioural 
microsleeps and OSA has not been established in the literature.  It was hypothesized that APAP 
treatment would reduce microsleeps.  Effective APAP treatment should reduce the number of micro-
arousals that are associated with upper airway patency – a major factor in the aetiology of OSA.  
Reducing sleep arousals should allow for the restoration of normal sleep architecture and improve 
daytime sleepiness levels.  However, our study found no association between moderate OSA and 
microsleeps, at either baseline or follow-up. 
In summary, all six hypotheses have been rejected.  Even in retrospect they are valid hypotheses, 
clinically relevant and informed by the literature.  While our study has had negative results, it is possible 
that either studying participants with severe OSA or a larger cohort participating with moderate OSA 
would have assisted in detecting signals supporting the hypotheses.  We are reassured regarding the 
quality of our local research as other researchers studying small cohorts of participants with moderate 
OSA have reported similar results.  That our results are supportive of other studies (Aloia et al., 2004; 
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Baril et al., 2015), makes a strong contribution to our understanding of moderate OSA consequences.  
In particular, the role of cerebral autoregulation has been raised as a possible factor that explains why 
people with moderate levels of OSA can maintain good cerebral blood flow. 
6.4 Critique of this project 
The objectives of this study were to determine the effects of moderate OSA and six months of APAP 
treatment on cerebral perfusion, cognition, and microsleeps.   
The lower than desired recruitment numbers in our study would have had a negative impact on the 
ability to detect differences between cohorts, if such differences existed.  Our recruitment of clinical 
participants was impacted by substantially fewer moderate OSA patients presenting to the Christchurch 
Hospital Sleep Unit than expected.  This could have been resolved by recruiting from the general-public, 
however, that would have incurred addition costs the study was not funded for.  Accordingly, 
recruitment was best done through the Canterbury District Health Board Sleep Unit who had previously 
tested the potential member as meeting the “moderate OSA” criteria using either Lvl II or Lvl III 
polysomnography.  Furthermore, the rationale for our study was that moderate OSA was rarely tested 
as a standalone group and given the number of international and national epidemiology studies pointing 
towards an increase in OSA prevalence, understanding the deficits incurred by people with moderate 
OSA was important.  Therefore, recruiting participants with a severe level of OSA would not 
compliment the study’s objective.  Finally, at the time we set study parameters, recruitment was 
expected to be straightforward given the number of moderate OSA presentations to the Christchurch 
Hospital Sleep Unit at that period.   
Funding for this study had to be used within a specified time-period that because of slow recruitment 
for the moderate OSA group was at risk of expiring.  This meant that 10 potential controls had to have 
their Level II polysomnographs done without first screening them with much less expensive Level III 
polysomnographs.  Subsequently, there were 7 controls who met our specification of an AHI < 5 and a 
further 7 recruits with AHI ≥ 5.  The recruitment number of 11 for the untreated cohort was also less 
than the 15 planned, as was the 14 members of the treated cohort.   
The self-selection of one member of the treated cohort was a potential source of bias in this study, as 
was allowing four participants who were unable to tolerate APAP treatment to change to the untreated 
cohort.  It is acknowledged that this was a design flaw that has decreased the scientific rigour of our 
study and therefore potentially reduced our ability to interpret the findings from the 6-month follow-up 
component of our study.  However, it was done on the basis that the risk of bias to perfusion, microsleep 
and cognition results would be less than the risk of low sample sizes in the experimental groups due to 
recruitment and withdrawal from the study by participants who were not committed i.e., attrition bias 
(Asendorpf et al., 2014).  Furthermore, this assessment was made within the context of the study having 
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already invested substantial time and funding.  However, this potential bias only applied to the results 
following the treatment period.  The results at baseline were without bias because the assignment to 
either the treated or non-treated cohorts took place following those tests.     
Several procedures could have been employed to minimise the biases of a longitudinal study at the trial 
planning and trial implementation phases  (Coolican, 2005; Pannucci & Wilkins, 2010).  At the planning 
stage, bias can be attributed to flawed study design, selection bias and channelling bias.  This study 
used validated methods for collecting MRI (Innes et al., 2015), cognitive (Lezak et al., 2004) and 
microsleep data (Buckley et al., 2014; Poudel et al., 2008).  Bias can also be attributed to selection bias.  
However, that bias can be reduced by selecting participants from the same general population, which is 
what this study did.  We also tried to match participants for age and sex.  Finally, at the planning stage 
there is channelling bias.  This can be avoided by assigning participants to study cohorts using rigorous 
criteria.  This our study did by using order of presentation to the Sleep unit.  However, the transfer of three 
participants, who could not tolerate APAP treatment, from the treated cohort to the untreated cohort could have 
introduced some selection bias.  At the trial implementation stage, Pannucci and Wilkins (2010) listed six sources 
of bias  Those biases are, interviewer bias, chronological bias, recall bias, transfer bias (attrition bias), 
misclassification of exposure and outcome, and performance bias.  To prevent Interviewer bias this study’s 
interviewer interaction with participants was standardized.  However, being blind to the participant did not occur.  
Chronological bias can be reduced by using a prospective process, as was done in this study.  To reduce recall 
bias this study used mainly objective data sources although the inclusion of quality-of-life instruments, such as 
ESS, PSQI, and MS 36-SF, were subjective and a possible source of bias.  Nonetheless, those results were able to 
be validated against other published data which gave a degree of confidence.  Outcome and exposure 
misclassification can occur if the exposure itself is poorly defined.  In this study all the exposures, tests, 
scans, and polysomnographies are standardized processes, so outcome and exposure misclassification 
should not have occurred.  Finally, there is performance bias.  To minimise bias introduced by 
performance bias there was only the one investigator who conducted all of the cognitive and microsleep.  
In addition, the MRI scans, and polysomnographies were all conducted by registered technicians, 
thereby minimising bias.  Furthermore, performance bias on the part of the participant could have been 
prevented by the use of a placebo APAP machine (Rodway et al., 2010).  However, this was an expense 
that could not be afforded. 
It is noted that the test results from the four members who were transferred from the treated cohort to 
the untreated cohort were not significantly different to the results from the other members of that cohort.  
In only one instance was two standard deviations exceeded and that was for microsleeps.  Accordingly, 
confidence remains high that no bias was introduced because of those transfers.  Furthermore, because 
of the steps taken as outlined above, study bias would not have been excessive, 
Another area of improvement would be to quantify the participants sleep state prior to the MRI scan by 
administering the Karolinska Sleep Study and the Stanford Sleep Study. Blood pressure should also 
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have been recorded as hypertension is understood to impact CBF (Innes et al., 2015). Furthermore, 
according to Fantini et al. (2016), a change in posture and exercise can also influence CBF.  These tests 
were omitted because the complexities of cerebral autoregulation were not fully appreciated at the time 
the study was being designed. 
Financial management constraints (a deadline for spending set by the financial year) in conjunction 
with slower than expected recruitment, meant we ended up making a considerable investment in each 
control, only to find some were unsuitable because of AHI levels > 5 that placed them in the mild-
obstructive sleep apnoea category.  Ideally, each control should have undergone a much cheaper level-
3 polysomnography confirming their non-apnoeic status before asking them to commit to the study.  
Only then should they have undertaken the level-2 polysomnography that because they are reliant on 
sleep technologists to first set up and then to process are much more expensive.  However, adding the 
level 3 polysomnography to the process, would also add extra time to the recruitment; time that was not 
available. 
Another area of improvement was the length of time between tests that varied widely.  We were unable 
to make advanced bookings for polysomnography tests, MRI scans, and cognitive testing.  Moreover, 
MRI scans and cognitive testing were reliant on polysomnography test results that were reliant on Sleep 
Unit staff members working outside of normal worktime and consequently, not always available.   
Nonetheless, our study benefitted from the dedication of the Sleep Unit staff members in processing the 
sleep studies.  It also benefitted from the helpful approach shown towards the study by members of 
Pacific Radiology, who were responsible for conducting the MRI ASL studies.  Using these two 
professional bodies was a strength of this study as it ensured no participants were lost to the study 
because of unusable data.  A further strength came from the diversity and contribution of its research 
members with both clinical and research advocates freely contributing.  The diversity of ideas has given 
the study depth. 
6.5 Future directions 
There are indications from our study and those of others that cerebral perfusion is related to sleep apnoea 
severity levels.  Is there a severity level above which normal homeostatic processes regulating cerebral 
perfusion are no longer effective, thus resulting in disrupted cerebral perfusion?  The validity of this 
question is unchanged.  Our study added to the literature by not detecting an impact in people with sleep 
apnoea of a moderate level as has previously being published. 
The identification of phenotypes useful to researchers would help to make better sense of the data 
heterogeneity.  Currently, most phenotypes are for clinicians.  Although the APPLES research project 
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(Kushida et al., 2012) has made a valuable contribution, more work needs to be done to validate those 
results and to identify other useful phenotypes for research settings. 
It is also noteworthy that the long-term consequences of OSA have yet to be fully elucidated.  Although 
it is suggested in the literature that OSA contributes to neurodegenerative dementias such as 
Alzheimer’s, Parkinson’s and dementia with Lewy bodies (Andrade et al., 2018; Kaminska et al., 2015; 
Manni & Terzaghi, 2015; Meng et al., 2020; Sun et al., 2020) more work is required to identify and 
confirm pathological causeways linking the two constructs.   
A useful study would be to investigate the impact of a much broader range of AHI scores then just those 
defining a moderate level of sleep apnoea, on perfusion, cognition, and microsleeps.  One objective 
would be to identify a threshold at which changes to perfusion manifest.  Part of this proposed study 
could be to review different measures of severity i.e., ST90, ODI, hypoxic burden, as better measures 
of severity than breathing patterns reflected in the AHI (Terrill, 2020).  This understanding could lead 
to revised severity classifications where mild, moderate, or severe categories are reflective of clinical 
consequences and not arbitrarily set limits.  As our understanding of OSA pathology improves, these 
broad-based severity classifications will lose their clinically relevance (Won et al., 2018).  The 
refinement of a clinically relevant threshold at which point OSA impacts cerebral perfusion, cognition, 
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Appendix A  Screening checklist 
OSA PARTICIPANT Name:   
 
Screening at first contact (i.e., before First Session if possible) 
Ensure that the following criteria are met: 
 
 
Date of birth _________________________________    Over 18?   
 
YES / NO 
When do you normally go to bed?    
(Is this time between 10 pm and 12 pm?)  
YES / NO 
When do you normally get out of bed in the morning?    
(Is the time between going to bed and getting up between 7 – 9 hours?) 
 
YES / NO 
Do you drink 4 or more caffeinated drinks (like coffee, coke, or tea) per day? YES / NO 
Do you suffer from claustrophobia? YES / NO 
Do you have any metallic implants? (May affect your ability to undertake and 
MRI) 
YES / NO 
Do you have metallic braces or jewellery, such as a bracelet, ring, or piercing 
that you can’t take off?  (May affect your ability to undertake and MRI) 
YES / NO 
Have you ever had brain surgery, stroke, or brain injury (including concussion)? YES / NO 
Have you ever been diagnosed with a psychiatric or neurological disorder 
(including migraine)? YES / NO 
Have you ever been diagnosed with a sleep disorder? YES / NO 




Cellphone number:  
 
Email address:  
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This study will look at the effects of moderate obstructive sleep apnoea (OSA) and how this might 
change after treatment.  We will investigate the structure of the brain, blood flow, your ability to think 
clearly, and how sleepy you get.  Most previous research has only included people with severe OSA.  
However, we are interested in looking at people with more moderate levels of OSA severity. 
You are invited to take part in a research study to measure the impact of six months Continuous Positive 
Airway Pressure (CPAP) treatment for moderate OSA.  During the study, we will check how well you 
sleep.  We will then assess your ability to stay alert – Daytime Sleepiness Assessment.  We will also 
check your mental ability.  Finally, we will take a series of pictures of your brain.  This will allow us to 
measure the brain’s blood flow and structure.  Overall, these tests will be completed twice; initially and 
again six months later.  Between the two sets of tests, you will be required to undertake APAP treatment.   
Before you make a decision, it is important that you understand what is involved in this research. 
Study Procedures 
Where will the study be conducted?  
This study will be conducted at your home, the New Zealand Brain Research Institute at 66 Stewart 
Street, Christchurch, and Hagley Radiology (in the same building as the Brain Research Institute next 
to Hagley College). 
How are participants chosen for this study? 
People with moderate OSA will be chosen from people referred to the Sleep Unit at the Christchurch 
Hospital.  They will then be screened to ensure they meet important selection criteria, such as normal 
sleep habits, minimum age, etc. 
What will you have to do if you participate in this study? 
This is a study that measures changes over a six month period.  So at the beginning of the study you 
will complete: 
Overnight ‘Sleep Recording’ in your own home, unless you have recently completed one. 
Daytime Sleepiness Assessment 
Set of Mental Tasks 
MRI scan   
Six months later we repeat the same tests. 
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In between you will complete a six-month treatment period using Continuous Positive Airway Pressure.  
This is the normal treatment for OSA.  The treatment involves an air-pump that delivers a gentle flow 
of air via a flexible hose and mask which you wear while you sleep.  The air pressure helps to keep your 
airway open allowing you to breathe and sleep more easily.   
During this period, we will monitor your treatment and provide support.  We will record the number of 
hours you use the APAP machine each night and the number of days each week it is used.  It is expected 
that you will comply with the treatment by using the APAP machines for a minimum 4 hours per night 
on at least 5 out of seven nights. 
The APAP machines and masks we will use are manufactured by ResMed.  The APAP machine is an 
Airsense 10 Autoset with humidifier.  These are premium machines for the treatment of sleep apnoea.  
Although you will be offered every support and encouragement to use these machines, they are not for 
everyone and some people have difficulty tolerating them.  If the compliance levels noted above cannot 
be met after a reasonable length of time we will have to withdraw the machines so they can be used by 
other participants. 
The APAP machines have been lent to the research project by the manufacturer and at the conclusion 
of the research project we are expected to return them.  However, for those who have benefitted from 
the treatment, we expect to be able to offer you an option that will allow the APAP treatment to be 
continued.   
Unless you have recently undergone a sleep study you will need to do so so we can confirm your level 
of OSA.  The Sleep Recording will mean coming into Christchurch Hospital on a Wednesday evening.  
There a sleep technologist will attach sensors to your head and chest that will record information about 
your breathing patterns, heart rhythms, and brain activity.  You will also have a band-aid like sensor 
wrapped around your finger to measure the amount of oxygen in your blood.  The sensors are all 
attached and removed painlessly.  You are welcome to have family/Whanau support present throughout 
the attachment of recording sensors.  The sleep technologist will not monitor the recording nor be 
present during the night. 
After the Sleep Recording, you will be asked to come to the New Zealand Brain Research Institute to 
pick up a small sleep monitor, a sleep diary, and a set of questionnaires about your sleep habits.  The 
small sleep monitor looks like a wristwatch and measures time spent asleep or awake.  You will be 
asked to fill in the diary and wear the small sleep monitor over the next week.   
You will then come back to the New Zealand Brain Research Institute.  There you will complete a set 
of mental tasks followed by a daytime sleepiness assessment.  On that day you should eat and drink and 
take any medication as per normal.  However, you should not consume any food or drinks which contain 
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alcohol or caffeine (or any other stimulants or depressants).  You should also not smoke cigarettes for 
at least one hour before your appointment. 
You will be asked to complete a set of mental tasks that test attention, memory, planning, and mental 
dexterity. These tests are expected to take about 1 hour.  Following those tests and after a short break, 
we will ask you to undertake a Daytime Sleepiness Assessment This session will also take around 1 
hour.  It will consist of a 10-minute reaction time task and a 50-minute tracking task.  During this last 
task your eyes will be videoed and your tracking responses will be recorded so we can tell if you briefly 
fall asleep.   
MRI Study 
Finally you will need to come to Hagley Radiology (in the same building as the Brain Research Institute) 
on a Saturday afternoon for a 20-min MRI scan to measure the blood flow in your brain.  You should 
eat and drink and take any medication as normal.  However, you should not eat or drink anything that 
day, which contains alcohol or caffeine (or any other stimulants or depressants).  You should also not 
smoke cigarettes for at least one hour before your appointment. 
Benefits 
As a participant in this research study, there may be no direct benefit for you; however, information 
from this study should help other people in the future.  
Risks 
MRI is a safe and well established technique.  It does not use harmful radiation.  However, the strong 
static magnetic field it uses can in some cases be a danger if any metallic objects, such as a bracelet, 
necklace, watchs, hair clips, or electronic heart pacemakers are worn inside the scanner.  The MRI 
technician will ask you to remove anything metallic that could be dangerous.  If it cannot readily be 
removed, you will not be allowed to continue to participate any further. 
In the unlikely event of a physical injury as a result of your participation in this study, you may be 
covered by ACC under the Injury Prevention, Rehabilitation and Compensation Act.  ACC cover is not 
automatic and your case will need to be individually assessed. If your claim is accepted by ACC, you 
still might not get any compensation.  This will depend on a number of factors such as whether you are 
an earner or non-earner.  ACC usually provides only partial reimbursement of costs and expenses and 
there may be no lump sum compensation payable.  There is no cover for mental injury unless it is a 
result of physical injury.  If you are covered by ACC, this may affect your right to sue the investigators.   





Although blood flow and structural images of your brain will be recorded during the study, these will 
not be viewed by a clinical neurophysiologist or radiologist.  The research is not a clinical diagnostic 
facility and as such does not inspect the MRI data for abnormalities.  However, from time to time an 
anomaly may be observed on an MRI scan.  We can only indicate that further advice might be sought.  
The presence or absence of an unusual reading is not an indication of the presence or absence of disease.  
If an unusual observation is made, we will inform you of this and, if you agree, inform your Doctor. 
Remuneration 
You will not be paid a wage for taking part in this study.  However, any expenses incurred in travelling 
to and from the Institute and any parking charges for the purpose of this study will be reimbursed by a 
fixed $75 paid via cheque for the initial assessment and the a further $75 will be paid at the completion 
of the six-month assessment.   
Confidentiality 
Your data will be only be made available to the researchers listed on page 1.  However, if you agree we 
will store your data for future research where it could be useful in other New Zealand-based microsleep 
or brain blood flow studies.  These studies would first need approval from a New Zealand accredited 
ethics committee before going ahead.  You may still take part in this study if you do not consent for us 
to use your data this way. 
Participation  
Taking part in this study is voluntary.  If you decide to take part, you can change your mind at any time 
and withdraw.  Your decision to withdraw will not change any present or future relationships with the 
Christchurch Hospital, and the New Zealand Brain Research Institute or their associated organisations. 
Further Information: 
If you have any questions about this study, please contact Russ Buckley or one of the other researchers 
by phone or email.  If you have any questions or concerns about your rights as a participant you can 
contact an independent health and disability advocate.  This is a free service provided under the Health 
and Disability Commissioner Act. 
Telephone (NZ wide): 0800 555 050 





If you have any questions or concerns about your rights as a participant in this research study from a 
Maori perspective, you may wish to consult Nga Ratonga Hauora Maori, Maori Health Services, you 
can contact them directly on telephone 03 364 0640 ext. 88797 or through Te Komiti Whakarite on 
telephone 03 364 0640 ext. 86160 or email Catherine.Grant@cdhb.health.nz 
Note: 
This study has been approved by the Health and Disability Ethics Committees and by Te Komiti 
Whakarite (Canterbury District Health Board Research Consultation with Maori committee).
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Dr Carrie Innes 
Neuroscientist 
Department of Medical Physics and Bioengineering, Canterbury District Health Board 
C/ New Zealand Brain Research Institute 
66 Stewart Street, Christchurch 8011 
Phone: 03 378 6096 Email: carrie.innes@nzbri.org 
 
Primary Researchers:   
 
Russ Buckley 
PhD Candidate  
University of Otago 
C/ New Zealand Brain Research Institute 
66 Stewart Street, Christchurch 801 




Professor Richard Jones 
Director, Christchurch Neurotechnology Research Programme 
Department of Medical Physics and Bioengineering, Canterbury District Health Board 
C/ New Zealand Brain Research Institute 
66 Stewart Street, Christchurch 8011 
Phone: 03 378 6077 Email: richard.jones@nzbri.org 
 
Professor Lutz Beckert 
Head, Department of Medicine 
University of Otago, Christchurch 
PO Box 4345, Christchurch 8140 
Phone: 03 641 8461 Email: lutz.beckert@cdhb.health.nz 
Dr Michael Hlavac 
Sleep and Respiratory Physician 
Respiratory Services, Canterbury District Health Board 
Private Bag 4710, Christchurch 8011 
Phone: 03 364 1914 Email: michael.hlavac@cdhb.health.nz 
Dr Paul Kelly 
Team Leader 
Sleep Unit, Canterbury District Health Board 
Private Bag 4710, Christchurch 8011 
Phone: 03 378 6239 Email: paul.kelly2@cdhb.health.nz 
 
Introduction 
Obstructive sleep apnoea (OSA) is a sleep disorder that affects respiration.  It occurs during sleep and 
causes the upper airway to close temporarily.  It affects approximately 20% of women and 50% of 
men.  OSA has been associated with excessive daytime sleepiness and an increased risk of accidents.  
In addition, it has been associated with heart disease, diabetes, and dementia.  It is readily treated by 
Continuous Positive Airway Pressure (CPAP), a treatment not freely available to all. 
This research study aims to measure the impact of PAP treatment for people with moderate severity 
obstructive sleep apnoea (OSA). We will investigate the structure of the brain, blood flow, the ability 
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to think clearly, and sleepiness in people with moderate OSA both before and after treatment.   You 
are invited to take part as a member of the control group against which measurements from those who 
have OSA can be compared. This is important for the integrity of the study.   
To undertake the role of a control it is important that you do not have OSA.  Therefore, the first step 
will be to complete a sleep study so we can confirm you do not have OSA.  We will then measure 
how well you can stay alert – Daytime Sleepiness Assessment.  We will take a series of pictures of 
your brain.  This will allow us to measure the brain’s blood flow and structure.  Finally, we will 
measure your cognitive ability at base line and again six months later.  
Before you decide, it is important that you understand what is involved in this research. 
Study Procedures 
Where will the study be conducted?  
This study will be conducted at your home (sleep studies), the New Zealand Brain Research Institute 
at 66 Stewart Street, Christchurch (Cognitive testing), and Hagley Radiology for the brain scan (in the 
same building as the Brain Research Institute next to Hagley College). 
How are participants chosen for this study? 
People without OSA will be chosen from an existing database of healthy volunteers held by the 
University of Otago, and closely match to the clinical group for gender and age.   
What will you have to do if you participate in this study? 
This is a study that measures changes over a four to six-month period.  So at the beginning of the study, 
you will complete: 
• Initial Overnight ‘Sleep Recording’ in your own home.  If this indicates that you do not have 
obstructive sleep apnoea, then a more thorough sleep study will be undertaken. 
• Daytime Sleepiness Assessment 
• Set of Mental Tasks to measure cognition 
• MRI scan   
Four to six months later we will repeat the tests. 
Sleep Study 
The initial sleep study is a simpler and more economical test conducted in your own home.  It involves 
wearing a small light weight recorder while you sleep.  If the results of this study indicate you do not 
have OSA, then we would schedule a more thorough sleep study.  This study will mean coming into 
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Christchurch Hospital on a Wednesday evening.  There a sleep technologist will attach sensors to your 
head and chest that will record information on your breathing patterns, heart rhythms, and brain activity.  
You will also have a band-aid like sensor wrapped around your finger to measure the amount of oxygen 
in your blood.  You then go home to sleep.  The sensors are all attached and removed painlessly.  You 
are welcome to have family/Whanau support present throughout the attachment of recording sensors.  
The sleep technologist will not monitor the recording or be present during the night.  Two sleep studies 
are necessary because of funding constraints.  The more thorough sleep study provides the best 
information, but it is expensive. 
Cognitive testing 
After the sleep study. You will be asked to complete a set of standard mental tasks that test attention, 
memory, planning, and mental dexterity.  The results will form a benchmark against which we can 
compare the results from the OSA group.  These tests are expected to take about 1 hour.  Following 
those tests and after a short break, we will ask you to undertake a Daytime Sleepiness Assessment This 
session will also take around 1 hour.  It will consist of a 10-minute reaction time task and a 50-minute 
tracking task.  During this last task your eyes will be videoed, and your tracking responses will be 
recorded so we can tell if you briefly fall asleep.   
On that day you should eat and drink and take any medication as per normal.  However, you should not 
consume any food or drinks which contain alcohol or caffeine (or any other stimulants or depressants).   
MRI Study 
Finally you will need to come to Hagley Radiology (in the same building as the Brain Research Institute) 
on a Saturday afternoon for a 20-min MRI scan to measure the blood flow in your brain.  You should 
eat and drink and take any medication as normal.  However, you should not eat or drink anything that 
day, which contains alcohol or caffeine (or any other stimulants or depressants).   
Benefits 
As a participant in this research study, there may be no direct benefit for you; however, information 
from this study should help other people in the future.  
Risks 
MRI is a safe and well established technique.  It does not use harmful radiation.  However, the strong 
static magnetic field it uses can in some cases be a danger if any metallic objects, such as a bracelet, 
necklace, watchs, hair clips, or electronic heart pacemakers are worn inside the scanner.  The MRI 
technician will ask you to remove anything metallic that could be dangerous.  If it cannot readily be 
removed, you will not be allowed to continue to participate any further. 
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In the unlikely event of a physical injury as a result of your participation in this study, you may be 
covered by ACC under the Injury Prevention, Rehabilitation and Compensation Act.  ACC cover is not 
automatic and your case will need to be individually assessed. If your claim is accepted by ACC, you 
still might not get any compensation.  This will depend on a number of factors such as whether you are 
an earner or non-earner.  ACC usually provides only partial reimbursement of costs and expenses and 
there may be no lump sum compensation payable.  There is no cover for mental injury unless it is a 
result of physical injury.  If you are covered by ACC, this may affect your right to sue the investigators.   
If you have any questions about ACC, contact your nearest ACC office or the investigator. 
Clinical Assessments 
Although blood flow and structural images of your brain will be recorded during the study, these will 
not be viewed by a clinical neurophysiologist or radiologist.  The research is not a clinical diagnostic 
facility and as such does not inspect the MRI data for abnormalities.  However, from time to time an 
anomaly may be observed on an MRI scan.  We can only indicate that further advice might be sought.  
The presence or absence of an unusual reading is not an indication of the presence or absence of disease.  
If an unusual observation is made, we will inform you of this and, if you agree, inform your Doctor. 
Similarly, a sleep study will also be completed.  If the results indicate that you have moderate OSA you 
will be invited to participate in the study as a member of the OSA group.  If the results indicate that 
your level of OSA is severe then the Sleep Unit will discuss those results with you. 
Remuneration 
You will not be paid a wage for taking part in this study.  However, any expenses incurred in travelling 
to and from the Institute and any parking charges for the purpose of this study will be reimbursed by a 
fixed $75 for the initial assessment and a further $50 will be paid at the completion of the six-month 
assessment.   
Confidentiality 
Your data will be only be made available to the researchers listed on page 1.  However, if you agree we 
will store your data for future research where it could be useful in other New Zealand-based microsleep 
or brain blood flow studies.  These studies would first need approval from a New Zealand accredited 
ethics committee before going ahead.  You may still take part in this study if you do not consent for us 




Taking part in this study is voluntary.  If you decide to take part, you can change your mind at any time 
and withdraw.  Your decision to withdraw will not change any present or future relationships with the 
Christchurch Hospital, and the New Zealand Brain Research Institute or their associated organisations. 
Further Information: 
If you have any questions about this study, please contact Russ Buckley or one of the other researchers 
by phone or email.  If you have any questions or concerns about your rights as a participant, you can 
contact an independent health and disability advocate.  This is a free service provided under the Health 
and Disability Commissioner Act. 
Telephone (NZ wide): 0800 555 050 
Free Fax (NZ wide): 0800 2787 7678 (0800 2 SUPPORT) 
Email: advocacy@hdc.org.nz 
If you have any questions or concerns about your rights as a participant in this research study from a 
Maori perspective, you may wish to consult Nga Ratonga Hauora Maori, Maori Health Services, you 
can contact them directly on telephone 03 364 0640 ext. 88797 or through Te Komiti Whakarite on 
telephone 03 364 0640 ext. 86160 or email Catherine.Grant@cdhb.health.nz 
Note: 
This study has been approved by the Health and Disability Ethics Committees and by Te Komiti 



















Appendix F.  Individual z-scores








































































18.4 -0.53 -0.29 -0.49 1.33 -0.68 -2.05 0.23 0.46 -0.94 0.57 -0.30 0.00 0.74
16.3 -1.65 0.33 0.41 1.51 0.16 -0.10 -0.22 -0.13 -0.62 -0.21 -0.52 0.50 -2.27
26.4 -1.28 -0.17 0.63 0.97 0.72 0.83 0.31 0.46 -0.49 -0.26 0.60 0.50 0.18
29.9 0.18 -2.40 -0.94 0.17 -1.52 -0.05 0.23 0.31 0.32 0.39 0.49 -0.50 0.47
27.3 -3.35 0.52 -1.39 1.18 -2.08 0.00 0.23 0.46 -0.72 0.24 0.33 1.00 -0.05
19.2 -0.05 0.64 -0.27 1.41 -0.68 0.11 0.31 0.31 0.32 -0.12 0.55 1.00 0.28
23.4 0.22 0.18 -0.04 -0.54 1.28 0.72 0.27 0.16 1.23 0.31 -0.39 3.00 0.02
21 -0.15 0.67 0.18 -0.80 0.44 -0.36 0.31 0.31 0.14 0.51 0.84 0.00 -0.10
26.3 -1.29 0.69 -0.27 0.03 -1.52 -1.22 0.31 -0.42 -0.01 -0.41 0.22 -0.50 -0.40
19.4 -0.41 0.31 0.18 0.38 -1.24 0.85 0.31 -0.13 -0.31 0.19 0.16 0.50 0.66
17.8 0.22 0.69 -0.27 -0.38 -0.40 0.85 0.23 0.46 -0.13 1.22 1.14 3.00 0.55
17 1.29 0.63 -0.04 -0.42 0.72 -1.77 0.15 -0.56 -1.00 -0.74 -0.47 -1.00 -0.83
24.5 -0.39 0.54 -1.17 -1.05 0.72 0.00 0.31 0.46 -0.97 1.00 0.68 -0.50 0.47
19.2 1.03 0.37 -0.72 -2.07 -0.40 1.17 0.31 0.46 0.35 -1.09 -0.33 1.00 0.11
27.8 0.47 -0.98 -1.17 -0.63 -2.08 -1.03 -4.87 -1.44 0.08 0.11 0.35 2.50 0.22
15.6 0.33 0.12 -1.17 -1.22 -0.12 -0.24 0.31 0.46 -0.87 -0.18 -0.01 -1.00 0.69
17.1 -0.06 0.32 -1.39 -0.01 0.72 0.58 -1.99 -1.29 0.36 1.12 0.58 1.00 -0.49
27.6 0.48 -2.54 -1.39 -1.03 -1.24 -2.28 -0.35 0.46 -1.63 0.70 0.88 0.50 0.06
24.6 0.12 0.47 -0.04 -0.14 0.44 -0.69 0.27 0.46 0.97 1.37 0.84 1.50 0.74
27.8 0.75 -0.45 -0.27 -0.33 0.72 0.93 0.31 0.46 0.76 -0.19 -0.28 -1.00 -0.03
19.8 -1.49 0.66 -0.49 0.73 0.44 0.93 0.31 0.31 -0.77 -0.11 -0.64 -0.50 0.32
18.1 0.94 0.67 1.98 0.60 1.28 0.67 0.31 0.46 -0.03 0.11 0.70 0.50 0.49
17.6 0.14 0.27 0.18 1.91 -0.12 -1.27 0.31 0.16 0.04 0.58 1.26 0.00 -0.15
19.1 0.33 -3.25 -0.27 -0.60 -0.40 -1.34 0.06 0.46 0.33 0.04 -0.66 1.00 -0.56
0.3 1.08 0.70 1.75 -0.74 1.00 0.07 0.31 0.46 0.21 1.55 0.73 1.00 0.18
4.9 -0.68 -0.17 1.08 -1.90 1.00 1.07 0.31 0.46 -0.13 0.81 -0.42 -1.00 -0.23
0.2 0.48 -0.20 0.18 0.97 0.44 0.40 0.31 0.31 0.74 0.79 0.31 1.50 0.69
4.8 1.27 0.65 0.18 0.31 1.28 1.01 0.23 -0.56 -0.36 0.04 -0.06 0.50 0.81
2.7 0.86 0.70 1.98 -0.54 0.16 1.17 0.31 0.46 0.65 1.73 0.98 0.50 -0.02
3.6 0.45 0.31 1.08 0.89 -0.40 0.42 0.27 -4.64 0.56 0.53 0.77 1.50 0.95


















































































0.64 0.19 0.94 -0.58 -0.30 -0.54 -0.14 -0.29 0.55 0.31 0.82
-0.38 -0.83 1.94 -0.37 0.15 0.48 0.55 -0.30 1.30 -0.39 0.41
1.33 0.85 0.53 -0.18 0.53 -0.06 -0.55 -0.30 -0.34 -0.29 0.10 0.21 -0.04 0.13
-0.25 -0.53 -1.40 0.43 0.87 5.94 0.33 -0.19 -0.96 -0.02 0.13 0.51 -0.06 -0.89
0.81 0.85 -0.11 1.45 -1.87 2.94 -0.56 -0.36 -0.34 -0.23 -1.29 -0.42 -0.49 1.03
-0.47 0.31 -0.25 0.64 -0.84 -1.06 0.57 -0.30 -0.13 -0.29 0.51 0.89 -0.27 0.40
0.13 0.69 0.24 0.84 -0.65 0.94 -0.07 -0.24 0.07 -0.80 0.34 0.74 -0.71 -1.10
0.67 0.05 -0.20 0.03 0.81 -3.06 0.59 -0.30 -0.34 -1.87 -2.41 -0.88 -2.39 0.52
-2.51 -2.92 -0.20 -0.18 0.29 1.94 0.88 -0.30 0.90 -0.99 0.69 0.92 -0.03 0.15
0.75 -1.98 0.13 -0.59 0.24 2.94 0.22 0.00 0.48 0.40 -0.06 0.29 0.64 -0.24
-0.18 0.88 3.94 -0.42 -0.30 -0.34 0.88 -0.67 -1.04 0.11 2.16
-0.09 -5.99 -0.15 -0.59 0.47 1.94 2.55 -0.07 0.00 0.89 1.66 0.99 1.12 -2.15
1.20 0.42 -0.14 2.88 1.27 -1.06 -0.56 -0.30 -1.37 2.10 0.52 -0.47 1.20 0.26
-0.15 -0.11 -2.51 -0.38 0.59 -4.06 0.00 -0.30 -0.34 0.06 1.81 0.16 0.27 -0.26
-1.49 0.36 0.78 -1.20 0.28 -0.06 0.69 6.36 -0.34 -0.39 0.23 -0.49 -0.66 0.52
0.00 0.84 0.29 -0.38 1.51 -2.06 -0.48 0.00 -0.54 2.35 2.11 -0.04 2.66 1.48
-1.35 0.40 -0.02 -0.18 -2.03 -3.06 -1.79 -0.47 1.31 0.48 0.08 0.75 0.70 -1.22
-1.21 -1.37 1.74 1.86 0.51 -0.06 -0.08 0.55 -0.75 1.07 -1.71 -1.89 0.49 0.41
0.65 0.04 -0.07 0.23 -0.05 0.94 -0.10 -0.24 -0.34 -1.22 -0.61 -0.79 -0.95 0.80
-0.64 -0.03 0.37 2.07 0.37 0.94 0.10 -0.30 -0.54 0.04 0.23 -1.14 0.96 -0.03
-0.04 0.93 -0.23 -0.59 -1.02 -2.06 -0.60 -0.30 -0.13 1.80 1.41 0.03 1.79 -1.71
0.00 0.56 -0.18 -1.61 -0.14 -5.06 -0.29 -0.30 -0.54 0.45 0.03 -0.97 -0.25 -1.04
-0.18 -0.02 -2.98 -0.79 0.28 1.94 -0.33 0.00 0.07 -2.21 -1.97 -0.60 -2.47 1.83
0.00 0.84 3.20 -0.59 0.43 -4.06 -0.35 0.04 -0.54 -0.50 0.43 3.19 -0.28 -0.76
-0.59 -0.14 0.94 0.63 -0.30 -0.34 -0.58 0.52 0.40 -0.47 1.11
Z-score within + 1 0.23 0.28 0.94 -0.09 -0.30 -0.54 -0.14 -0.22 -1.26 -0.16 -0.05
Z-score >1 -0.99 0.43 -0.06 -0.20 0.00 -0.13 -0.15 0.05 0.84 -0.24 -0.91
Z-score >3 0.43 -0.45 -1.06 -0.19 -0.19 0.90 0.04 -0.30 -0.33 -0.30 0.23
Z-score >4 -0.59 -0.33 0.94 -0.22 -0.30 -0.54 -0.31 -0.43 -0.78 -0.07 -0.95
-0.79 -0.02 0.94 0.75 -0.24 6.45 -0.73 -0.15 0.35 -0.24 -0.42
-0.99 0.16 0.94 0.50 -0.30 -0.34 -0.24 -0.43 -1.04 0.20 -0.53
